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1 Hepcidin in human iron disorders: diagnostic implications
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This chapter is in press in Clinical Chemistry
Hepcidin in human disorders: diagnostic implications
Abstract
Background: The peptide hormone hepcidin plays a central role in regulating dietary iron 
absorption and body iron distribution. Many human diseases are associated with alterations 
in hepcidin concentrations. The measurement of hepcidin in biological fluids is therefore a 
promising tool in the diagnosis and management of medical conditions in which iron 
metabolism is affected.
Content: We describe hepcidin structure, kinetics, function, and regulation. We moreover 
explore the therapeutic potential for modulating hepcidin expression and the diagnostic 
potential for hepcidin measurements in clinical practice.
Summary: Cell culture, animal and humans studies have shown that hepcidin is 
predominantly synthesized by hepatocytes where its expression is regulated by body iron 
status, erythropoietic activity, oxygen tension, and inflammatory cytokines. Hepcidin lowers 
serum iron concentrations by counteracting the function of ferroportin, a major cellular iron 
exporter present in the membrane of macrophages, hepatocytes and the basolateral site of 
enterocytes. Hepcidin is detected in biologic fluids as a 25 amino-acid isoform hepcidin-25, 
and two smaller forms, i.e. hepcidin-22 and 20; however, only hepcidin-25 has been shown 
to participate in the regulation of iron metabolism. Reliable immunochemical and mass 
spectrometry-based assays to measure hepcidin in blood and urine have been developed. 
Proof-of-principle studies highlight hepcidin as a promising diagnostic tool and therapeutic 
target for iron disorders. However, before hepcidin measurements can be utilized in routine 
clinical practice, efforts will be required to assess the relevance of hepcidin isoform 
measurements, to harmonize the different assays, to define clinical decision limits, and to 
increase assay availability for clinical laboratories.
Introduction
Iron is required for the function of oxygen-binding molecules, mainly hemoglobin and 
myoglobin, and iron-containing enzymes, including the cytochrome system in mitochondria. 
Cellular iron is mostly bound within iron protoporphyrin (heme) and iron-sulphur clusters, 
which serve as enzyme cofactors, or stored within the core of ferritin multimers. Without 
adequate iron, cells lose their capacity for electron transport and energy metabolism. 
However, the redox activity of iron can also cause damage, primarily by the production of 
reactive oxygen radicals. As such, iron concentrations must be tightly regulated both at the 
cellular and the systemic level. To maintain systemic iron homeostasis, effective 
communication between cells that absorb iron from the diet (duodenal enterocytes), utilize 
iron (mainly erythroid precursors) and store iron (hepatocytes and tissue macrophages) is 
crucial. The peptide hormone hepcidin is now recognized as the key regulator of systemic 
iron homeostasis, by its interaction with the cellular iron exporter ferroportin. Here, we 
review the major advances from studies on the structure, kinetics, regulation and function of 
hepcidin and the current state-of-the-art in hepcidin assays. We furthermore summarize 
human studies of hepcidin in physiological and pathophysiological states, and discuss the 
evidence of the therapeutic potential of modulating hepcidin concentrations. We conclude 
by highlighting the most promising applications of hepcidin assays in diagnostic medicine.
Hepcidin synthesis and structure
Human hepcidin is predominantly produced by hepatocytes as an 25 amino-acid (aa) peptide 
(MW of 2789.4 Da),1,2 that is secreted into the circulation. Subsequent amino-terminal
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processing of the 25 aa form can result in the appearance of two smaller hepcidin forms of 
22 and 20 amino acids. These hepcidin peptides form a hairpin structure, with four intra­
molecular disulfide bridges (Figure 1).3 Some studies report hepcidin to bind divalent metals 
(Cu2+, Fe2+, Zn2+ and Ni2+), but these findings are inconsistent, e.g. some studies suggest 
the presence of iron in the core of the peptide by a tetrahedral sulphur coordination,4-6 
whereas others provide evidence for an amino-terminal Cu(2+)-Ni(2+)-binding (ATCUN) 
motif.7,8 The ability of hepcidin to bind iron or other divalent metals suggests there may be a 
non-hormonal role for hepcidin in iron metabolism or a conformational mechanism for 
uptake of divalent metals as part of its hormonal role in regulating ferroportin degradation. 
Much is still unknown on the origin of the smaller isoforms, although data suggest that a 
calcium independent tissue activity present in pancreas extracts might be responsible for the 
systemic N-terminal truncation of hepcidin-25 to hepcidin-22, and that dipeptidylpeptidase 4 
is involved in the processing of hepcidin-22 into hepcidin-20.9-10 Under physiological 
conditions hepcidin-20 and -22 are present in the urine, but not, or at very low 
concentrations, in the serum.11-13 Interestingly, these smaller hepcidin isoforms only occur in 
serum in diseases that are associated with increased concentrations of hepcidin-25, such as 
acute myocardial infarction (AMI), sepsis, anemia of chronic disease (ACD), metabolic 
syndrome and chronic kidney disease (CKD) (Figure 2).12-17 In vivo studies in mice have 
demonstrated that only the full-length 25-amino acid hepcidin induces significant 
hypoferremia when injected intraperitoneally.18 These findings are corroborated by in vitro 
studies that showed,the truncated 22-amino acid and 20 amino acid forms have greatly 
diminished and almost complete loss of ferroportin regulatory activity, respectively, as 
compared with the 25-amino acid hepcidin.19
Recent studies demonstrate hepcidin expression by cells other than hepatocytes, although 
at much lower levels by comparison. These include kidney tubule, heart, retina, monocytes, 
neutrophils, fat cells, alveolar, pancreatic 3-cells and cardiomyocardal cells.20-27 The hepcidin 
produced by these cells, however, is unlikely to make a significant contribution to systemic 
circulating concentrations, but may exert local effects in these tissues (see below).
Figure 1. Molecular structure of hepcidin. A model of the structure of hepcidin-25 according to Jordan et al.3 is 
shown, with the 3-sheets (grey arrows), the peptide backbone (grey), the disulfide bonds (1-8, 2-4, 3-6 and 5­
7) (yellow), positively charged Arginine and Lysine residues (blue) and the negatively charged Aspartic acid 
residue (red).
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TOF MS
Hepc-20 Hepc-22 IS Hepc-25
Figure 2. MALDI-TOF MS profiles of serum and urine of a healthy control and serum of a CKD patient.13 The
spectra show hepcidin-25 (m/z 2789.4), internal standard (IS) hepcidin-24 (m/z 2673.9), hepcidin-22 (m/z 
2436.1) and hepcidin-20 (m/z 2191.8) isoforms. CKD, chronic kidney disease. Note that in contrast to the 
healthy control, the CKD serum clearly contains all three hepcidin isoforms.
Hepcidin kinetics
Recently circulating hepcidin was found to be bound to a2-macroglobulin with relatively 
high affinity and to albumin with relatively low affinity. Based on theoretical calculations, 
11% of hepcidin was estimated to be freely circulating.28 Whether binding to these carrier 
molecules influences the functional properties of hepcidin is uncertain.
Hepcidin clearance is assumed to occur via cellular co-degradation with ferroportin at its 
sites of action, and via excretion by the kidneys. Based on its low molecular weight and small 
radius, unbound hepcidin is likely to freely pass into the glomerular filtrate. In small human 
studies the fractional excretion of hepcidin has been calculated as low as 0-5%,29,30 either 
because it is reabsorbed, similar to other small peptides, or because it is not freely filtered. 
Evidence for the latter explanation comes from the finding of only 1-6 fold elevation of
15 16 29 31 32serum hepcidin concentrations in patients with glomerular dysfunction,15,16,29,31,32 compared 
to the 20-30 fold increase of serum 32-microglobulin. The excretion of the latter low 
molecular weight protein is known to be almost completely governed by glomerular 
filtration. Possibly, binding to a2-macroglobulin or other carrier proteins prevents circulating 
hepcidin from being freely filtered. Alternatively, the otherwise expected increased 
circulating concentrations in patients with decreased renal filtration may be offset by a 
compensatory feedback decrease in hepatic hepcidin production.
It is speculative, but conceivable, that in certain conditions hepcidin can escape renal tubular 
reabsorption. This might be relevant as several disorders of iron metabolism in which 
increased concentrations of urine hepcidin have been found, such as inflammation, iron 
overload and malaria, are associated with tubular dysfunction.33,34 Interpretation of urine as 
a mirror of serum hepcidin concentrations in such studies must also take into account 
possible local tubular production 25 as well as possible defective tubular reabsorption of 
hepcidin. Further studies on the possibility that local urinary infections or tubular 
dysfunction can contribute to hepcidinuria are warranted.
10
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Hepcidin function
Hepcidin-25 is thought to be the major regulator of dietary iron absorption and cellular iron 
release. It exerts its regulatory function by counteracting the function of ferroportin, the 
major cellular iron exporter in the membrane of macrophages, hepatocytes and the 
basolateral site of enterocytes. Hepcidin-25 induces the internalization and degradation of 
ferroportin,35-38 resulting in increased intracellular iron stores, decreased dietary iron 
absorption, and decreased circulating iron concentrations (Figure 3).
Erythrocytes 
~2500 mg
Bone marrow 
~300 mg
/  2 0 -2 5   ^
Mg/day
Iron loss 
1 -  2 mg/day 
Iron absorption
Macrophages ~600 mg
Figure 3. Iron uptake and recycling. Most of the utilized body iron is recycled from senescent erythrocytes by 
macrophages, and returned to the bone marrow for incorporation in erythroid precursors. The liver and 
reticuloendothelial macrophages function as major iron stores. Importantly, the total amount of iron in the 
body can be regulated only by absorption, whereas iron loss occurs only passively from sloughing of skin and 
mucosal cells as well as from blood loss. This results in the absorption and loss of 1-2 mg iron every day. The 
liver-produced peptide hepcidin controls the plasma iron concentration by inhibiting iron export by ferroportin 
from enterocytes and macrophages. As a consequence, an increase in hepcidin production leads to a decrease 
in plasma iron concentrations. Hepcidin expression is regulated by body iron status, inflammation, erythroid 
iron demand, and hypoxia via regulation pathways involving expression of HFE, TfR2, and HJV genes. Adapted 
from 142,224. Fe-Tf, transferrin bound iron; HFE, hemochromatosis gene; TfR, transferrin receptor; HJV, 
hemojuvelin.
In addition to its role in regulating systemic iron metabolism, hepcidin may also contribute to 
host defense. Hepcidin was originally identified as an antimicrobial peptide.1,11 
Although in vitro studies suggest bacteriocidal effects of hepcidin, this would require 
concentrations higher than those observed in the circulation. Such concentrations may be 
achieved locally for instance in phagosomes of infected macrophages.39 Hepcidin might also 
contribute indirectly to host defense by reducing plasma iron concentrations. Iron is
11
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necessary for microbial growth, and reductions in plasma iron are bacteriostatic. Moreover, 
hepcidin was found to modulate LPS-induced transcription in both cultured macrophages 
and in vivo mouse models.40 This latter observation suggests a role for hepcidin in 
modulating acute inflammatory responses to bacterial infection.
Hepcidin produced by various cell types other than hepatocytes (see above) may have local 
effects in these tissues. Through an autocrine interaction with ferroportin, local hepcidin 
may protect the nearby cells from iron deficiency, prevent extracellular oxidative stress, 
affect inflammatory reponses, and/or deplete extracellular iron pools that are available for 
extracellular pathogens.27,40-42 While the smaller forms of hepcidin do not elicit a 
hypoferremic response, it is currently unknown whether they retain other identified
a ^ 11 43
biological functions of hepcidin-25 (e.g. in host defense or in metal-binding). , , ,
Hepcidin regulation
Several physiologic and pathologic processes regulate the synthesis of hepcidin (Figure 3) 
(reviewed in 44). Situations in which demand for circulating iron is increased (particularly 
erythropoietic activity) elicit a decrease in hepatocellular hepcidin synthesis. These 
conditions include iron deficiency, hypoxia, anemia, and conditions characterized by 
increased erythropoietic activity. A decrease in hepcidin results in the release of stored iron 
and an increase in dietary iron absorption. On the other hand, infection or inflammation 
causes an increase in hepcidin synthesis. This leads to a deficiency of iron available for 
erythropoiesis, and is considered to be the mechanism underlying the reticulo-endothelial 
(RE) iron sequestration, intestinal iron absorption impairment, and low serum iron 
concentrations characteristic of anemia of chronic disease.
The functional signaling routes by which 1) iron status, 2) erythropoietic activity, 3) hypoxia 
and 4) inflammation affect hepcidin expression are increasingly being investigated. These 
routes comprise four highly interconnected regulatory pathways (Figure 4).
Regulation by iron status
Liver iron stores and circulating ferri-transferrin (Tf-Fe2) each provide distinct signals to 
influence hepatocyte hepcidin expression 44-46 and will be considered separately (Figure 4). 
Circulating transferrin appears to be sensed via a hepatocellular complex which includes 
transferrin receptor-1 (TfR1), TfR2 and hemochromatosis iron protein (HFE). Defects in TfR2 
and HFE lead to decreased hepcidin concentrations via the extracellular signal-regulated 
kinases: 1) mitogen-activated protein kinase (ERK/MAPK) pathway and/or 2) the bone 
morphogenetic protein / mothers against decapentaplegic homologue (Drosophila) 
(BMP/SMAD) pathway (Figure 4 and legend). Intracellular iron stores communicate with 
hepcidin via BMPs, particularly BMP-6, in a paracrine or autocrine fashion. These 
extracellular signaling molecules act on hepatocellular BMP receptors to activate the 
intracellular SMAD signaling pathway and increase hepcidin transcription. Hemojuvelin 
(HJV), a BMP-coreceptor,47 is crucial for hepcidin expression as various hepcidin regulatory 
pathways converge at this membrane bound protein. Under low iron conditions, membrane 
bound HJV is cleaved by Matriptase-2, a transmembrane protease serine 6, encoded by the 
TMPRSS6 gene, expressed predominantly in the liver,48,49 weakening the BMP-signaling.
12
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Figure 4: Molecular and functional pathways of hepatocyte hepcidin synthesis. Three molecular pathways can 
be distinguished: 1. the HFE/TfR2 pathway 2. BMP/SMAD and 3. JAK/STAT. This proposed model depicts two 
iron signals to hepcidin, one mediated by intracellular iron stores (Fe) and the other by circulating iron (ferri- 
transferrin, Tf-Fe2). Hepatocellular iron stores increase the expression of bone morphogenetic protein 6 (BMP- 
6), which serves as an autocrine factor by interacting with surface BMP receptors. Hemojuvelin (HJV) is a BMP 
co-receptor which augments BMP binding. The consequent activation of intracellular SMAD proteins 
transduces a signal to increase hepcidin transcription. HJV is subject to cleavage by furin, which is regulated by 
iron and hypoxia, to form a soluble component (sHJV).61 sHJV can subsequently act as a decoy co-receptor and 
antagonist of BMP-6 induced hepcidin synthesis. Under low iron conditions membrane bound HJV is also 
cleaved by matriptase-2 (scissors) again weakening the BMP-6 signal. Extracellular Tf-Fe2 mediates a second 
iron signal. In this scheme, Tf-Fe2 displaces HFE from TfR1. HFE is then liberated to interact with TfR2. The HFE- 
TfR2 complex activates hepcidin transcription via BMP/SMAD signaling. Several studies provide indirect 
evidence for the involvement of the hepatic ERK/MAPK signaling pathway in hepcidin regulation by iron 
through TfR2 and/or HFE (reviewed in 44). Recent studies in mice, however, demonstrate that acute and 
chronic enteral iron administration did not activate the ERK/MAPK pathway, suggesting that this route may not 
be of physiological relevance for iron homeostasis in vivo.46 Hypoxia influences liver specific stabilization of the 
hypoxia-inducible factor 1 (HIF-1), which induces Matriptase-2 and the subsequent cleavage of HJV.62 The latter 
pathway may be synergistic to the increased release of sHJV upon its cleavage by furin under hypoxic 
conditions.
Erythropoiesis is controlled in part by erythropoietin (EPO) production in the kidney and communicates with 
the hepatocyte by the proteins GDF15 and TWSG1 that inhibit the BMP/SMAD signaling to hepcidin. 
Inflammatory stimuli such as IL-6, induce hepcidin synthesis through the JAK/STAT pathway. These pathways 
have recently been reviewed.44
pO2: partial oxygen pressure; HIF: hypoxia inducible factor; EPO: erythropoietin; TfR: transferrin receptor; sTfR: 
soluble TfR; HFE: hemochromatosis iron protein; P2M: p-2 microglobuline; HJV: hemojuvelin; sHJV: soluble HJV; 
BMP: bone morphogenetic protein; BMPR: BMP receptor; P: phosphate; SMAD: mothers against 
decapentaplegic homologue (Drosophila); IL: interleukin; IL-6R: interleukin-6 receptor; JAK: Janus kinase; STAT: 
signal transducer and activator of transcription; HAMP: hepcidin anti-microbial peptide gene. Adapted from
133,225
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Regulation by erythropoietic signals
ESA administration was found to decrease (hepatocyte) hepcidin production in murine, 
human and in vitro studies.50-53 Erythropoiesis requires considerable amounts of iron, so 
suppression of hepatic hepcidin synthesis by erythropoietic signals is of great physiological 
importance. However, how erythropoiesis regulates hepcidin is not clear yet. The hypothesis 
that EPO could act directly on hepatocyte receptors in cell culture 51 could not be confirmed 
in animal models for anemia, which showed that decreased hepcidin expression was 
dependent on erythropoiesis and not directly mediated by EPO.53,54
Recent observations suggest that the erythropoietic signal may include one or more proteins 
released at sites of active erythropoiesis, i.e. growth differentiation factor-15 (GDF15) and 
twisted gastrulation protein homolog-1 (TWSG1). These molecules, like BMPs are members 
of the TGF-3 family and thus possibly act through effects on the BMP/SMAD pathway (Figure 
4).55-57 Correlations between TWSG1 expression, serum iron parameters, and serum hepcidin 
concentrations have not yet been determined in humans. Neither of these factors, however, 
appears to be required to mediate the decrease in hepcidin observed with EPO 
administration. Likely, additional erythropoietic factors down-regulating hepcidin expression 
will be identified.
Regulation by hypoxia
Decreased hepcidin expression has been reported in response to hypoxia in vivo.58-59 This 
effect might be due in part to the effect of hypoxia on erythropoietin expression and thus 
erythropoietic activity and/or possibly via a direct interaction with hepatocyte receptors.51 
Additionally, the lower hepcidin concentrations observed in response to hypoxia may be 
attributed to liver specific stabilization of the hypoxia-inducible factor 1 (HIF1),60 with 
downstream effects on the BMP/SMAD signaling pathway.61,62 Whether or not hypoxia- 
inducible factors (HIF) directly bind to the hepcidin promoter is currently controversial. 
However, there are indirect mechanisms by which HIFs may regulate hepcidin expression. 
Increased HIF activity is associated with increased matriptase-mediated cleavage 
hemojuvelin and thus decreased hepcidin expression.62 Moreover, the systemic iron 
regulation by the hepcidin-ferroportin axis acts in harmony with the enterocyte cellular iron 
homeostasis control system. Mice lacking intestinal HIF2a have decreased expression of 
both ferroportin and the Divalent Metal Transporter 1 (DMT1), the principal iron importer at 
the apical surface of duodenal enterocytes, and thus fail to induce iron absorption even 
upon lowering of hepcidin expression.63 These data suggest that in hypoxic (or iron deficient) 
conditions, expression of HIF2a promotes iron absorption from the intestine via increased 
activity of DMT1 and ferroportin. This implies that, HIF2a induced changes in iron transport 
can override the effects of the hepcidin-ferroportin regulatory axis.
Regulation by inflammation
The increase in hepcidin expression with inflammation is primarily mediated by interleukin-6 
(IL-6)/IL-6. The hepatocellular interaction of IL-6 with its receptor activates the Janus Kinase 
(JAK) and signal transducer and activator of transcription (STAT)-3 signaling (JAK-STAT) 
pathway (Figure 4 ).59,64-66 Hepcidin expression is also increased by oxidative or endoplasmic 
reticulum (ER) stress. This stress response can be controlled by the transcription factor 
cAMP-Response-Element-Binding-protein-H (CREBH)67 or by the stress-inducible 
transcription factors CCAAT-enhancer-binding protein (C/EBPa) and C/EBP-homologous 
protein (CHOP).68 An alcohol dependent down regulation of C/EBPa, probably through
14
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radical oxygen species (ROS), might be responsible for a decrease of hepcidin expression and 
subsequent (mild) iron overload in heavy drinkers.69,70
Interaction between hepcidin regulatory pathways
The activation of the hepcidin regulatory pathways described above all depend on 
interactions of circulating or autocrine factors with hepatocyte membrane sensors to control 
the hepatic production of hepcidin for proper maintenance of systemic iron homeostasis 
(reviewed in 44). There are multiple potential opportunities for cross-communication among 
these pathways, and experimental evidence shows that these pathways do not function 
completely independent of each other.
Serum hepcidin concentrations appear to be determined by the relative strengths of the 
individual regulators. In an attempt to delineate relative strengths of these regulators in 
patients with iron metabolism disorders, we constructed an algorithm to predict relative 
hepcidin concentrations based on certain serum parameters (CRP, transferrin saturation, 
soluble transferrin receptor) that reflect inflammation, serum iron and erythropoietic 
regulatory pathways.71 This algorithm provided insight in the interrelation of these pathways 
by showing that i) hepcidin inhibition by erythropoiesis strongly interferes with hepcidin 
upregulation by iron and ii) inflammation strongly increases hepcidin regardless of iron 
status and erythropoietic activity. These findings are in agreement with studies 
demonstrating that high erythroid demand for iron is able to blunt hepcidin induction by a 
concomitant inflammatory response.50,72-75 Other studies showed that increased and/or 
ineffective erythropoiesis blunts the induction of hepcidin by increased body iron stores.52,73 
Reports on the effect of a defective HFE/TfR2 pathway on hepcidin upregulation by 
inflammation are not consistent. One study, showed a blunted hepcidin response to 
inflammatory stimuli in HFE-knock-out (KO) mice,76 whereas others using either the same 
mice or a HFE-mutated patient suggest that inflammatory induction of hepcidin is 
independent from the HFE protein.77,78 Clearly, future large and well-designed studies are 
needed to better understand this hepcidin regulatory network in various disorders of iron 
metabolism.
Hepcidin methods
Since the discovery of hepcidin, there has been a substantial interest in developing a reliable 
assay of the peptide hormone in body fluids. Accurate determination of hepcidin 
concentrations in serum and urine will improve our understanding of iron metabolism 
disorders and may provide a useful tool in the differential diagnosis and clinical management 
of such diseases.
Challenges for hepcidin assays
The quantification of hepcidin has been found to be complicated by its tendency to 
aggregate79 and to stick to laboratory plastics, necessitating implementation of robust 
laboratory procedures. Furthermore, progress in developing a conventional 
immunochemical hepcidin assay has been hampered by difficulties to generate specific anti- 
hepcidin antibodies in hosts such as rabbit. This is due to: i) the small and compact structure 
of hepcidin leaving scarce antigenic epitopes (Figure 1), and ii) the high degree of 
conservation of hepcidin among a wide range of species, diminishing the elicitation of an 
immune response in host animals.50
15
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Interpretation of hepcidin test results might be influenced by whether the various assays are 
detecting freely circulating hepcidin, hepcidin bound to a carrier protein or both these 
hepcidin species. Lastly, the presence of hepcidin-22 and -20 isoforms, which play no role in 
the regulation of iron metabolism, can interfere with the quantification of hepcidin-25 in 
immunoassays that use antibodies that react with all these hepcidin isoforms.
First generation (semi-quantitative) hepcidin assays
Several early studies utilized a commercial serum-based immunoassay that measures the 
hepcidin precursor prohepcidin rather than the bioactive peptide.80 The relevance of these 
studies is questionable, due to the fact that prohepcidin concentrations correlate with 
neither urinary and serum hepcidin concentrations, nor do they correlate with relevant
71 81-83physiological responses. , - The first assays to measure bioactive hepcidin-25 were an 
immunodot assay,59 and Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass
12 15 84Spectrometry assays (SELDI-TOF MS). , , However, these assays were only able to 
measure hepcidin in semi-quantitative manner.
Second generation (quantitative) hepcidin assays
In recent years, substantial progress was made by the introduction of an internal standard to 
quantify hepcidin-25 in serum and urine by an updated TOF-MS assay.13,30 In addition, Ganz 
et al.29 developed a competitive (c)ELISA for human serum hepcidin. Other groups have also 
reported reliable hepcidin assays that can be divided in three main methodologies: i) mass 
spectrometry,85-95 ii) immunochemical assays, comprising c-radioimmunoassay (cRIA),96,97 
cELISA,13,29,98,99 and a 2-site ELISA,100 iii) and a ligand-binding assay43 (Table 1). Of the 
currently available commercial immunochemical research kits for serum hepcidin, we found 
the RIA and enzyme-immunoassay (EIA) kits of Bachem (Bachem LTD, purchased November 
2009 and August 2010, respectively) to be suitable to differentiate between hepcidin 
concentrations in serum samples of controls and patients with various iron disorders, 
whereas the bioactive hepcidin kit of DRG (DRG Instruments GmbH, purchased October 
2009) gave similar concentrations for all samples and could not discriminate between iron 
metabolism disorders (Kroot, Geurts-Moespot, Swinkels, unpublished results).
Table 1. Currently available hepcidin methods.
Mass Spec. Reference Immunochemical Reference Hepcidin binding Reference
HPLC-UPLC MS/MS 87,88 c-ELISA 13,29,98,99 ^ c h e m  lt d , UK) Q-TOF LC/MS 92
LC-MS/MS 85,86,89 c-RIA 96,97 (Bachem LTD, UK) HBD Assay 43
MALDI-TOF MS 13,30,91 Sandwich ELISA 100
SELDI-TOF MS 90,94,95
MS, mass spectrometry; LC, liquid chromatography; HPLC, High-Performance LC; UPLC, ultra-high pressure LC; 
MS/MS, tandem MS; MALDI, matrix assisted laser desorption/ionisation; SELDI, surface enhanced laser 
desorption/ionisation; TOF, time-of-flight; c-ELISA, competitive enzyme linked immuno sorbent assay; RIA, 
radio immuno assay; Q, quadrupole; HBD, hepcidin binding domain.
Strengths and limitations of current plasma and urine hepcidin assays
Mass spectrometry (MS) assays require relatively expensive equipment, but they have the 
advantage of distinguishing between hepcidin-25, -22 and -20.13 ELISA assays will measure 
total hepcidin concentrations, with (depending on the specificity of the antibody) different 
contributions from each of these three isoforms. However, this concern might be overcome 
by exploiting antibodies that are hepcidin-25 specific.100 At the same time it should be noted 
that the relevance for measuring hepcidin-25 instead of total hepcidin for clinical decision
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making has not been systematically investigated yet. Immunoassays have the potential for
more widespread use in clinical laboratories. Furthermore, sample throughput is likely to be
101,102higher for ELISA than for MS assays. However, MS methods can also be automated, , 
which would have to be optimized for hepcidin as its amphiphatic character makes it readily 
stick to laboratory plastics, especially when using relatively small sample volumes in large 
tubes.
Further comparison of the analytical characteristics of various published assays is 
incomplete, because not all studies have reported these characteristics in accordance with 
the STARD (STAndards for the Reporting of Diagnostic accuracy studies) procedures103 or 
validated the reported assays according to recommendations of the International 
Conference of the Harmonization (ICH) of analytical procedures.104 Nonetheless, the 
scientific and medical community was informed on the status and agreement of the current 
hepcidin methods by a recent international send-out of samples for urine and serum 
hepcidin measurement in 2009, the so called "Round Robin 1". In this study the correlations 
between the participating methods were generally high and the between-sample and 
analytical variation of most methods were similar.105 However, absolute hepcidin 
concentrations differed widely between the assays. This latter variation is not surprising 
given the absence of a reference methodology106 and a validated commutable calibrator or 
other material for assay harmonization. These differences in level assignment hinder the 
comparability of data collected by the various methodologies and preclude the definition of 
universal reference intervals and cut-off values for clinical decision making. Therefore, a 2nd 
Round Robin for plasma hepcidin was initiated to explore word-wide hepcidin harmonization 
by exchanging synthetic materials for assay harmonization. and native samples. Results are 
expected during 2011 (Kroot, van Herwaarden, Swinkels, et al. unpublished data).
Urine hepcidin measurements may be attractive especially for research, children and the 
underdeveloped world, because this matrix allows non-invasive sampling. Nevertheless, 
although a significant relationship was found between the hepcidin concentrations of urine- 
serum sample pairs from healthy controls and patients with disorders of iron 
metabolism,12,29,107 urine hepcidin concentrations may not always accurately reflect serum 
hepcidin concentrations. Interpretation of urinary hepcidin data is difficult because urine 
concentrations may also depend on glomerular filtration, tubular reabsorption, local 
production by tubular epithelial cells,25 and production by interstitial inflammatory cells.108 
These issues make measurement of hepcidin somewhat disadvantageous in urine compared 
to serum, and imply that for reliable interpretation of urine hepcidin concentrations as an 
alternative for serum concentrations, information on renal hepcidin production and handling 
is needed. Moreover, in a previous study we found a relatively high (pre)-analytical variation 
for urine hepcidin measurements.107 Another potential drawback of urine hepcidin 
measurements is its sensitivity for oxidation30 and the relatively high concentration of the 
smaller hepcidin isoforms, which cannot be distinguished from hepcidin-25 by most 
immunoassays. Altogether, these limitations should be kept in mind during the 
interpretation of urine hepcidin data and the decision to develop dedicated point-of-care 
devices for urine hepcidin measurements.
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Reference intervals for serum hepcidin
Small and large studies of healthy controls report considerable inter-individual variation in 
hepcidin concentrations, resulting in wide "reference" intervals.12,29,96,97,107,109 This suggests 
that reference intervals may have limitations when used for the interpretation of individual 
hepcidin concentrations. It appears that hepcidin values, like other hormones, should be 
interpreted in the context of other indices of iron metabolism. For instance, it is possible 
that "normal" concentrations of hepcidin in iron deficiency anemia (IDA) are inappropriately 
high, and perpetuate iron restriction.
The wide reference intervals may at least partly be attributed to the increase of hepcidin
concentrations in the course of the day.12,29,96,97,107 This apparent circadian rhythm of 
hepcidin concentrations may be regulated by transcription factors such as Upstream 
Stimulatory Factor (USF) and c-Myc/Max through E-boxes.110 Genes that are regulated 
through E-boxes, including the Clock genes PER1, TIMELESS and CLOCK, tend to be under 
circadian rhythmic transcriptional control. However, circadian variation in hepcidin could be 
secondary as well, since it might be driven by the influence of iron intake during the day. As 
such, we recommend standardization of sampling time to minimize within-subject and 
(pre)analytical variability in clinical studies exploiting hepcidin measurements.
To date, difference in hepcidin concentrations between the sexes has not been consistently 
found.12,29,85,96,97,107 We recently assessed age and sex stratified serum hepcidin reference 
intervals in a reference set selected from a large, well-phenotyped sample of the general 
population of the Dutch city of Nijmegen.109 We observed lower serum hepcidin 
concentrations in premenopausal women than for post menopausal women (median 4.1 
nmol/L vs 8.5 nmol/L).109 Hepcidin concentrations in men were constant over age (median 
7.8 nmol/L). In this study serum hepcidin was strongly associated with serum ferritin in men
29,30,107,111,112and women, confirming findings of smaller previous studies. , , , , Hepcidin 
concentrations have not been consistently compared between races and there are few
113-120studies in children. - To the best of our knowledge there are 2 studies reporting hepcidin 
concentrations in pregnant women, which both show that hepcidin of anemic pregnant 
women is lower than in non-anemic pregnant women, but are not related to cord-blood or
114,121newborn hepcidin, or other fetal iron parameters. ,
As discussed before, basal hepcidin concentrations greatly depend on the applied 
methodology.105 This implies that until harmonization is achieved, reference intervals as well 
as clinical decision limits for certain patient populations specific to the assay methods should 
be used. Harmonization of the methodologies, by using reliable calibrators or other 
materials for harmonization will enable translational scientists as well as physicians in clinical 
practice around the world to collectively define criteria for the use of hepcidin assays in 
diagnosis, staging, monitoring and assessing treatment indication of iron disorders.
Hepcidin in human iron disorders
The development and validation of hepcidin assays paved the way for a large number of 
human studies that considerably increased our understanding of the physiology and 
pathophysiology of iron homeostasis and moreover demonstrated promising applications for 
hepcidin in diagnostic medicine (Table 2).
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Disorders associated with hepcidin deficiency 
Hepcidin in hereditary hemochromatosis
Hereditary hemochromatosis (HH) comprises several genetic disorders of iron homeostasis 
characterized by body iron excess. This results in body iron overload which can progress to 
organ injury, such as liver fibrosis and cirrhosis.122 Patients with most forms of HH have the 
inability to appropriately upregulate hepcidin synthesis in response to increased iron stores. 
This dysregulation is caused by defects in the synthesis of certain positive regulators of 
hepcidin (HFE, TfR2, HJV) or, rarely, hepcidin (HAMP) itself (reviewed in 123,124). The low 
hepcidin state relative to ferritin in these patients,125-127 leads to increased intestinal iron 
absorption and body iron overload. Hepcidin concentrations in untreated patients with rare 
juvenile forms of HH, tend to be very low.127 Mutations in the gene encoding the cellular iron 
exporter ferroportin can also cause HH. However, there are two classes of ferroportin 
mutations with different phenotypic consequences: 1) loss-of-hepcidin-regulation and 2)
36,128-130loss-of-ferroportin-function. , - The former defect leads to greater than normal 
ferroportin activity and thus is often described as a "gain of function" ferroportin mutation. 
As expected, patients with these mutations have a phenotype similar to classical HH. 
However, because the defect is "downstream" of hepcidin, these patients do not have low 
hepcidin concentrations. After treatment with phlebotomy that normalized iron stores (as 
assessed by serum ferritin) these patients have been found to have normal to increased
128 131serum hepcidin concentrations. , The relatively high hepcidin concentrations in some 
patients might be a consequence of the transferrin saturation that remained increased 
despite phlebotomy. By contrast, mutational defects that result in the loss of ferroportin 
function cause cellular iron overload due to compromised iron export. Such patients thus 
have some phenotypic characteristics which vary from classical HH, and have been reported 
to have high (urinary) hepcidin concentrations when untreated.127
Iron depleted HFE C282Y patients have been shown to have very low serum hepcidin 
concentrations, reflecting the combined effects of the HFE mutation and phlebotomy on 
hepcidin expression.125,132 These patients demonstrated an exaggerated increase in serum 
iron concentrations upon oral iron loading.132 This observation draws further attention to the 
concern that lowering hepcidin concentrations by phlebotomy in HH patients may 
exacerbate the underlying pathophysiology, exacerbating the excess release of iron into the 
circulation, with an ensuing vicious circle of more frequent maintenance phlebotomies in HH 
patients.125,126
We foresee the following potential applications of hepcidin measurements in patients 
diagnosed with or suspected for HH: i) screening for the presence of HH in patients with 
increased ferritin concentrations, ii) prioritization of genes to be investigated (very low 
hepcidin concentrations point to juvenile HH forms), iii) prediction of which C282Y- 
homozygous patients will be at risk for iron overload and iv) monitoring of phlebotomy 
treatment.123,133
Hepcidin in iron loading anemia's
In congenital iron loading anemias, such as 3-thalassemia (major and intermedia) and 
congenital dyserythropoietic anemia (CDA) I and II, but also in acquired forms such as 
myelodysplastic syndrome (MDS) types RA (refractory anemia) and RARS (RA with ring 
sideroblasts), the diseased erythron dysregulates iron homeostasis by inhibiting hepcidin 
synthesis, even in the presence of iron overload.134-140 The hepcidin/ferritin ratio is also
135,137,138,140-142found to be low in patients with these disorders,135,137,138,140-142 The consequences of
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ineffective erythropoiesis on hepcidin expression thus appear to trump the consequences of 
excessive iron stores. In sickle cell disease (SCD), patients demonstrate the additional 
confounding factor of inflammation. Possibly the consequent increase in hepcidin by 
inflammatory signals attenuates iron toxicity than would otherwise be observed in SCD 
patients.141,143
In patients with heritable forms of anemia, information on hepcidin concentrations may be 
of value i) to identify the most severely affected patients and ii) to predict and monitor 
parenchymal iron overload.
Hepcidin in acquired forms of non-hemochromatotic iron overload
Several non-hereditary liver diseases such as excessive alcohol consumption, nonalcoholic 
fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are associated with mild 
hepatic iron overload. In these so called non-hemochromatotic iron overload diseases, 
hepcidin concentrations are increased, but relatively low for the level of iron overload, 
suggesting ineffective liver iron sensing. In these conditions, dysregulation of hepcidin 
synthesis as a consequence of reactive oxygen species, ER stress and cytokine tumor 
necrosis factor-a (TNF-a)-mediated pathways may contribute to relatively decreased 
hepcidin synthesis and iron accumulation.59,67-70,144 Measurement of serum hepcidin may 
prove to be useful as a marker of iron dysregulation in these forms of iron overload.
Hepcidin in iron deficiency anemia
In IDA, but also in patients with low ferritin concentrations without anemia secondary to 
blood losses or insufficient dietary intake, hepcidin concentrations have been found to be 
very low, often below the lower limit of detection of the employed assays.13,29
Effect of Iron administration on hepcidin concentrations
Several studies have addressed the relationship between iron absorption and hepcidin 
concentrations. In healthy human volunteers hepcidin in urine and serum increased upon 
oral iron dosing, although non-responders were reported.29,59,112,145-147 Some studies report a 
weak, but significant negative correlation between serum hepcidin concentrations and iron
112,146,147absorption. , , These results suggest that quantification of serum hepcidin 
concentrations could be a predictor for the therapeutic effect of oral iron administration. 
Moreover, the response of the hepcidin to oral iron might prove to be a useful test to 
evaluate iron absorption in iron deficiency.
Disorders associated with hepcidin excess 
Hepcidin in Iron Refractory Iron Deficiency Anemia
Most patients with iron refractory iron-deficiency anemia (IRIDA) are resistant to dietary iron 
supplementation, due to a defect in the TMPRSS6 gene encoding Matriptase-2. Repeated 
intravenous iron infusions on the other hand have been reported to (partially) increase Hb
119,120,148-151and mean cell volume. , , - Loss of Matriptase-2 activity results in an inability to 
reduce hepcidin synthesis during iron deficiency.49 Accordingly, patients have increased 
innate hepcidin concentrations resulting in extremely low transferrin saturation percentages
118,119,120,148-151and low to normal ferritin concentrations. , , , - Therefore, assessment of hepcidin 
concentrations can serve to exclude or raise the suspicion for Matriptase-2 deficiency in 
unexplained iron deficiency anemia. This could help to avoid unnecessary burden associated 
with multiple diagnostic testing and delayed or ineffective treatment.
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Hepcidin in infection and inflammation
Infections are associated with marked changes in iron homeostasis.152 Malaria-associated 
anemia has been found to be associated with low serum iron and increased hepcidin 
concentrations, causing iron withholding in the RE system that ultimately leads to iron-
115,118,153-156restricted erythropoiesis. , , - Possibly, these increased hepcidin concentrations might 
be advantageous in the protection against extracellular growing micro-organisms by 
decreasing the extracellular supply of iron. On the other hand, increased hepcidin 
concentrations may lead to iron deficiency and blunt the efficacy of iron fortification 
programs by decreasing iron absorption.157 Conversely, the increased hepcidin 
concentrations seen with inflammation might increase the virulence of bacteria which 
depend upon macrophage iron for their proliferation within these cells (e.g. Salmonella and 
Mycobacteria spp.). Such pathogens are common in malaria-endemic regions. Perhaps in 
such areas, untargeted iron supplementation among iron-replete children might result in 
severe adverse events by increasing the proliferation of latent pathogens.158 
Hepcidin has been demonstrated to be important in the pathogenesis of other infectious 
agents as well. In patients with hepatitis C virus (HCV), increased transferrin saturation and 
increased concentrations of serum ferritin and hepatic iron have been observed. Consistent 
with this iron loading, low hepcidin concentrations have been found in these patients, along 
with other changes in the expression of iron-transport genes (reviewed in 159). In a pediatric 
study, no relationship was found between H. pylori infection and hepcidin and between 
cytokine and hepcidin concentrations, suggesting that H. pylori-induced inflammation does 
not influence iron status through increased hepcidin production in childhood.118 
In ACD, IL-6 and other cytokines induce hepcidin concentrations, resulting in iron 
sequestration in macrophages leading to hypoferremia. Subsequently, iron availability for 
the erythron becomes limiting and contributes to the development of ACD.59,75,81,160,161 
Elderly people often suffer from anemia. In a recent study among elder subjects (> 65 years), 
the presence of anemia could not be attributed to increased hepcidin concentrations, as 
urinary hepcidin concentrations were significantly lower among participants with 
inflammation anemia and iron deficiency, compared with non-anemic controls. This finding 
raises the possibility that in this population hepcidin-independent mechanisms can cause 
hypoferremia and anemia of inflammation, and/or that even otherwise "normal" hepcidin 
concentrations are sufficient to sustain anemia once it is initiated.162
At present, there is no single laboratory test that can definitively distinguish ACD from
160,163IDA. , Therefore, differentiation between these conditions is often achieved by 
combining various biochemical markers of iron metabolism. Studies to assess the role of 
hepcidin in ACD are complicated by the lack of a gold standard methodology. As a result the 
outcomes of studies to assess the diagnostic value of hepcidin largely have depended on the 
definition of surrogate gold standards. Some studies found that hepcidin is an appropriate 
marker in the differentiation of ACD and IDA/ACD but not of IDA and IDA/ACD,75 whereas 
others have reported that hepcidin allowed distinguishing IDA from IDA/ACD but not ACD 
from IDA/ACD.13,164 Another study has suggested that hepcidin concentrations can serve as 
an appropriate marker to differentiate between all three groups.165
Hepcidin measurements appear to have potential utility in diagnostic algorithms to 
distinguish IDA from ACD and the combined presence of IDA/ACD. Further studies in which 
hepcidin response to iron supplementation is used as a proxy for the gold standard of iron
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status would be informative. Hepcidin measurement also may be useful in anticipating 
consequences of iron supplementation in infectious and inflammatory diseases.
Hepcidin in renal diseases
The introduction of ESA, such as EPO, has allowed effective treatment of anemia in patients 
with CKD. However, the optimal target concentration of hemoglobin is debated and many 
patients become ESA-resistant. Soon after its discovery and the years thereafter hepcidin 
was recognized as potentially relevant in CKD as it may be responsible for the often 
observed imbalance between iron homeostasis and ESA resistance.50,166 As such hepcidin 
was described as a promising companion diagnostic to predict ESA responsiveness, and to 
guide treatment with ESA and intravenous iron. In addition, hepcidin's potential to become a 
target of treatment was quickly acknowledged. These promises brought about a large series 
of studies that examined hepcidin concentrations in patients with CKD. In general, these 
studies have reported increased hepcidin concentrations as compared with healthy 
controls.15,16,29,31,32,88,89,96,167-169 Because these patients tend to be anemic, even a mild 
hepcidin excess can be considered to be inappropriately high for the level of anemia. 
Virtually all studies on hepcidin in CKD patients reported a strong positive relationship 
between hepcidin and ferritin concentrations. Some of these studies also found correlations
169,170between hepcidin and iron or transferrin saturation. , Hepcidin in CKD also has been 
associated with iron restricted erythropoiesis, as reflected by the relation of hepcidin with
31 169 171lower Hb and/or reticulocyte counts. , , Furthermore, CRP and IL-6 were shown less
16,170,172-175relevant predictors in the setting of renal insufficiency.16,170,172-175 Intravenous iron 
administration was found not to influence hepcidin concentrations in hemodialysis (HD) 
patients that were withheld from iron and ESA therapy for 2 weeks,169 whereas it increased 
hepcidin in iron naive CKD patients.31,96 In HD patients on ESA, hepcidin did not predict which 
patients increase their Hb after iron loading.17 As mentioned earlier, several papers have 
reported a decrease in hepcidin concentrations after erythropoietin 
administration.31,50,169,170 This again suggests that the erythroid demand for iron might be a 
more powerful regulator of hepcidin expression than inflammatory or iron induced hepcidin 
formation. To allow proper interpretation of the effect of the erythropoietic drive on 
hepcidin production, EPO and hepcidin concentrations should be assessed simultaneously in 
selected patients with anemia of CKD.
Interestingly, hepcidin also was evaluated as a predictor of ESA response in several relatively 
small human studies. One study found that hepcidin concentrations of EPO responders did 
not differ from those of the hypo-responders,176 whereas cross-sectional studies among HD 
patients and a prospective study among patients with combined CKD and chronic heart 
failure (CHF), reported that non-responders had low hepcidin concentrations.32,170,177 
Possibly hepcidin should be regarded as a marker of response rather than resistance to ESA 
treatment in these patients.
Although hepcidin is a promising companion diagnostic for ESA therapy, patients with renal 
insufficiency are a rather complex population in which consistent results have been difficult 
to obtain.175 Clinical stability, time of sampling in relation to iron and ESA therapy, and iron 
and EPO dosage and dialysis regimes differ between studies and are likely to influence 
results. Therefore, there is need for further studies on serum hepcidin concentrations in 
larger and well-designed studies to resolve the aforementioned discrepancies in the 
literature.
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In addition to its potential as a marker of iron metabolism in patients with CKD, combined 
urinary and serum hepcidin concentrations may serve as a marker for renal disease itself. For 
instance, studies suggest that smaller increases in urinary hepcidin, relative to serum 
hepcidin, may be associated with a greater risk of acute kidney injury (AKI) after coronary
178 179artery bypass graft (CABG) surgery in patients with stable renal function. , In a study on 
urine biomarkers in patients with lupus nephritis, urinary concentrations of hepcidin, 
possibly secreted by interstitial inflammatory cells, were identified as markers of renal lupus 
nephritis flare.108
Hepcidin in obesity related diseases
Adipose tissue is an active endocrine organ that releases several cytokines and adipokines, 
which can contribute to the development of a low-grade systemic inflammation. 
Furthermore, adipose tissue also can produce hepcidin.21 The low-grade inflammation in 
obese and dysmetabolic iron overload syndrome (DIOS) patients, (characterized by the 
association of increased body iron stores and metabolic features), is associated with
117 180-182increased hepcidin concentrations, leading to poor iron absorption and causing ACD. , - 
Serum hepcidin concentrations decreased, and an increase in iron status and intestinal
183 184absorption was observed in individuals with weight loss. , Thus, in chronic mild 
inflammatory conditions, such as obesity or the metabolic syndrome, even a mild hepcidin 
excess may be sufficient to alter the balance between iron loss and iron uptake towards iron 
deficiency.
Hepcidin in heart diseases
Anemia of CHF has found to be associated with low hepcidin concentrations, making (low-
185 186grade) inflammation less likely as the sole underlying mechanism. , A study on acute 
cardiac ischemia showed a transient increase in serum hepcidin-20 concentrations for the 
majority of patients studied, whereas hepcidin-25 remained increased 7 days after the 
incident. The authors concluded that hepcidin-20 rather than hepcidin-25, may be helpful for 
the diagnosis of acute myocardial infarction.14 Several reports suggest the potential use of 
hepcidin concentrations in determining cardiovascular risk. It has been hypothesized that 
increased hepcidin concentrations may enhance cardiovascular risk, by increasing 
intracellular macrophage iron concentrations, and by increasing their atherogenic
187-190potential. - Furthermore, recent studies reported increased hepcidin production in 
patients with (low-grade) inflammation, obesity and NAFLD, which are traditionally
21 144 191 192associated with cardiovascular disease (CVD). , , , Additional data suggesting an 
atherogenic function of hepcidin were reported in a study which found that ex vivo hepcidin- 
25 treatment of differentiating monocytes from patients with the metabolic syndrome, 
induced the monocyte chemoattractant protein (MCP)-1.193 Moreover, hepcidin 
concentrations in these patients were associated with increased concentrations of MCP-1 
and vascular damage. These observations raise the possibility that hepcidin may prove to be 
a novel determinant for CVD risk.
Hepcidin in cancer
Patients with cancer often suffer from anemia, generally in association with other markers of 
inflammation. Studies in patients with multiple myeloma suggest that hepcidin is 
upregulated in these patients by both IL-6 dependent and IL-6 independent mechanism that 
may play a role in the anemia often observed in these patients. The IL-6 independent
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pathway may be attributed to increased BMP-2 concentrations, which have been suggested 
to act synergistically with IL-6 to induce hepatocyte hepcidin synthesis.194,195 
For Hodgkin lymphoma we recently demonstrated that increased IL-6 production is 
associated with an induction of hepcidin, which contributes to the iron-restricted anemia of 
chronic disease often observed at Hodgkin lymphoma diagnosis. However, in this study 
increased hepcidin concentrations appeared insufficient for the development of anemia,196 
suggesting that compensation by increased erythropoiesis through increased EPO 
production may explain the lack of anemia in cancer despite increased hepcidin
197concentrations.
In a study among anemic cancers patients receiving ESA therapy, those with relatively low 
hepcidin concentrations at baseline showed a better response.198 Surprisingly, these results 
are not fully consistent with those found for patients with CKD (see above), but suggest that 
baseline hepcidin concentrations may play a potential role as a predictive marker to identify 
patients who either are going to respond adequately to EPO therapy or need to be excluded 
from anemia correction with ESA due to a low chance of responding.
Although the number of studies on the role of hepcidin in the anemia of cancer is limited, 
these studies have contributed to our insights regarding the mechanisms involved. Future 
studies are needed to assess the position of hepcidin in clinical decision making in these 
patients.
Hepcidin in sports medicine
The prevalence of iron deficiency is high among athletes. A number of exercise-generated 
mechanisms may contribute to this low iron status of athletes, including hemolysis,
199 200-202 203hematuria, sweating and gastrointestinal bleeding. Recently, several - but not all 
studies found increased urinary hepcidin concentrations after exercise. These findings of 
increased hepcidin concentrations made Peeling et al. propose that exercise-induced 
increase in hemolysis and hepcidin expression may have two effects. First, any post-exercise 
free iron uptake by the reticulo-endothelial macrophages may be trapped within the 
scavenger cell due to the action of hepcidin on the ferroportin transporters, thereby 
affecting the recycling of iron back into the circulation. Second, an increased hepcidin 
activity post-exercise may reduce the absorption of iron from the diet.204 Hepcidin might 
thus be a mediator of the high incidence of iron deficiency amongst athletes.
Hepcidin modulating agents
Hepcidin-targeted therapies may improve treatment options for patients suffering from iron 
disorders. Although no specific hepcidin therapies are available yet, several compounds are
205 207under development as hepcidin agonists or antagonists (reviewed in - ). Hepcidin 
agonists could be useful to prevent iron overload attributed to hepcidin deficiency, such as 
HH, and especially 3-thalassemias and other iron-loading anemias, and possibly some 
acquired forms of non-hemochromatotic iron overload diseases. Hepcidin antagonists, on 
the other hand, might be expected to benefit patients with diseases of hepcidin excess 
manifested as iron-restricted anemia and systemic iron deficiency, such as IRIDA, ACD 
(rheumatic diseases, inflammatory bowel diseases, auto-immune diseases) CKD, multiple 
myeloma and other cancers, obesity-related iron deficiency and CVD.
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Hepcidin agonists
Pre-clinical and some clinical studies have provided proof-of-concept for synthetic hepcidin-
25, small hepcidin peptides, BMP agonists, and HIF stabilizers to prevent iron overload 
attributed to hepcidin deficiency.
Small hepcidin peptides based on its amino-terminal domain have been shown to act as 
agonists in mice in vivo.207 Gardenghi et al. reported that transgenic hepcidin overexpression 
in ß-thalassemia intermedia mice decreased iron overload, and even ameliorated ineffective 
erythropoiesis.208
Table 2. Most promising applications of serum hepcidin in diagnostic medicine.
Disease Condition Expected hepcidin levels* Potential added value of 
Hepcidin diagnostics
Classical hereditary 
hemochromatosis
low, maybe compensated by iron 
overload over time
• screen for the presence 
of hemochromatosis
• predict which homozygotes 
will be at risk for iron overload
• determine the phlebotomy 
interval
• prioritization of genes to 
be investigated
Iron loading anemia's low, maybe compensated by 
transfusional iron overload over 
time
• identify the most severely 
affected patients
• predict and monitor 
(parenchymal) iron overload
Acquired forms of iron 
overload
miscellaneous • a marker of iron dysregulation
Iron refractory iron 
deficiency anemia
inappropriately high • screen for primary defect 
in hepcidin regulation
Inflammation and infection high • differentiate ACD and IDA
• guide iron supplementation 
therapy
Chronic kidney diseases high, decreases upon EPO treatment • to predict EPO response
• to guide treatment with 
EPO, iv iron
Kidney diseaseA high (urine) • to diagnose kidney injury
Treatment by hepcidin 
antagonists and agonists
depending on the disorder • monitoring and assessment 
of indication
ACD, anemia of chronic disease; IDA, iron deficiency anemia; EPO, erythropoietin.
*, In serum, unless stated otherwise.
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Hepcidin concentrations can also be induced by targeting the BMP pathway (Figure 4). BMP-
2 administration in mice was found to increase liver hepcidin expression and reduce serum 
iron concentrations in vivo.209 Supra-physiological doses of exogenous BMP-6 for 10 days 
also were reported to improve hepcidin deficiency, reduce serum iron and redistribute tissue
iron to appropriate storage sites (RE macrophages, spleen) in a mice model for Hfe
210 211 hemochromatosis. HIF antagonists are used in cancer to inhibit tumor angiogenesis.
Blocking HIF could also be of interest to increase hepcidin concentrations in iron overload
diseases.
Hepcidin antagonists
Pre-clinical and clinical studies have also shown that hepcidin antagonists such as hepcidin 
antibodies, BMP antagonists, cytokine receptor antibodies and HIF stabilizers can decrease
209 212-219hepcidin expression and reverse iron abnormalities.209,212-219
In a proof-of-principle study, Sasu et al. neutralized hepcidin by a monoclonal antibody in the
B. abortus mouse model of anemia of inflammation and found it to restore responsiveness 
to erythropoietin.212 This study suggests that administration of anti-hepcidin therapies alone 
or in combination with erythropoiesis stimulating agents may improve patients' 
erythropoietic response and allow the use of lower erythropoietin doses to avoid the 
potential detrimental effects of high EPO concentrations. Notably, monitoring of the 
bioactive serum hepcidin during treatment by these hepcidin antagonists appears to be 
complicated by the interference of the compounds in the assays.220
Several components can interfere with the BMP-SMAD pathway. Administration of 
Dorsomorphin, a small inhibitor of BMP signaling, prevented hepcidin induction by iron in 
mice.213 GDF-15 and TWSG-1 are both BMP antagonists produced by erythroblasts and 
putative components of the erythroid regulator that can inhibit hepcidin expression in vitro. 
Although their physiological relevance remains to be defined, these proteins might have 
therapeutic potential. Soluble HJV, also acting as a antagonist of BMP signaling, decreases 
hepcidin baseline expression in mice, mobilizes RE-system (splenic) iron stores, increases 
liver iron content and concurrently increased serum concentrations.209 Also, heparin and 
heparin derivatives have recently been shown to inhibit hepcidin expression in vitro and in 
vivo by interfering with BMP signaling.219
Anti-IL-6 antibody (tocilizumab) was shown to suppress IL-6 induced hepcidin production in 
Castleman disease (a rare disorders with systematic inflammation and anemia) and 
improved anemia in arthritic monkeys.215-218 Inhibitors of the key initiators of the cellular 
hypoxic response such as prolyl hydroxylases prevent inactivation and degradation of HIF
and as such could also be effective hepcidin suppressors, and restore the natural iron
221,222regulation in anemia. ,
To assess the efficacy of the hepcidin-related therapies there is an increasing demand for 
pre-clinical tools. Therefore, the diagnostic toolbox for hepcidin peptide measurements in
75,220,223animal models should preferably be improved and extended. , , Moreover, well- 
designed large clinical studies addressing safety and long-term efficacy are needed to clarify 
the risks and benefits of hepcidin-targeted treatments.
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Concluding remarks
Since the discovery of hepcidin 10 years ago, multiple studies have contributed insights into 
the regulation of hepcidin and its functional properties. The first reliable assays to quantify 
hepcidin in human body fluids have recently been developed, and proof-of-principle studies 
in human iron disorders highlight hepcidin as a promising novel tool in diagnostic medicine 
as outlined in Table 2. However, the use of different assay technologies to assess hepcidin 
concentrations in patients with disorders of iron metabolism makes interpretation of results 
throughout the literature sometimes difficult. For instance, it should be realized that the 
accumulation of hepcidin-22 and -20 isoforms could interfere with the interpretation that 
the measured concentrations reflect bioactive hepcidin-25 when certain immunoassays 
were used. Moreover, there is a need for harmonization of the various assays to enable 
world-wide reference intervals and clinical decision limits. Large and well-designed studies 
exploiting harmonized assays are required to more firmly establish the position of hepcidin 
in diagnostic medicine. Furthermore, as the field moves towards the use of hepcidin-related 
therapies, it should be realized that the outcome of assays that are used to monitor the fate 
of hepcidin during anti-hepcidin therapy, may very well be affected by the hepcidin- 
interfering compounds. In these cases, assays need to be re-validated for this specific 
application before definite conclusions on the efficacy of the therapy can be drawn. In 
conclusion, hepcidin is a promising diagnostic tool but efforts need to be undertaken to 
assess the relevance of specifically measuring hepcidin-25, to harmonize assay outcomes 
throughout the world, to define clinical decision limits, and to make assays available to the 
clinical laboratories before hepcidin assays can be fully included in clinical practice.
Scope of this thesis
The aim of this thesis was i) to develop, improve and compare our in house hepcidin assays 
and assess the importance of a low (pre)analytical variation, ii) to analytically compare and 
harmonize the world wide available hepcidin assays and iii) to perform proof-of-principle 
studies on hepcidin as a biomarker in different iron metabolism disorders.
Chapter 2 describes the development, optimization and comparison of in house hepcidin 
assays, performed on mass spectrometry and immunochemical platforms. A good 
correlation was found between the assays when applied to samples of patients with various 
diseases, but only the mass spectrometry methodology was suitable to separately quantify 
hepcidin-25 and its smaller isoforms hepcidin-22 and 20, of which the biological function is 
not known yet. Based on the results of the study of the diurnal rhythm of hepcidin in urine 
and serum in Chapter 3 we recommend that to minimize variability, sampling time should be 
standardized and measurements should be done in serum. To further assess causes of 
variation in hepcidin results, we then set up an international study to determine the 
analytical variations and level assignments of worldwide available hepcidin assays. The large 
differences in absolute plasma hepcidin values between the international hepcidin assays, 
presented in Chapter 4, motivated us to make the first steps towards harmonization. 
Therefore, in Chapter 5, we developed an algorithm to enable the worldwide hepcidin 
community to report in international hepcidin consensus (HEPCON) values, which will 
facilitate the definition of universal reference ranges and clinical decision limits.
Chapters 7-9 illustrate the suitability of hepcidin measurements to increase our 
understanding of the pathophysiology of disorders of iron homeostasis. Chapter 7 describes 
the regulation of hepcidin by inflammation in a hemochromatosis patient, suggesting that 
chronic inflammation protects patients with hemochromatosis from iron accumulation and
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supports the importance of an HFE-independent cytokine-hepcidin axis in the development 
of hypoferremia and anemia of inflammation. Findings of Chapter 8, suggest that hepcidin 
may be an important modulator of anemia in systemic inflammation in septic patients, while 
observations of increased hepcidin levels in subjects with characteristics of the metabolic 
syndrome in Chapter 9 suggest the presence of a mechanism by which hepcidin may 
augment the risk of cardiovascular disease (Chapter 9).
Finally Chapter 2 and 6 provide data on the potential clinical utility of hepcidin, e.g. in i) the 
differentiation between iron deficiency anemia (IDA) and the combination of IDA and 
anemia of chronic disease (Chapter 2) and ii) the identification and treatment of sickle cell 
disease patients at risk of iron mediated tissue damage (Chapter 6).
In the general discussion we conclude that hepcidin is a promising diagnostic tool but efforts 
need to be undertaken to assess the relevance of specifically measuring hepcidin-25, to 
harmonize assay outcomes throughout the world, to define clinical decision limits, and to 
make assays available to the clinical laboratories before hepcidin assays can be fully included 
in clinical practice.
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Abstract
BACKGROUND: Hepcidin is an iron-regulatory peptide hormone that consists of 3 isoforms: 
bioactive hepcidin-25, and inactive hepcidin-22 and hepcidin-20. Hepcidin is instrumental in 
the diagnosis and monitoring of iron metabolism disorders, but reliable methods for its 
quantification in serum are sparse, as is knowledge of their relative analytical strengths and 
clinical utility.
METHODS: We developed a competitive (c)-ELISA and an immunocapture TOF mass- 
spectrometry (IC-TOFMS) assay. Exploiting these 2 methods and our previously described 
weak cation exchange (WCX)-TOF-MS assay, we measured serum hepcidin concentrations in 
186 patients with various disorders of iron metabolism and in 23 healthy controls.
RESULTS: We found that (a) the relative differences in median hepcidin concentrations in 
various diseases to be similar, although the absolute concentrations measured with c-ELISA 
and WCX-TOF-MS differed; (b) hepcidin isoforms contributed to differences in hepcidin 
concentrations between methods, which were most prominent in patients with chronic 
kidney disease; and (c) hepcidin concentrations measured by both the c-ELISA and IC-TOF- 
MS correlated with ferritin concentrations <60 ng/L, and were suitable for distinguishing 
between iron deficiency anemia (IDA) and the combination of IDA and anemia of chronic 
disease.
CONCLUSIONS: c-ELISA is the method of choice for the large-scale quantification of serum 
hepcidin concentrations, because of its low limit of detection, low cost, and high- 
throughput. Because of its specificity for bioactive hepcidin-25, WCX-TOF-MS can be 
regarded as a valuable special-purpose assay for disorders with variable concentrations of 
hepcidin isoforms, such as chronic kidney disease.
Introduction
Hepcidin is a hepatocyte-produced peptide hormone that regulates systemic iron 
homeostasis.1,2 The mature bioactive form of hepcidin is a 25 amino acid peptide. Other 
isoforms in human blood and urine are the N-terminal truncated hepcidin-20 and -22 
peptides, which are without apparent biological function.3 By modulating hepcidin 
production, an organism controls intestinal iron absorption, iron uptake, and mobilization 
from stores to meet the body iron need.1,2 Hepcidin concentrations are decreased in 
conditions that demand increased serum iron concentrations (i.e., increased erythropoietic 
activity and iron deficiency), whereas concentrations are increased in infection and 
inflammation.4,5
Since the discovery of hepcidin and its crucial role in iron homeostasis, there has been 
substantial interest in developing reliable assays to measure hepcidin concentrations in body 
fluids. Accurate assessment of hepcidin concentrations in serum would improve our 
understanding of iron metabolism disorders and allow hepcidin to become a useful tool in 
the differential diagnosis and clinical management of these diseases.
Few investigative tools have been available for measuring hepcidin in biological fluids.6-9 We 
and others have reported related serum hepcidin quantification methods.10-18 Assays based 
on mass spectrometry (MS)6 require relatively expensive equipment, but these methods are 
advantageous because they can be used to distinguish between hepcidin-25, -22, and -20. 
Immunoassays, on the other hand, are more accessible for clinical laboratories, but measure 
only total hepcidin concentrations. Differences in methods and their analytical performance 
hinder the comparability of hepcidin data.19
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Here we report the development and validation of a competitive (c)-ELISA as a replacement 
for our previously described RIA,17 and a novel immunocapture (IC)-TOF-MS method, which 
combines antibody-based capture of hepcidin by IC and detection by TOF-MS. We compared 
hepcidin concentrations measured by using these novel methods with concentrations 
measured with our previously described weak cation exchange (WCX)-TOF-MS assay10,18 in
186 samples from patients with different iron metabolism disorders and 23 healthy controls. 
We determined the differences in absolute concentrations, and the degree to which the 
presence of hepcidin isoforms influenced the concentrations.We assessed the extent to 
which these methods reflect physiological responses to low iron stores, and whether the 
methods were able to differentiate between samples from patients with iron-deficiency 
anemia (IDA) and those with the combined presence of IDA and anemia of chronic disease 
(ACD).
Materials and Methods
SAMPLES
For our study of 3 hepcidin assays we used serum samples from 186 patients with a variety 
of iron disorders and 23 healthy volunteers. Samples were collected from all study 
participants from February 2006 to May 2009. Blood was drawn into BD Vacutainer® SST™ II 
Advance collection tubes and centrifuged for 10 min at 3600g. Serum was then divided into 
aliquots that were placed in polypropylene tubes, stored at -80 °C, and thawed immediately 
before use. The samples were collected in accordance with protocols approved by the 
relevant institutional review boards, and informed consent was obtained in accordance with 
the Declaration of Helsinki. The definition of sample selection is described in detail in 
Addendum 1. Briefly, for the overall comparison of the 3 hepcidin assays, a total of 209 
samples were collected from (a) healthy controls (n = 23),20 (b) IDA patients (n = 10), (c) ACD 
patients (n =10), (d) multiple myeloma patients (n = 6), (e) HFE-hereditary hemochromatosis 
(HH) patients at presentation (n = 9), (f) iron-depleted HFE-HH patients (n = 8),21 (g) 
C282Y/H63D HFE compound-heterozygous HH patients at presentation (n = 5), (h) iron- 
depleted hemojuvelin-mutated HH patients (n = 3),22 (i) chronic kidney disease (CKD) 
patients (n = 84),18 (j) coronary artery bypass graft surgery patients (n =22),23 (k) septic shock 
(sepsis) patients (n=19), (l) healthy volunteers who were injected with lipopolysaccharide (n 
= 5),7 and (m) metabolic syndrome patients (n = 5).
To evaluate the clinical utility of the 3 hepcidin assays, we selected samples from 27 anemic 
patients with rheumatoid arthritis (RA), and 19 samples from patients with ferritin 
concentrations <60 ng/L, all of whom had laboratory results that excluded the presence of 
inflammation, HH, or matriptase-2 defects.24
LABORATORY MEASUREMENTS
Using an Abbott Aeroset analyzer, we measured total serum iron by the ascorbate/FerroZine 
colorimetric method, serum creatinine by enzymatic/colorimetric detection (Roche 
Diagnostics B.V.), and C-reactive protein by immunologic agglutination detection with latex­
coupled polyclonal anti-C-reactive protein antibodies (Abbott B.V. Diagnostics Division). We 
quantified serum ferritin with an Immulite 2500 immunometric assay (Siemens). Routine 
hematologic characteristics were assessed by a Sysmex XE-2100 analyzer (Goffin Meyvis).
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STUDY DESIGN
Hepcidin concentrations were measured in a blinded fashion by 3 different in-house- 
developed methods: our previously described WCX-TOF-MS assay,10,18 a c-ELISA, and IC-TOF- 
MS. The latter method was developed to measure samples with concentrations below the 
lower limit of detection (LLOD) (<0.5 nmol/L) of the WCX-TOF-MS assay.
WCX-TOF-MS and c-ELISA were used to quantify hepcidin concentrations in all 209 samples, 
whereas IC-TOF-MS was used to measure hepcidin in 25 samples with hepcidin 
concentrations below 0.5 nmol/L as assessed by WCX-TOF-MS. These samples were obtained 
from patients with IDA (n = 10), iron depleted juvenile HH (n = 3), HFE-related HH (n = 9), and 
multiple myeloma (n = 1), and from healthy female controls (n = 2).
We further explored the clinical utility of the 3 assays by using samples from 27 anemic RA 
patients, categorized by conventional parameters into 3 groups (see Addendum 1), i.e., IDA 
(n = 8), combined IDA and ACD (n = 8) and ACD (n = 11), and samples from 19 patients with 
ferritin <60 ng/L. The samples from these 19 patients with ferritin <60 |ag/L included all 10 
samples from patients with IDA included in the total group of 209 samples described above, 
and samples from 9 additional patients. In this study, we expressed hepcidin concentrations 
in nanomoles per liter (1 nmol/L = 2.789 ng/L).
BLANK AND REFERENCE SERUM, ANTIBODIES, AND HEPCIDIN ISOFORMS
The blank serum used in this study was obtained from an iron-depleted patient with juvenile 
hemochromatosis.10,22 Hepcidin concentrations in this patient were below the LLOD as 
assessed by WCX-TOF-MS.10,18
The reference sample used in the immunochemical assays (denoted 140799) was generated 
by pooling 474 routine patient serum samples collected at the Department of Laboratory 
Medicine of the Radboud University Nijmegen Medical Center. The pool was divided into 
aliquots that were placed in glass vials (500 ^L/vial), lyophilized, sealed, and stored at 4 °C. 
For the immunochemical assays we used a previously described in-house prepared 
polyclonal rabbit-antihepcidin-25 antibody.17
Hepcidin-20 [isoelectric point (pI), 8.53], hepcidin-22 (pI, 8.53), hepcidin-24 (pI, 8.51), and 
hepcidin-25 (pI, 8.22) were used to determine cross-reactivity in the various methods 
(ExPASy Proteomics Server, http://www.expasy.ch/tools/pi_tool.html). Isolated urinary 
hepcidin-20 and -22 were kindly provided by E. Nemeth, University of California, Los 
Angeles. Synthetic hepcidin-24 and -25 were obtained from Peptide International 
(www.pepnet.com).
We assessed the concentration of all hepcidin isoforms by direct MALDI-TOF-MS analysis, 
using hepcidin-24 as an internal standard. The final assigned concentration of hepcidin-25 
was identical to that provided by Peptide International (assessed by amino acid sequence 
analysis).
PREVIOUSLY DESCRIBED HEPCIDIN ASSAY
We performed WCX-TOF-MS as described previously by a combination of WCX bead-based 
hepcidin enrichment followed by TOF-MS.10,18 An internal standard (synthetic hepcidin-24; 
Peptide International) was used for quantification. Mass-to-charge (m/z) spectra were 
generated by using MALDITOF-MS (Microflex LT, BrukerDaltonics). Spectra were analyzed by 
using Bruker Daltonics FlexAnalysis software. A detailed protocol of this method is described 
in Addendum 2. Total hepcidin concentration was defined as the sum of hepcidin-25, -22, 
and -20 concentrations.
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The LLOD of this method for serum was 0.5 nmol/L, with an intraassay CV of 3.7% at 7.9 
nmol/L, 2.3% at 13.4 nmol/L, and 2.2% at 3.1 nmol/L. The interassay CV was 9.1% at 7.8 
nmol/L and 3.9% at 12.9 nmol/L. The median reference concentration of serum hepcidin-25 
has previously been determined to be 4.2 nmol/L (range 0.5-13.9 nmol/L).18
NOVEL HEPCIDIN ASSAYS 
Competitive ELISA
96-Well plates (Nunc Maxisorb™ flat bottomed) were coated overnight with goat-anti-rabbit 
IgG (Fc) antibody, blocked with BSA for 2 h, and then incubated with rabbit-antihuman 
hepcidin antibody for 2 h.17 Next, the study samples, the reference sample, and a 
biotinylated hepcidin-25 calibrator were added to the wells and incubated overnight at 4 °C. 
The plates were then incubated for 1 h with conjugate, and substrate was added for 15 min. 
The color reaction was stopped and absorbance measured at 492 nm. A more detailed 
protocol is described in Addendum 3.
Immunocapture TOF-MS
Rabbit-antihuman hepcidin antibody was first coupled to protein A sepharose beads.17 Next, 
serum and the internal standard, hepcidin-24, were incubated for 1 h with the 
beadsantibody complex. Hepcidin was then eluted from the beads with 50% acetonitrile and
0.5% trifluoroacetic acid, and 1 |aL was applied to a MicroScout Plate 96 polished steel plate, 
and mass-to-charge (m/z) spectra were generated by using TOF-MS as described for the 
WCX-TOF-MS assay. A detailed protocol is described in Addendum 4.
Validation of c-ELISA
We used hepcidin-25 as a calibrator to generate the dose-response curve for the c-ELISA. 
The analytical LLOD was estimated as the minimum hepcidin concentration evoking a 
response 2.5-fold the SD of the zero calibrator. To assess the functional LLOD, we 
constructed plots of CVs of duplicate measurements of different serum samples measured in 
several dilutions vs concentration. Duplicate CVs of the reference preparations in all hepcidin 
assays were used to assess the intra- (n = 12) and interassay (n = 40) imprecision. Assay 
specificity was tested by constructing dose-response curves for hepcidin-20, hepcidin-22, 
and hepcidin-25. The analytical sensitivity was calculated at the 95% level of confidence on 
the basis of general variance of experimental data around the calibration curves. The 
functional sensitivity was calculated from the precision profile (at 20%) constructed from the 
CVs of duplicate measurements of 953 routine samples.
All measurements were performed in duplicate. The dose-response curve was approximated 
in a sigmoid 4 parameter logistic model: y = [d + (a)d]/[1 +(x/c)b], in which x stands for the 
analyte concentration and y for the intensity measured.
Validation of IC-TOF-MS
The functional LLOD was determined as a peak intensity of a signal/noise ratio = 3. The 
intraassay CV for hepcidin-25 was determined with 3 human serum samples with 
concentrations of 0.1, 0.2, and 1.3 nmol/L, respectively (n = 8 for all samples).
Cross-reactivity of the antibody with hepcidin-24 was tested by the addition of both peptides 
(hepcidin-24 and -25) to a blank serum in a similar concentration. After the immunocapture 
procedure, the hepcidin-24 concentration relative to that of hepcidin-25 was assessed.
We calculated recovery of hepcidin-25 as described for the WCX-TOF-MS method (n = 4).
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STATISTICAL ANALYSIS
The Spearman correlation, the t-test of the independent samples, and the Bland-Altman 
analysis were used to determine relationships and differences between the various 
variables, as indicated in the results section and Figure legends. A 2-sided P = 0.05 was 
considered statistically significant. All statistical analyses were performed with Statistical 
Package for the Social Sciences (SPSS) 16.0 statistical software, except for the Bland-Altman 
plots, which were obtained by using GraphPad Prism 4.0 software (GraphPad Software). 
When hepcidin concentrations were determined to be <LLOD, a value of 0.5 x LLOD was 
assigned for statistical analysis, which implicates a value of 0.25 nmol/L for the WCX-TOF-MS 
results and 0.05 nmol/L for the IC-TOF-MS results.
Results
POPULATION CHARACTERISTICS
The population characteristics for the 209 samples from patients with various iron disorders 
are depicted in Addendum 1, Table 1.
Table 1. Analytical characteristics of hepcidin assays.
WCX-TOF-MS c-ELISA IC-TOF-MS
Analytical LLOD, pmol/L NAa 20.8 NAa
Functional LLOD, pmol/L 500 26.5 100
Intraassay CV, range, % 2.2-3.7 4.8 3.9-13.1
Interassay CV, range, % 3.9-9.1 11.2 -
Recovery, range; mean, % 96.102; 99 86-114; 98 95-105; 100
Linearity Yes Yes Yes
Parallelism - Yes -
Cross-reactivity hepcidin-20, % 0b 68 0b
Cross-reactivity hepcidin-22, % 0b 47 0b
a NA, not applicable; - not determined; analytical LLOD, lowest level that can be detected based on a protein 
standard; functional LLOD, lowest level that can be detected based on human serum samples. 
b No cross-reactivity was indicated because MS results are specific for hepcidin-25.
CHARACTERISTICS OF HEPCIDIN ASSAYS
The analytical characteristics for the WCX-TOF-MS, c-ELISA, and IC-TOF-MS methods were 
determined in parallel and are summarized in Table 1 and described in detail in Addendum 3 
and 4.
Next, hepcidin concentrations in clinical samples (see Addendum 1, Table 1) were measured 
by these 3 methods: WCX-TOF-MS (n = 209), c-ELISA (n = 209), and IC-TOF-MS (n = 25, all 
samples that measured <0.5 nmol/L in the WCX-TOF-MS). Hepcidin medians and ranges 
obtained by these 3 methods for the various diseases are shown in Addendum 1, Table 2. 
Overall, median total serum hepcidin concentrations measured by the c-ELISA were 
moderately, but significantly, higher (P <0.0001) compared with hepcidin-25 concentrations 
measured by WCXTOF-MS (median 6.6 nmol/L, range 0.17-77.5 vs 4.6 nmol/L, range <0.5­
82.5 nmol/L, n = 209; Addendum 1, Table 2). We found significant positive Spearman 
correlations (P < 0.001) between hepcidin-25 as well as total hepcidin measured by WCX- 
TOF-MS and c-ELISA total hepcidin (R = 0.912, Fig. 1A; R = 0.920, Fig. 1B). In addition, IC-TOF- 
MS hepcidin-25 concentrations correlated significantly (P< 0.0001) with total hepcidin 
measured by c-ELISA (R= 0.743, Fig. 1C).
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Bland-Altman plots illustrated these overall higher concentrations measured by c-ELISA 
compared with WCX-TOF-MS (Fig. 1, D and E). The relative differences between c-ELISA and 
WCX-TOF-MS measurements were similar for WCX-TOF-MS-assessed hepcidin-25 (Fig. 1D) 
and total hepcidin concentrations (Fig. 1E). The hepcidin concentrations obtained by c-ELISA 
were substantially higher than those measured by IC-TOF-MS (Fig. 1, C and F).
Figure 1. Relation between the serum hepcidin methods.
Correlation of c-ELISA hepcidin concentrations with: (A), WCX-TOF-MS hepcidin-25 in the whole 
hepcidin range (n = 209); (B), WCX-TOF-MS total hepcidin in the whole hepcidin range (n = 209); and 
(C), IC-TOF-MS hepcidin-25 for samples measured as <0.5 nmol/L by WCX-TOF-MS (n = 25). Bland- 
Altman plots for (D), c-ELISA and WCX-TOF-MS (hepcidin-25) (bias = 31.9%, SD = 51.0%); (E), c-ELISA 
and WCX-TOF-MS (total hepcidin) (bias = 19.7%, SD = 49.7%); and (F), c-ELISA and IC-TOF-MS 
(hepcidin-25) (bias = 107.6%, SD = 46.1%). Total hepcidin of the MS assay is the sum of hepcidin-25, - 
22, and -20. Spearman R and the regression formula are shown. *, Significant with P < 0.001. The 
solid lines in D-F represent the mean percent differences with 95% limits of agreement of the 
samples. The limits of agreement are obtained by using the SDs of the percent differences between 
the methods. The dotted line represents the zero difference between methods depicted on the y 
axis.
HEPCIDIN CONCENTRATIONS IN DISEASES WITH MEASURABLE ISOFORMS
The observed differences in absolute concentrations may be due to the inability of the c- 
ELISA to distinguish between the hepcidin isoforms, because it cross-reacts 47% and 68% 
with the respective hepcidin-22 and -20 isoforms in a given sample. This contrasts with TOF- 
MS assays, which are able to separately detect and quantify the hepcidin-25, -22, and -20 
isoforms by their different masses. In serum samples from healthy controls and patients with 
low hepcidin concentrations, no isoforms were detected. However, exploiting this feature of 
WCX-TOF-MS, we detected hepcidin-22 and -20 isoforms in 67 of 84 patients with CKD, 2 of 
22 patients after coronary artery bypass graft, 12 of 19 sepsis patients, and 7 of 10 patients 
with ACD. For patients with these disorders, the median percent hepcidin-25 concentrations 
of total hepcidin were 80.8% (range 31.6%-100.0%), 100.0% (83.5%-100.0%), 86.5% (55.9%- 
100.0%), and 85.3% (69.9%-100.0%), respectively. These wide ranges show that the 
contribution of hepcidin-25 to total hepcidin is not fixed and differs between diseases and 
patients.
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Figure 2. Bland-Altman plots for the comparison between c-ELISA and WCX-TOF-MS hepcidin-25 
and total hepcidin concentrations for (A,B) 84 CKD patients with (n = 67) and without (n = 17) 
hepcidin isoforms (bias = 32.6%, SD = 40.5%; bias = 8.1%, SD = 32.8%, respectively) and (C,D) in all 
patients without isoforms, CKD patients excluded (n = 104 of 209) (bias = 33.7%, SD = 60.3%, for 
both).
The solid lines represent the mean percent differences with 95% limits of agreement of the samples. 
The limits of agreement were obtained by using the SDs of the percent differences between the 
methods.
The prevalence and median contribution of isoforms to total hepcidin was highest for the 
CKD patients. More specifically, in the lower range (hepcidin-25 <5 nmol/L) 17.6% of the CKD 
patients had isoforms that contributed >50% to the concentration of total hepcidin, whereas 
for the whole range this was the case only for 8.3% of the patients. Therefore, we used this 
patient group (n = 84) to evaluate the contribution of hepcidin isoforms to total hepcidin 
concentrations in more detail. The mean CKD hepcidin-25 concentrations measured by 
WCXTOF- MS were 1.4 times lower than the mean c-ELISA (total) hepcidin concentrations. 
This difference substantially decreased toward 1.1 times lower when we compared mean 
WCX-TOF-MS total hepcidin concentrations with c-ELISA hepcidin concentrations. The 
Bland-Altman plots (Fig. 2) illustrate these observations by showing that, for patients with 
isoforms, the relative difference between the c-ELISA and WCXTOF-MS was higher when 
plotted for WCX-TOF-MS hepcidin-25 (Fig. 2A) than for WCX-TOF-MS total hepcidin (Fig. 2B). 
These differences between WCXTOF-MS total hepcidin and hepcidin-25 plots were not 
observed in patients without isoforms (Fig. 2, C and D).
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Figure 3. Hepcidin concentrations in the various iron disorders as measured by the WCX-TOF-MS 
(hepcidin-25, closed bars; total hepcidin, striped bars) and c-ELISA (total hepcidin, open bars) 
hepcidin assays.
The boxes represent the 25th-75th percentiles and the error bars represent the minimum and 
maximum values with the median. LPS, healthy volunteers injected with lipopolysaccharide; MM, 
multiple myeloma; ACD, anemia of chronic disease; MetS, metabolic syndrome; CABG, coronary 
artery bypass surgery; CKD, chronic kidney disease; HH_C282Y_pres, homozygous hemochromatosis 
at presentation, before iron depletion therapy; HH_C282Y/H63D_pres, HFE C282Y/H63D compound 
heterozygotes before iron depletion therapy; HH_C282Y_depl, C282Y homozygous HFE 
hemochromatosis after iron depletion therapy; HH_HJV_depl, juvenile HH after iron depletion 
therapy; IDA, iron deficiency anemia; Ctrls, healthy controls.
CLINICAL UTILITY OF HEPCIDIN ASSAYS
To specifically address the potential clinical utility, we evaluated the extent to which our 
assays had the ability to distinguish between patient groups and to measure hepcidin 
concentrations reflecting a physiological response. For this evaluation we used the hepcidin 
concentrations that were determined in the 209 samples from patients with different iron 
metabolism disorders and healthy controls.
As shown in Fig. 3, the relative differences between median hepcidin concentrations 
observed for all diseases were similar for the WCX-TOF-MS and the c-ELISA. We also found 
that both methods reflected physiological responses, i.e., the median hepcidin 
concentrations were (a) higher for the inflammatory diseases (septic shock, 
lipopolysaccharide, ACD, and metabolic syndrome), (b) lower for IDA compared to controls, 
and (c) similar for iron overloaded HH patients and controls, but lower in iron-depleted HH
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patients. Moreover, wide concentration ranges for heterogeneous diseases such as CKD and 
the metabolic syndrome were observed (Fig. 3).
To assess if WCX-TOF-MS, c-ELISA, and ICTOF-MS reflected the physiological response to low 
iron stores in the very low hepcidin range, we selected patients with IDA or ferritin 
concentrations <60 ng/L, in the absence of iron disorders other than iron deficiency. As 
expected, ferritin did not correlate with hepcidin concentrations measured by WCX-TOF-MS, 
because the majority of these samples had hepcidin concentrations below the LLOD of this 
method (Fig. 4A). In contrast, ferritin correlated significantly with hepcidin concentrations 
measured by c-ELISA and ICTOF-MS (R = 0.773, P < 0.001 and R = 0.789, P < 0.001, 
respectively; Fig. 4, B and C). Occasionally, however, the c-ELISA provided relatively high 
hepcidin concentrations in samples for which, based on low ferritin concentrations, a low 
hepcidin response was anticipated (Fig. 4B).
Finally, we assessed the ability of all 3 methods to differentiate between 3 forms of anemia 
in RA patients. These analyses indicated that both the c-ELISA and ICTOF-MS were more 
suitable than WCX-TOF-MS (Fig.4, D-F) for distinguishing patients with IDA from those with 
ACD and IDA.
Figure 4. Clinical utility of low hepcidin concentrations as assessed by the different assays.
Correlation of hepcidin concentrations of the hepcidin assays with ferritin concentrations (<60 ^g/L; 
n = 19). (A), WCX-TOF-MS; (B), c-ELISA; and (C), IC-TOF-MS. Spearman R is shown; *, significant with P 
< 0.001. Hepcidin concentrations in patients with IDA, ACD, and both IDA and ACD, categorized 
according to conventional criteria and determined by (D), WCX-TOF-MS (the detection limit of 0.5 
nmol/L for WCX-TOF-MS is indicated as a dotted line); (E), c-ELISA; and (F), IC-TOF-MS.
Discussion
Our c-ELISA and IC-TOF-MS methods for quantifying serum hepcidin concentrations allowed 
us to perform a comparison of immunochemical and MS serum hepcidin assays, including 
our previously developed WCX-TOF-MS-assay. We assessed the pros and cons of these 
different methodologies for the quantification of serum hepcidin concentrations for a broad 
variety of patients with iron metabolism disorders.
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Absolute hepcidin concentrations differed between c-ELISA and the WCX-TOF-MS, 
corroborating previous findings.17 These differences might be attributed to different 
standards used, and the absence of a validated calibrator. However, this cause is unlikely in 
our case, because we used hepcidin-25 as an external standard for the c-ELISA and hepcidin- 
24 as an internal standard for the WCX-TOF-MS methods. These 2 standards were found to 
have identical binding characteristics to the surface of the WCX beads. Other factors that 
may have contributed to different concentrations measured by the different methodologies 
include: (a) differential aggregation of the synthetic or native hepcidin during workup;25 (b) 
serum matrix effects that differentially influence the recognition of the antibody for 
biotinylated synthetic hepcidin-25 or native hepcidin or differentially affect enzyme-linked 
coloration reactions in the c-ELISA assay; and (c) differences between the methods in 
measuring free or hepcidin bound to a-2-macroglobuline or albumin.26 Unfortunately, it is 
currently unknown if WCX-TOF or c-ELISA measures free or protein-bound hepcidin. This 
important question is a subject of our ongoing investigations.
Hepcidin isoforms were shown to be present in serum of patients with diseases 
characterized by increased hepcidin concentrations, such as ACD, sepsis, and CKD. The 
presence of hepcidin isoforms has been reported previously for patients with CKD and 
hemodialysis6,18 and these isoforms likely contributed to the here described differences in 
reported WCXTOF-MS (hepcidin-25) and c-ELISA (total) hepcidin concentrations. To date, the 
role of hepcidin-20 and -22 isoforms in iron homeostasis is unclear. We therefore believe, 
especially in individual patient care, that it is important to be able to selectively quantify 
hepcidin-25, particularly in patients with diseases for which a high occurrence of hepcidin 
isoforms has been reported. Alternatively, immunochemical methods exploiting monoclonal 
antibodies that selectively recognize hepcidin-25 may prove to be useful.
Comparison of c-ELISA and IC-TOF-MS methodology, which is also referred to as mass 
spectrometric immunoassay, is not novel but has provided valuable insights as to the 
isoform specificity of assays.27 Here, we found that hepcidin concentrations in both assays - 
using the same antibodies- showed an increasing physiological response with increasing 
ferritin concentrations in the iron-deficiency range. Occasionally, however, the c-ELISA 
provided relatively high hepcidin concentrations in samples for which, based on low ferritin 
concentrations, a low hepcidin response was anticipated. Apparently, in contrast to IC-TOF- 
MS, the c-ELISA is responsive to matrix differences in these very low hepcidin ranges, which 
affects the interaction of the hepcidin antibody with either the native or labeled synthetic 
hepcidin. In these cases the internal standard used in the MS assays might better correct for 
matrix differences than the external standard in the c-ELISA. These subtle differences in 
assay performance may become important when their outcomes are used to guide 
individual patient treatment.
We found both the c-ELISA and the IC-TOF-MS to better differentiate anemic RA patients 
with IDA from those with IDA and ACD than WCX-TOF-MS. Notably, Theurl et al., using liquid 
chromatography tandem mass spectrometry in somewhat differently defined patients with 
chronic infections, autoimmune diseases, and malignancies, were not able to distinguish IDA 
patients from those with the combined presence of IDA and ACD.28 Therefore, both of our 
novel methods might prove to be valuable in the guidance of iron supplementation in 
anemic patients, among whom are patients with rheumatic diseases and patients in malaria 
endemic regions.29
51
Serum Hepcidin Assays for Iron Metabolism Disorders
The results of our study revealed the pros and cons of the various hepcidin platforms. We 
found our c-ELISA to be more sensitive and less specific for hepcidin-25 compared to our 
WCX-TOF-MS assay. In our hands, sample throughput was higher for c-ELISA than for MS 
assays. In theory MS methods, however, can also be high throughput by automation.30,31 
This technique requires robust protocols, because hepcidin readily sticks to laboratory 
plastics, especially with the use of small sample volumes. Although MS is an increasingly 
used technology, ELISA is still more common in clinical laboratories because it precludes the 
need for expensive equipment. Altogether, we believe that these observations and thoughts 
on the analytical performance and the suitability of the methods for routine clinical use are 
representative for these assays in general. However, it should be realized that the relative 
performance of c-ELISA and ICTOF-MS assays (to be) developed in other laboratories is 
highly dependent on the affinity and specificity (crossreactivity) of the used hepcidin 
antibodies.
We conclude that c-ELISA is the current method of first choice for the quantification of 
serum hepcidin, because of its low limit of detection, low costs, and high throughput. MS is 
preferred in disorders with increased concentrations of hepcidin isoforms, such as CKD, 
because of its specificity for bioactive hepcidin-25.
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Imprecision, variability, and variations in serum and urine hepcidin
Abstract
The utility of urine and serum hepcidin measurements in the clinic depends on their 
reproducibility. We sought to expand our previous work on the within-subject variability and 
between-subject variability of this novel iron parameter in the serum and urine of 24 healthy 
controls by time-of-flight mass spectrometry at four different time points during the day. A 
linear mixed model for repeated data was used to distinguish three components of the total 
variability in the measurements: within-day/within-subject variability, between-subject 
variability, and additional residual or (pre)analytical variability. Differences in diurnal 
hepcidin patterns were observed between urine and serum. Urine levels remained similar 
during the course of the morning and increased significantly during the afternoon, whereas 
serum levels increased significantly throughout both the morning and afternoon. 
Furthermore, in serum the (pre)analytical variability (28.6%) was smaller than the between- 
subject (48.1%) and within-day/within-subject variability (30.3%) compared with urine 
variability (97.2% vs. 67.7 and 77.3%, respectively). High serum ferritin levels were 
associated with higher serum hepcidin levels but not with urine levels. Transferrin saturation 
did not correlate with hepcidin levels. To minimize variability, we recommend (i) 
standardizing for sampling time and (ii) measuring serum hepcidin levels.
Introduction
The iron regulatory peptide hormone hepcidin was discovered in 2001.1-3 Until recently, few 
investigative tools were available to measure hepcidin in human biological samples. Many 
studies measured the precursor prohepcidin using a commercially available enzyme-linked 
immunosorbent assay (ELISA). The relevance of these data is controversial because 
prohepcidin levels do not correlate with urinary and serum hepcidin, nor do they respond to 
relevant physiological stimuli.4-7 Early human studies are performed in urine samples by a 
dot blot assay using non-commercially available antibodies for the semiquantitative 
measurement of hepcidin.8 More recently, new assays have been developed using an ELISA 
approach9 and exploiting novel technologies, such as surface-enhanced laser 
desorption/ionization (SELDI) or matrix-assisted laser desorption/ionization (MALDI) time-of- 
flight mass spectrometry (TOF MS) and liquid chromatography tandem mass spectrometry 
(LC-MS/MS), that also enable hepcidin analysis in serum.10-16 With these assays, we (and 
others) observed different hepcidin levels in various diseases of iron metabolism (reviewed 
in Kemna et al.17).
In these proof-of-principle studies, our group found a significant relation between the 
hepcidin levels of 70 urine-serum sample pairs from patients with diverse disorders of iron 
metabolism.10 Moreover, we observed a diurnal variation in hepcidin concentrations in a 
small series of 3 healthy controls10 that may well account for the wide range in hepcidin
9 10 12 14 18levels described so far for reference populations.9,10,12,14,18
Here we expand our previous work on the within-subject variability and between subject 
variability of hepcidin and on the relationship to the underlying body iron status of healthy 
controls.10,14 Therefore, we quantified urine and serum hepcidin levels by our newly updated 
TOF MS assay14 as well as the serum iron parameters in healthy controls at various time 
points during the course of the day. These findings are instrumental to optimize sampling 
conditions and to facilitate interpretations of measurements of hepcidin as a potentially 
novel biomarker in future clinical studies.
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Materials and methods
STUDY POPULATION AND SAMPLING PROTOCOL
Approval for this study was obtained from the Radboud University Nijmegen Medical Centre 
institutional review board. The study was performed in June 2007 on 31 apparently healthy 
persons (15 men and 16 women) who were employees at the Radboud University Nijmegen 
Medical Centre (Nijmegen, The Netherlands). Written informed consent was obtained from 
all study participants.
In total, 24 volunteers were included in the study after 7 volunteers were excluded based on 
values outside the laboratory reference ranges such as elevated serum transferrin saturation 
(TS, n = 1), alanine-aminotransferase (ALT, n = 1), C-reactive protein (CRP, n = 2), and ferritin 
levels (n = 3).
Urine and serum samples were taken at consecutive time points during the day. The first 
morning void urine was collected after a minimum of 8 h overnight fast immediately after 
waking up between 6:00 and 7:30 am. The second urine sample and first serum sample were 
also taken fasted at 8:30 am when the subjects arrived at work. Participants were then 
allowed to eat, and subsequent serum and urine samples were taken at 11:00 am, 1:30 pm, 
and 4:00 pm during clinical practice of our hospital.
Urine and serum samples were processed, aliquoted, and stored in polypropylene tubes at - 
80 oC. Routine laboratory parameters and hepcidin levels were measured within 8 h and 6 
months of collection, respectively. Hepcidin is known to be stable for a period of 8 months 
(data not shown). In addition, CRP, TS, and serum and urine hepcidin were determined in the 
samples of all time points, whereas other biomarkers such as serum ferritin, hemoglobin 
(Hb), mean corpuscular volume (MCV), and ALT were assessed only for the samples collected 
at 8:30 am.
LABORATORY MEASUREMENTS
Using an Abbott Aeroset analyzer, we measured total serum iron by the ascorbate/FerroZine 
colorimetric method, urine creatinine by enzymatic/colorimetric detection (Roche 
Diagnostics B.V., Almere, The Netherlands), and CRP by immunologic agglutination detection 
with latex-coupled polyclonal anti-CRP antibodies (Abbott B.V. Diagnostics Division, 
Hoofddorp, The Netherlands). We quantified serum ferritin by the use of a solid-phase, two- 
site chemiluminescent immunometric assay (Immulite 2000 and 2500, Siemens, Breda, The 
Netherlands) and routine hematology characteristics by the use of a Sysmex XE-2100 
analyzer (Goffin Meyris, Etten-Leur, The Netherlands).
HEPCIDIN MEASUREMENTS
Serum and urine hepcidin measurements by the use of SELDI-TOF were performed in 
November and December 2007 by an update from our previously described method.10,14 In 
short, to quantify hepcidin levels, synthetic hepcidin-24 (THFPICIFCCGCCHRSKCGMC CKT, 
2673.9 Da, Peptide International, Louisville, KY, USA) as an internal standard was added to 
400 |al of serum or 500 |al of urine before total hepcidin was isolated from 50 or 100 ^l of 
sample, respectively, with Macro-PrepCMSupport beads (Bio-Rad Laboratories, Hercules, CA, 
USA) as described previously.2 Next, hepcidin was applied to a normal-phase chip (NP20, Bio­
Rad Laboratories), followed by the addition of energy-absorbing matrix, all in a nitrogen 
atmosphere. Mass-to-charge (m/z) spectra were generated using a Protein Biosystem IIc 
mass spectrometer (PBSIIc, Ciphergen Biosystems, Fremont, CA, USA). Concentrations of 
urinary hepcidin-25 were expressed as nanomoles per millimole of creatinine.
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The lower limit of detection (LLOD) of this method for serum was 0.5 nM with an intrarun 
coefficient of variation (CV) of 3 to 7% and an interrun CV of 7 to 9%. For the urine hepcidin 
application, the LLOD was 50 pM with intra- and interrun CVs of 3 to 7% and 10 to 13%, 
respectively.14 We attributed values of 0.5 nM and 0.01 nmol/mmol creatinine to serum and 
urine samples, respectively, when peak heights were below 3 signal/noise.
STATISTICAL ANALYSIS
First, the individual profiles of the biomarkers during the day were analyzed using the 
multiple measurements per subject. A linear mixed model for repeated data was used to 
study systematic differences between gender and between the fixed time points during the 
day for each of the following variables separately: TS, serum hepcidin, and urine hepcidin 
(each original and log-transformed). The dependent variable was the marker in question. 
The independent class variables were the point of measurement and gender. The intercept 
of each subject was treated as a random variable to allow individual differences of the 
profiles. Initially, the interaction term between gender and time point also was included in 
the linear part of the model. However, because it appeared that both this interaction 
termand the variable gender were never statistically significant, these were omitted from 
the final model used. This indicates that the average profiles for men and women were 
similar. The back-transformed estimated mean at each time point with the appropriate 95% 
confidence interval (CI) using the final linear mixed model and the log-transformed variable 
are presented to indicate the estimated medians (95% CI) of the nontransformed data. 
Second, we estimated the three variance compounds of the total variability of the 
measurements: (i) within-day/within-subject variability, (ii) between-subject variability, and 
(iii) additional residual variability. The residual variability includes (unknown) biological and 
dietary variation, preanalytical variation (e.g., storage, sample handling), and analytical 
variation but is referred to as the (pre)analytical variability. A linear mixed model, similar to 
the one mentioned above, was used to estimate the three variance components. For this 
purpose, the time point was also treated as a random variable. The standard deviation (SD), 
CV relative to the mean, and percentage variance relative to the total variance of each 
component are presented.
Table 1. Characteristics of the study population.___________________
Men Women
Median Range Median Range
Gender (n) 11 13
Age (years) 38 18-50 43 22-63
BMI (kg/m2) 23.0 17.7-28.9 23.4 18.4-29.1
CRP (mg/L) <5 <5
ALT (U/L) 24 19-39 19 9-36
Hb (mmol/L) 9.1 8.7-9.8 8.3 7.9-9.3
MCV (fl) 86 83-92 87 82-93
sTfR (mg/L) 1.19 1.01-1.43 1.12 0.81-1.54
Body iron (mg/kg) 40.5 35.5-42.5 28.7 30.8-40.7
Note. Results are for the samples taken at 8:30 am. All characteristics for all subjects are within reference 
ranges of the laboratory. BMI, Body Mass Index; CRP, C-reactive protein; ALT, alanine-aminotransferase; Hb, 
hemoglobin; MCV, mean corpuscular volume; sTfR, soluble transferrin receptor. Body iron levels were 
calculated according to Cook and coworkers.22
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Results
CHARACTERISTICS OF THE STUDY POPULATION
In Table 1, the characteristics of the 24 healthy controls (11 men and 13 women) included in 
the study are shown. All biomarkers are within reference ranges as used in the Department 
of Clinical Chemistry at Radboud University Nijmegen Medical Centre.
10
URINE AND SERUM HEPCIDIN LEVELS
Table 2 shows the observed median and range of hepcidin levels and of some related 
biomarkers at each measurement point. Note that, consistent with our previous findings, 
the medians at 4:00 pm are higher than those at 8:30 am except for TS, where this is lower. 
We observed a weak but significant correlation between serum and urine hepcidin levels 
(8:30 am, Spearman's R = 0.55, P = 0.006) (Fig. 1). Furthermore, in comparing the medians 
and ranges, there is obviously some skewness in the data. Fig. 2 presents the individual 
profiles of urine and serum hepcidin and TS during the day of all men and women. It shows 
that for the majority of participants, hepcidin levels increased during the day, whereas TS 
decreased. Notably, the individual profiles during the day of urine hepcidin show some 
apparently high unexpected values, namely, for 1 man at 1:30 pm and for a few women at 
first morning (6:00-7:30 am), 11:00 am, and 4:00 pm. In our search to better understand 
these values, we remeasured all urine samples of these persons within 1 month after the 
initial measurement from different aliquots of the same samples. Again some unexpected 
values were observed, albeit at other time points. These unpredicted values found in the 
samples are not observed for serum samples despite identical analytical protocols for urine 
and serum measurements. Therefore, we conclude that these are caused by uncontrollable 
aspects of (pre)analytical origin, i.e., aggregation of hepcidin.
Serum Hepcidin
Figure 1. Urine hepcidin levels against serum hepcidin levels of all patients (n = 24) collected at 
8:30 am. Cr, creatinine.
Table 3 shows that the estimated median urine hepcidin levels at 6:00 to 7:30, 8:30, and 
11:00 am, obtained by the linear mixed model, were mutually not statistically significant 
(indicated by the brackets) but that all were significantly lower compared with those in the 
afternoon, that is, at 1:30 and 4:00 pm. Furthermore, the median urine level of 0.82 
nmol/mmol creatinine at 1:30 pm was significantly lower than the level of 1.32 nmol/mmol 
creatinine at 4:00 pm. As a result, urine hepcidin levels increased significantly during the 
afternoon. Serum hepcidin levels showed a different diurnal pattern compared with urine. 
The estimated median serum hepcidin levels were significantly different between all time
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points. Consequently, serum hepcidin levels increased significantly during the whole course 
of the day.
Table 2. Median and range values of serum and urine hepcidin and related parameters at different 
time points.
First morning 
(6:00-7:30 am) 
fasted
8:30 am fasted 11:00 am 1:30 pm 4:00 pm All time points
All (N = 24) Ferritin (^g/L) - 102 (12-224) - - - -
TS (%) - 32.7 (19.0-49.1) 35.2 (21.2-55.6) 31.9 (21.7-46.2) 29.6 (17.2-39.3) 32.7 (20.9-45.6)
Serum hepcidin (nM) - 2.9 (0.5-8.2) 4.2 (0.5-10.7) 4.3 (0.5-10.2) 5.9 (0.5-13.9) 4.4 (0.5-10.8)
Urine hepcidin 
(nmol/mmol cr)
0.3 (0.01-3.8) 0.3 (0.01-1.1) 0.4 (0.01-3.0) 1.1 (0.01-5.1) 2.0 (0.01-10.6) 0.9 (0.01-3.5)
Men (N = 11) Ferritin (^g/L) - 131 (41-224) - - - -
TS (%) - 31.8 (21.7-49.1) 33.8 (24.2-44.1) 31.4 (21.7-43.5) 28.6 (17.2-39.3) 31.4 (24.0-42.5)
Serum hepcidin (nM) - 3.3 (1.1-8.2) 4.4 (1.1-10.7) 4.4 (1.7-10.2) 6.8 (1.3-13.9) 4.5 (1.4-10.8)
Urine hepcidin 
(nmol/mmol cr)
0.6 (0.05-1.3) 0.3 (0.04-1.1) 0.4 (0.04-1.9) 1.1 (0.06-5.1) 2.1 (0.07-4.2) 0.9 (0.05-2.0)
Women (N = 13) Ferritin (^g/L) - 73 (12-124) - - - -
TS (%) - 37.0 (19.0-49.1) 36.5 (21.2-55.6) 37.0 (22.6-46.2) 32.1 (18.4-38.3) 34.0 (20.9-45.6)
Serum hepcidin (nM) - 2.1 (0.5-5.6) 4.0 (0.5-6.2) 4.2 (0.5-9.1) 5.3 (0.5-10.3) 4.3 (0.5-7.2)
Urine hepcidin 
(nmol/mmol cr)
0.2 (0.01-3.8) 0.2 (0.01-0.8) 0.2 (0.01-3.0) 1.1 (0.01-4.2) 2.0 (0.01-10 .6) 0.9 (0.01-3.5)
Note. -, not determined; TS, transferrin saturation; cr, creatinine.
WITHIN-DAY/WITHIN-SUBJECT, BETWEEN-SUBJECT, AND (PRE)ANALYTICAL VARIABILITY
In Table 4, the within-day/within-subject, between-subject, and (pre)analytical variability are 
displayed. The urine hepcidin measurement shows a (pre)analytical CV of 97.2%, which is 
larger than both the between-subject CV (67.7%) and the within-day/within-subject CV 
(77.3%). These results indicate a relatively inaccurate (pre)analysis as well as a relatively 
poor capability to distinguish urine hepcidin levels between individuals and within the day. In 
contrast, the (pre)analytical variability (28.6%) of the serum hepcidin assay is relatively small 
in comparison with its between-subject CV (48.1%) and within-day/within-subject CV 
(30.3%), implicating the better suitability of serum measurements to detect differences 
between subjects and within the day.
Table 3. Estimated medians with 95% CI at different time points during the course of the day using 
a linear mixed model on the log-transformed data.____________________________
Time point Urine hepcidin (nmol/mmol cr) Serum hepcidin (nM)
Median 95% CI Median 95% CI
6:00-7:30 am (fasted) 0.26 _ 0.11-0.46 - -
8:30 am (fasted) 0.20 - 0.11-0.35 2.24 1.63-3.06
11:00 am 0.30 J 0.17-1.44 3.43 2.51-4.70
1:30 pm 0.82 0.47-1.44 3.98 2.90-5.45
4:00 pm 1.32 0.75-2.32 5.04 3.68-6.90
Note. Cr. Creatinine; CI, confidence interval; vertical brackets, not statistically significant; -, not determined.
Next, we calculated the relative contribution of each source of variability to the total 
variance. The between-subject variability as a percentage of the total variance is largest for 
the serum hepcidin and TS (57 and 59%, respectively). In contrast, the relative (pre)analytical 
variability is highest for urine hepcidin (47%), indicating a poor reliability of the urine 
hepcidin results compared with the serum hepcidin and TS results (Table 4).
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8.30 am 11am 1.30 pm
Time-point
Figure 2. Serum hepcidin levels of men (A) and women (B), urine hepcidin levels of men (C) and 
women (D), and serum transferrin saturation (TS) levels of men (E) and women (F) throughout the 
day. Lines represent the individual daily profiles of each subject. FM, first morning; cr, creatinine.
Table 4. Estimated (pre)analytical, between-subject, and within-day/within-subject SDs and CVs of 
hepcidin and TS using a linear mixed model on the original nontransformed data.
Source Urine hepcidin (nmol/mmol cr)
SD CV (%) % of total variance
Serum hepcidin (nM)
SD CV (%) % of total variance
Serum TS (%) 
SD CV (%) % of total variance
(Pre)analytical 1.05 97.2 47 1.B0 2S.6 20 4.77 14.2 29
Between-subject 0.7B 67.7 B0 2.19 4S.1 57 6.SB 20.4 59
Within-day/within-subject 0.S4 77.B 2B 1.BS B0.B 2B B.0B 9.0 12
Note. (Pre) analytical variability represents the variation in results of several repeated measurements at the 
same time point on the same day (i.e. caused by aggregation).
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RELATIONSHIP WITH IRON STATUS BIOMARKERS
We found that ferritin was associated with serum hepcidin levels using an extended linear 
mixed model (i.e., ferritin was added as an extra independent variable). On average, there is 
a significant increase in serum hepcidin levels of 0.023 (SD = 0.008, P = 0.005) per unit of 
increase in ferritin baseline levels. This increase is similar for all time points during the day. 
However, no statistically significant regression of ferritin with urine hepcidin levels is 
observed. Furthermore, TS was not found to have a statistically significant association with 
urine and serum hepcidin levels.
Discussion
The results of the current study can be summarized in three main points. First, serum and 
urine hepcidin levels increase during the day but vary substantially both between and within 
healthy subjects. Urine levels remain similar during the course of the morning and increase 
significantly during the afternoon, whereas serum levels increase significantly throughout 
both the morning and afternoon hours. Second, between-subject variability was higher than 
(pre)analytical variability for serum but not for urine. Third, serum iron parameters as TS and 
ferritin do not have any significant relation with urine or serum hepcidin time-dependent 
relations. In addition, TS is not able to predict hepcidin levels in a human control population, 
whereas elevated ferritin levels are associated with increased hepcidin levels.
On the first point, increasing levels of hepcidin during the day for healthy individuals might 
be determined largely by the innate rhythm of hepatic hepcidin production or by dietary 
factors. The current study was designed to provide information that adds to the 
interpretation of hepcidin data obtained in the clinical setting. To this end, samples were 
taken during hospital day shifts without dietary restrictions except that participants needed 
to stay fasted until the first blood sample and second urine sample were taken. Of note is 
that Dutch people in general eat a simple breakfast between 7:00 and 9:00 am and a light 
lunch between noon and 2:00 pm. Thus, no definitive conclusions can be drawn on the 
causes of the overall daily increases in hepcidin concentrations. However, dietary intake is 
more likely to increase iron levels than to decrease them. Therefore, we believe that 
hepcidin production might be under pulsatile or rhythmic transcriptional control. Indeed, 
previous findings of Bayele and coworkers19 suggest that mouse hepcidin genes are 
regulated by upstream transcription factors USF1 and USF2, which are related to genes 
involved in rhythmicity. A limitation of the current study is that we did not study day-to-day 
variations as reported in Ganz and coworkers9 and Murphy and coworkers,12 day cycles of 
restricted food studies to determine which factor determines the diurnal pattern the most, 
and whether patterns demonstrated by each subject were consistently repeated over time. 
More studies on the influence of dietary intake and on hepcidin and the diurnal rhythm of 
hepcidin need to be done to investigate the specific contributions of these factors.
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Nevertheless, the current findings on the increase of hepcidin levels during the day prompt 
us to recommend standardizing for sampling time and collecting the samples preferably 
after an overnight fasting to prevent diurnal and/or dietary influences. Based on our 
previous observations,10 we also promote storing samples preferably at -80 oC and 
preventing freeze-thaw cycles to avoid hepcidin loss. The ultimate design of a novel study 
will then depend on the research question and the practicality of the forgoing 
recommendations.
On the second point, we found that the (pre)analytical variability in serum was lower than 
the between-subject variability, whereas for urine the (pre)analytical variability exceeded 
the between-subject variability. This relatively high (pre)analytical variability in urine 
measurements might be attributed to a breakdown of hepcidin in urine during its stay in the 
bladder as well as to differences in urine composition causing variation in hepcidin 
aggregation in a protein-poor environment. This high (pre)analytical variability also 
contributes to discrepancies between urine and serum hepcidin levels, resulting in a poor, 
albeit still significant, correlation between serum and urine hepcidin. The (pre)analytical 
variability represents the variation in results of several repeating measurements at the same 
time point on the same day, whereas the between-subject variability is the variation 
(distribution) of hepcidin levels in the population. A lower (pre)analytical variability 
contributes to a more precise value assignment to a measurement. Therefore, from our 
results, we conclude that serum is better suited to detecting small differences in hepcidin 
levels between subjects or patient groups.
On the third point, high ferritin levels induced higher serum hepcidin levels. Serum TS levels, 
however, did not have a statistically significant association with urine and serum hepcidin 
levels. The typical response of the body to low iron levels is to decrease hepcidin production, 
which in turn increases iron absorption from the diet and iron release from macrophages.20 
However, here in 24 healthy controls, we found that serum TS levels are not associated with 
serum hepcidin levels. These findings corroborate our previous findings in a group of 23 
healthy Italian controls.14 In contrast, in a more heterogeneous group of patients with 
various disorders of iron metabolism, we found high TS to be predictive of high serum 
hepcidin.5 Apparently, the range of TS in the healthy population is too small to exert 
significant effects on urine or serum hepcidin levels. Conversely, ferritin levels appear to vary 
enough within the current control population to show a positive correlation with serum
11 14 21hepcidin levels, in agreement with the scarce data provided in previous reports. , ,
The current study was performed on healthy controls. However, if there is a diurnal effect in 
diseased patient categories (i.e., in patients with inflammation), it is likely to also consist of 
an increase of hepcidin levels during the day. In that case, recommendations of the current 
study will also hold for these patient categories.
In conclusion, to minimize within-subject and (pre)analytical variability in clinical studies 
exploiting hepcidin measurements, we recommend standardizing for sampling time and 
selecting serum above urine.
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Standardization of hepcidin assays
Abstract
The recently discovered iron regulatory peptide hormone hepcidin holds promise as a novel 
biomarker in iron metabolism disorders. To date, various mass spectrometry and 
immunochemical methods have been developed for its quantification in plasma and urine. 
Differences in methodology and analytical performance hinder the comparability of data. As 
a first step towards method harmonization, several hepcidin assays were compared. 
Worldwide eight laboratories participated in a urinary and plasma round robin in which 
hepcidin was analyzed. For both urine and plasma: (i) the absolute hepcidin concentrations 
differed widely between methods, (ii) the between-sample variation and the analytical 
variation of the methods are similar. Importantly, the analytical variation as percentage of 
the total variance is low for all methods, indicating their suitability to distinguish hepcidin 
levels of different samples. Spearman correlations between methods were generally high. 
The round robin results inform the scientific and medical community on the status and 
agreement of the current hepcidin methods. Ongoing initiatives should facilitate 
standardization by exchanging calibrators and representative samples.
Introduction
Hepcidin plays a central role in iron metabolism, and could become a useful biomarker for 
the diagnosis and monitoring of iron disorders.1,2 Progress in human studies of hepcidin in 
normal physiology and various disease states has been hampered by the limited availability 
of hepcidin assays. Assays have been developed on mass spectrometry platforms including 
surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF 
MS), matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI- 
TOF MS) and liquid chromatography tandem-MS techniques (LC-MS/MS). Some methods use 
an internal standard, either hepcidin analogs or bioactive hepcidin-25 synthesized with 
stable isotopes.3-10
Recently, immunochemical (IC) assays for hepcidin-25 have also been developed, which 
comprise of competitive radioimmunoassay (RIA)11 and enzyme-linked immunosorbent 
assays (ELISA).12,13 Currently there is no reference method for hepcidin measurements. 
Therefore, to increase comparability of hepcidin data across clinical studies we evaluated the 
levels, between-sample variation and the analytical variation of hepcidin assays on a panel of 
urine and plasma samples in a so-called Round Robin.14
Design and Methods
STUDY DESING AND PARTICIPANTS
A prospective repeated measurement design with 12 replicates was used to assess 
concordance in urine and plasma hepcidin analysis. Six and eight laboratories participated in 
the urinary and plasma analyses, respectively, in six different countries. The study was 
coordinated by the Department of Clinical Chemistry of the Radboud University Nijmegen 
Medical Centre. All laboratories performed 12 replicates, that consisted of triplicate assays 
of each sample on four consecutive days. The only information provided about the samples 
were urinary creatinine levels.
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SPECIMENS
Eight urine samples with a wide range of hepcidin concentrations were collected from 
healthy subjects (samples 1-5) and patients (samples 6-8) (October 2007) with informed 
consent according to the declaration of Helsinki. Synthetic hepcidin-25 (Peptide Institute 
Inc., Osaka, Japan, net hepcidin peptide weight is precisely determined by amino acid 
analysis after acid hydrolysis) was added to a final concentration of 13.1 nmol/mmol 
creatinine to a urine sample that by SELDI-TOF MS7 was found to have a hepcidin 
concentration below the lower limit of detection of 0.5 nmol/L (sample 5). Seven plasma 
pools were composed from hospitalized patient sample remnants (March 2008), so as to 
cover a wide variation in hepcidin levels (samples 9-15). All samples were centrifuged for 10 
min at 2600 g, and immediately stored in aliquots at -80°C. Two weeks after collection and 
storage, the samples were shipped on dry ice to all participants, and measured within four 
weeks of receipt, except for method VI (see below), that was carried out in July 2008. All 
samples underwent only one freeze-thaw cycle before analysis to minimize changes that 
may differently affect the various methods, among which are the formation of hepcidin 
aggregates and breakdown products.
Table 1. Characteristics of methods used for plasma and urine hepcidin measurements.
Method Principle Method Hepcidin extraction Standard Urine Plasma
I Mass spectrometry SELDI-TOF MS Normal phase None X X
II Mass spectrometry SELDI-TOF MS Weak cation exchange External Synthetic hepcidin-24 X X
III Mass spectrometry MALDI-TOF MS Reversed phase External Synthetic hepcidin-25 X
SELDI-TOF MS Immobilized metal affinity 
Chromatography
External Synthetic hepcidin-25 X
IV Mass spectrometry LC-MS/MS Weak cation exchange Internal [15N,13C2]Gly-12,20-hepcidin X X
V Immunochemical Competitive ELISA None External Synthetic hepcidin-25 X X
VI Immunochemical Competitive RIA None External Synthetic hepcidin-25 X X
VII Mass spectrometry LC-MS/MS None Internal Synthetic hepcidin-25 X
VIII Immunochemical Competitive ELISA None External Recombinant hepcidin-25-His X
X: participation in hepcidin round robin for urine and/or plasma.
HEPCIDIN METHODS
Characteristics of the methods used for the plasma and urine hepcidin measurements of the 
present study are schematically presented in Table 1.
Method I is based on SELDI-TOF MS. Samples were directly applied to hydrophilic Normal 
Phase chips (NP20 ProteinChip; Bio-Rad Laboratories). Synthetic 25-hepcidin (Peptide 
Institute Inc.) was used for external mass calibration.
Method II is also based on SELDI-TOF MS. Hepcidin was first extracted from the sample using 
Macro-Prep® CM Support beads (Bio-Rad Laboratories). The extract was applied to NP20 
chips (Bio-Rad Laboratories). Synthetic hepcidin-24 peptide (custom made, Peptide Institute 
Inc.) was used as an internal standard.
For method III, urine samples were de-salted using C8 Clinprot beads (Bruker Daltonik) and 
analyzed by MALDITOF MS. Plasma samples were assayed by SELDI-TOFMS using Cu2+ 
loaded IMAC chips. Synthetic human hepcidin- 25 (Peptide Institute Inc.) was used as an 
external standard in both assays.
Method IV is based on LC-MS/MS. [15N,13C2]Gly12,20 hepcidin (heavy hepcidin) was added 
to plasma or urine as internal standard. Magnetic nanoparticles (Bruker Daltonik) were used 
to extract hepcidin from the samples followed by LC-MS/MS analysis using selected reaction 
monitoring of the triple charged precursor fragmenting to the double charged product ion 
for both heavy hepcidin and hepcidin.
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Method V is a competitive ELISA. 96-well plates were coated with in house-prepared anti­
human hepcidin antibody and biotinylated hepcidin-25 as tracer. Custom synthesized 
hepcidin-25 was used as an external standard.
Method VI is a competitive RIA using a 125I labeled synthetic hepcidin-25 (Bachem) with an 
in-house rabbit anti-hepcidin polyclonal antibody (against hepcidin-KLH conjugate) using a 
secondary antibody-PEG assisted separation. Synthetic hepcidin-25 (Bachem) was used as an 
external standard.
Method VII is based on LC-MS/MS. Isotopic human synthetic hepcidin-25 (Peptide Institute 
Inc.) was used as an internal standard.
Method VIII is a competitive ELISA: plates were coated with an in -house prepared hepcidin- 
25-His peptide and a polyclonal antibody against recombinant (in-house prepared) hepcidin- 
25-His was used to establish competition. Horseradish peroxidase labeled anti-rabbit 
antibody was used as secondary antibody. Hepcidin-25-His was used as an external standard.
STATISTICAL METHODS
The study was designed to compare hepcidin levels as well as the repeatability of the 
methods used for serum and urine, respectively. With respect to the repeatability, the 
magnitude of variation that exists between samples and between measurements of the 
same sample relative to the total variation are of interest. Accordingly, we partitioned the 
total variance of each hepcidin method into the following components: i) the between- 
sample variance and ii) the analytical variance. Our design allowed us to divide the latter into 
three subcomponents: the between-day variance, the between triplicate variance and the 
residual analytical variance, i.e. the part of the analytical variance that cannot be attributed 
to the other two.
A linear mixed model was used to estimate these variance components of each method 
separately. The dependent variable was hepcidin outcome, and the independent random 
variables were: sample (plasma: 7 levels, urine: 8 levels), day (4 levels) and repeated 
measurement (3 levels). We found that the estimated percentage variance due to the 
triplicate measurements was very small and considerably smaller than the variance due to 
the between-day variation. Consequently, this term was omitted from the final model and 
not presented separately. The SD (absolute error), the CV (relative error) and the percentage 
variance relative to the total variance of each random variable are presented and for each 
method separately.
Results and Discussion
Mean hepcidin levels for all (Table 2) samples differ considerably between all methods. 
Notably, hepcidin values of method V are relatively high, but trends and variability are 
similar to all other methods (Table 2). It is also of note that for this Round Robin study, we 
only used native urine and serum samples, except for one, i.e. urine sample 5 to which 
synthetic hepcidin was added to a final concentration of 13.1 nmol/mmol creatinine. We 
found that the mean hepcidin outcome of some methods (i.e. methods II, IV and VI) for this 
spiked urine sample are closer to this concentration than others. However, irrespective of 
whether the value assigned of the spiked hepcidin-25 by Peptide International is correct, 
these results cannot simply be extrapolated to native urine or serum samples, since it is 
presently unclear whether the various methods evaluated behave differently for spiked and 
native samples. In other words, the so called commutability of the spiked samples with 
native clinical samples for the various methods is unknown and its assessment may be part 
of future standardization efforts for hepcidin measurements.15
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Table 2. Mean (±SD) urine and plasma hepcidin levels presented by sample ID and method.
Body Sample Method I# Method II Method III Method IV Method V Method VI Method VII Method VIII
Fluid Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Urine 1 0.04 (0.01) <LLOD - 0.6 (0.4) 1.0 (0.6) 1.5 (0.3) 0.2 (0.01)9 - - - -
2 0.2 (0.1) 0.4 (0.1) 4.4 (4.0) 2.2 (0.7) 14.1 (0.5) 3.2 (0.2) 9 - - - -
3 0.5 (0.1) 0.6 (0.1) 1.9 (0.6) 2.4 (0.7) 19.0 (4.2) 2.3 (0.4) 9 - - - -
4 0.6 (0.2) 1.9 (0.4) 7.0 (0.7) 3.7 (1.1) 105.8 (176.0) 8.3 (1.0) 9 - - - -
5 1.2 (0.4) 12.0 (3.0) 27.1 (6.7) 14.7 (1.9) 115.4 (14.9) 12.1 (0.9) 9 - - - -
6 2.7 (0.5) 48.6 (6.3) 2.7 (0.6) 51.2 (14.7) 861.6 (308.2) 14.3 (1.6) 9 - - - -
7 6.3 (1.2) 35.1 (6.5) 14.4 (3.3) 52.9 (11.5) 659.6 (176.4) 12.9 (1.2) 9 - - - -
8 11.6 (2.7) 184.8 (36.0)11 49.2 (8.7) 153.0 (21.9) 1646.9 (597.1) 13.7 (0.9) 9 - - - -
Plasma 9 <LLOD - <LLOD - 0.2 (0.6) 1.1 (0.4) 2.4 (3.8) 0.5 (0.1) 0.3 (0.1) 61.1 (6.6)
10 4.6 (1.8) 4.3 (0.3) 14.3 (2.7) 7.1 (0.6) 39.7 (10.7) 9.4 (0.5) 4.1 (0.7) 32.7 (4.9)
11 4.1 (1.0) 5.6 (1.1) 16.2 (2.6) 7.2 (0.5) 61.3 (12.9) 9.9 (0.8) 4.6 (0.7) 19.4 (2.7)
12 7.5 (3.2) 8.4 (0.6) 23.4 (3.4) 14.1 (0.7) 128.9 (46.2) 21.2 (1.4) 9.3 (1.7) 23.1 (2.8)
13 8.7 (3.6) 7.6 (2.4) 24.9 (3.9) 15.0 (1.0) 100.9 (53.5) 23.3 (0.9) 10.1 (1.8) 43.3 (5.4)
14 18.3 (5.6) 23.8 (3.6) 52.6 (9.0) 34.7 (1.6) 259.5 (37.0) 29.6 (1.5) 29.2 (5.9) 58.0 (5.2)
15 25.1 (6.0) 28.2 (2.6) 59.9 (12.2) 35.7 (1.5) 279.9 (44.2) 27.2 (2.0) 29.3 (4.0) 52.6 (6.7)
N, number of measurements if different from 12 (i.e., 3 measurements on four different days); urine results in 
nmol/mmol creatinine, plasma results in nmol/L; 1nmol hepcidin-25=2.789 ^g hepcidin-25; #, Results reported 
in arbitrary Units, e.g. Mint/mmol creatinine for urine and in Mint/L for plasma; < LLOD, below lower level of 
detection, for method I: signal/noise < 3, for method II: < 50 pM and < 0.5 nM for urine and plasma, 
respectively. Mass spectrometry methods are highlighted in black.
In general, differences in hepcidin levels between methods might be due to: (i) the use of 
different calibration solutions with level assignments based on different techniques; (ii) to 
hepcidin aggregation of either the standard solution or the sample; or (iii) hepcidin binding 
to a2-macroglobuline or albumine16 or (iv) the existence of three hepcidin isoforms 
hepcidin-25, 22 and 20. These four points may differentially affect IC and MS measurements, 
and urine and serum quantifications. More specifically, it was recently found that around 
90% of the circulating hepcidin is bound to a2-macroglobulin in the blood. These 
observations not only raise the question whether we should measure total, bound or 
unbound hepcidin, but also what the methods evaluated actually measure. The search for an 
answer to these questions is a new challenge for which much can be learned from the 
measurements of steroid and thyroid hormones. Another cause for differences between IC 
and MS methods is that IC methods lack the selectivity to distinguish hepcidin-25 from 
hepcidins-20 and -22. However, the implications of including the latter two isoforms in the 
assay on the total hepcidin values reported in the various iron disorders are not yet known. 
Most methods are similar in both analytical variation and between-sample variation (Table 
3). Of note is that the between-sample CV is lower for plasma than for urine hepcidin. This 
might indicate that the difference between urine and plasma is not due to the method, but 
more to biological mechanism, e.g the hepcidin excretion pathways. MS methodologies II, IV 
and VII, exploiting an internal standard, show slightly lower contribution of the analytical 
variance to the total variance compared to the other MS methods I and III. These findings 
corroborate the assumption that the use of an internal standard decreases the analytical 
variation of the MS-techniques. IC-method V shows a high between-sample CV in 
combination with a relatively high analytical CV. Furthermore, IC-methods VI and VIII express 
the lowest between-sample CV compared to all other methods. However, both methods also 
display low analytical variation. This relatively low between-sample variation of both the 
latter IC-methods illustrates the difficulties in the generation of specific antibodies for 
hepcidin.
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Table 3. Sample means and variations by method for urine and plasma hepcidin levels.
Body fluid
Method
Between-sample Between-day
Analytical variation
Residual analytical variation
Mean ALL 
sample
SD CV (%) % of total 
variance
SD CV (%) % of total 
variance
SD CV (%) % of total 
variance
Urine I #2.9 .1 139.9 93.4 *<0.1 <0.1 <0.1 .1 37.3 6.6
II 44.4 66.1 148.8 95.9 4.9 11.0 0.5 12.8 28.9 3.6
III 13.4 16.9 125.9 93.7 1.8 13.3 1.1 4.0 29.8 5.2
IV 35.1 52.3 148.9 96.3 <0.1 <0.1 <0.1 10.2 29.1 3.7
V 427.1 587.8 137.6 85.4 102.8 24.1 2.6 220.6 51.6 12.0
VI 7.9 5.7 72.2 97.2 0.6 7.2 1.0 0.8 9.9 1.8
Plasma I *11.4 *8.4 73.6 81.3 *1.6 14.4 3.1 *3.7 32.2 15.6
II 13.0 10.3 79.1 96.0 0.4 3.2 0.2 2.1 15.8 3.9
III 27.4 21.3 77.9 92.1 0.7 2.6 0.1 6.2 22.6 7.6
IV 16.4 13.6 83.2 99.5 0.2 1.2 <0.1 1.0 6.0 0.5
V 124.6 107.0 85.8 89.4 26.1 20.9 5.3 26.0 20.8 5.3
VI 17.3 10.8 62.3 98.8 0.1 0.6 <0.1 1.2 6.8 1.2
VII 12.4 119 96.3 94.4 <0.1 <0.1 <0.1 2.9 23.4 5.6
VIII 41.5 16.7 40.2 90.9 3.1 7.5 3.1 4.3 10.4 6.0
Between-sample, segment due to variation between samples; analytical variation, segment due to repeated 
measurements; SD, standard deviation, i.e.absolute error; CV: coefficient of variation, i.e. relative error; % of 
total variance, % of variance-segment to the total variance; sample means and SDs in nmol/mmol creatinine 
and nmol/L for urine and plasma, respectively, unless otherwise stated; #, mean and SD in Mint/mmol 
creatinine for urine and in Mint/L for plasma. Mass spectrometry methods are highlighted in black.
Importantly, the contribution of the analytical variation to the total variance is low for all 
methods (Table 3), which indicates the potential suitability of all methods to distinguish 
hepcidin levels of different samples. However, of note is that the higher the analytical 
variation of a method the lower the probability that populations with only small differences 
in hepcidin levels can be distinguished, e.g. hepcidin levels of healthy controls from that of 
patients with low-grade inflammation due to the presence of features of the metabolic 
syndrome.
Spearman correlations between the individual sample mean hepcidin values obtained by 
most methods were generally high (range 0.62-1.00), except for correlations with method 
VIII that are somewhat disappointing (range 0.04-0.18). This should be interpreted with 
caution due to the small number of samples analyzed (n=7 and n=8 for plasma and urine, 
respectively).
In summary, hepcidin levels reported by the various methods vary considerably but 
analytical variance is generally low and similar for all methods. We recommend further 
harmonization of the various hepcidin assays by: (i) introducing an internal standard for all 
the MS-based methods used for clinical studies; (ii) reaching consensus on level assignment 
and level adjustment of the calibrators used in every procedure; (iii) production of a 
calibrator that mimics patient sera and (iv) regular testing of shared samples and/or 
calibrators that are commutable and have been value assigned for quality control.
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Harmonization of hepcidin methods
Abstract
In a recent sample send out we showed that plasma hepcidin levels reported by the various 
methods platforms around the world vary considerably. Therefore, in this 2nd round robin 
we seek to investigate whether a better agreement between methods can be achieved by 
harmonization.
Native plasma pools (n=11) of a variety of hepcidin concentrations and blank plasma spiked 
with 3 different quantities of synthetic hepcidin-25 purchased from 2 different commercial 
sources (n=6), were sent out in duplicate to 16 laboratories worldwide, participating with a 
total of 21 methods.
Methods differed substantially in absolute values and reproducibility. According to the CLSI 
C53-P protocol we compared results obtained for synthetic hepcidin with native hepcidin 
samples in various method couples by Bland-Altman plots and for the majority of the 
methods found synthetic hepcidin-25 samples to differ >2 normalized SD from native 
samples, implying non-commutability. Next, we excluded 7 methods because of relatively 
low reproducibility (n=6, within sample VC>10% of total variance) and low correlation with 
the other methods (n=1, p< 0.90), leaving 14 methods for harmonization attempts by using 
native samples. We then verified 2 methods as showing the best agreement in the x=y 
comparison of native results and calculated consensus values as the medians for the 11 
duplicate native samples obtained by these two methods. Finally, we calculated method 
specific regression lines enabling the laboratories to calculate the (international) hepcidin 
consensus (HEPCON) value using their own native hepcidin results.
In conclusion, until commutable materials for harmonization are defined, harmonization can 
be achieved by exploiting specific algorithms allowing each lab to report in HEPCON (version 
1) values. This study is the first step towards harmonization of plasma hepcidin methods and 
facilitates the definition of clinical decision limits.
Introduction
Hepcidin plays a central role in iron metabolism,1,2 and could become a target of treatment 
and useful biomarker for the diagnosis and monitoring of iron disorders (reviewed in 1,3). 
Hepcidin is downregulated in diseases that demand increased iron concentrations (i.e. 
increased erythropoietic activity, iron deficiency and hypoxia) and upregulated in 
inflammation and infection.1,2,4,5 Hepcidin causes degradation and internalization of the 
cellular iron exporter ferroportin,6 leading to iron retention in the cell and less iron available 
in the circulation for red blood cell synthesis.
Quantitative hepcidin methods have been developed on Mass Spectrometry (MS)7-19 and 
Immunochemical (IC) platforms.19-25 In our previous send out of samples for the comparison 
of hepcidin methods, the so called first Round Robin for hepcidin methods,26 we found low 
within sample variations but large differences between absolute hepcidin levels measured 
by the various methods. This precludes comparability between the data obtained by 
methods and hinders the use of plasma hepcidin method in medical practice.
To address this variation in hepcidin outcomes between methods we aimed to harmonize 
the various available hepcidin methods by sending out plasma samples in a second Round 
Robin. In this Round Robin-2, we i) tested two commercially available synthetic hepcidin-25 
preparations to assess their suitability as a harmonisator for level assignment and ii) 
determined method specific regression of native samples with (consensus) values. We 
anticipated this study to further contribute to harmonization of hepcidin methods, which 
should allow the definition of universal reference values and clinical decision limits for 
plasma hepcidin values.
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Materials & Methods
SAMPLE COLLECTION AND PARTICIPANTS
A prospective blinded measurement design was used to assess concordance in plasma 
hepcidin analysis. Eleven MS, 9 IC methods and one ligand binding method (later referred to 
as IC method) of in total 16 laboratories participated in the analysis, with a total of 21 
methods. The study was coordinated by the Department of Laboratory Medicine, Laboratory 
of Genetic, Endocrine & Metabolic Disorders of the Radboud University Nijmegen Medical 
Centre.
The study was designed to compare hepcidin levels in 11 biological samples as well as in 6 
samples composed of blank plasma spiked with different concentrations of 2 harmonisators,
i.e. human synthetic hepcidin-25 purchased from two different companies.
SPECIMENS
Ten heparin plasma pools were composed from hospitalized patient sample remnants 
(March 2010), so as to cover a wide variation in hepcidin levels, one plasma sample was 
composed from a iron depleted patient with juvenile hemochromatosis (blank plasma).27 All 
samples were centrifuged for 10 min at 2600 g. Six additional plasma samples were 
composed from the blank plasma and spiked with three concentrations (namely 5, 12.5 and 
20 nM, assuming the values given in the inserts as nett amounts determined by amino acid 
analysis) of human synthetic hepcidin-25 purchased from Peptide International Inc. 
(Louisville, KY, USA) and Bachem LTD (St. Helens, UK). In a later stage of the study we 
discovered that we added less Bachem peptide to the blank sera than we originally assumed, 
as Bachem provided a gross amount of 68.6% hepcidin on the vial that we did not correct for 
in the preparation of the samples. As a result, we added 5, 12.5 and 20 nM hepcidin from 
Peptide International and 3.4, 8.6 and 13.7 nM of the Bachem hepcidin peptide to the blank 
samples.
According to manufacturers protocol both peptides had disulfide bonds between Cys1- Cys8, 
Cys2-Cys7, Cys3-Cys6, and Cys4-Cys5,28 purity as assessed by amino acid analysis was >99% 
for Peptide Int. hepcidin and >95% for Bachem hepcidin.
Each sample, of the total of 17 samples, was split into two aliquots and coded (blind) for 
each participating laboratory and stored at -80oC. Three weeks after collection and storage, 
the samples were shipped on dry ice to all participants, and measured within two months of 
receipt. All laboratories performed single measurements on the 34 samples (17 duplicate 
samples). All samples underwent one freeze thaw cycle before analysis (except for two 
methods for which the samples underwent 2 freeze thaw cycles). However, a previous study 
showed that serum samples are not susceptible to loss of hepcidin by 2 freeze-thaw steps.7
HEPCIDIN METHODS
Characteristics of the methods used for the plasma hepcidin measurements of the present 
study are schematically and in random order presented in Table 1.
Mass spectrometry based methods that are available for quantitative hepcidin measurement 
and participated in this round robin are based on matrix assisted laser desorption/ionization 
(MALDI), surface enhanced laser desorption/ionization (SELDI), or electrospray ionization 
(ESI) for generation of ions with time of flight (TOF) or quadrupole analyzers for MS 
principles. Hepcidin enrichment was achieved by weak cation exchange chromatography, 
liquid chromatography, reversed phase extraction, solid phase extraction and protein 
precipitation. Internal and external standards that were used were synthetic hepcidin 
analogues, stable isotope labeled hepcidin-25 and recombinant hepcidin-25 (Table 1).
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Immunochemical based methods that are available for quantification of hepcidin and 
participated in this round robin are either competitive or sandwich immunochemical 
methods (with biotinylated hepcidin-25 or 125I-hepcidin-25 as tracer for quantification) and 
a hepcidin ligand binding method (Table 1). Internal and external standards that were used 
were synthetic hepcidin-25, recombinant hepcidin-25, modified hepcidin-25 fragments and 
125I-hepcidin-25 (Table 1).
8-10,12-14,18-25,29Most methods have been published previously,8-10,12-14,18-25,29 although some have only been 
described for urine samples.15,17
STATISTICAL METHODS
Analytical characteristics of the methods
At first we studied the repeatability of the methods for plasma (native samples). Therefore, 
we partitioned the total variance of each hepcidin method into the following components: i) 
the between-sample variance and ii) the within-sample variance (analytical variation). With 
respect to repeatability, the magnitude of the within-sample variance is of interest.
A linear mixed model was used to estimate these variance components of each method 
separately. The dependent variable was hepcidin outcome and the independent random 
variables were native sample (11 levels) and duplicate measurement (2 aliquots). Because 
we were interested in the analytical variation on a single measurement of each method, we 
omitted the last term from the final model and did not present the variation due to the 2 
aliquots separately.
The standard deviation (SD) (absolute error) and the percentage variance relative to the 
total variance of both, the within- and the between- (native) sample, are presented for each 
method separately. The Spearman rank correlation between each combination of two 
methods was calculated, using all 22 paired hepcidin values (11 samples, two aliquots).
Selection of “well performing" methods
At first, methods were selected showing within-sample variation of less than 10% of the 
total variation of this method. Of the remaining methods, those with a Spearman correlation 
> 0.90 with all other methods were then designated as "well performing" methods.
Commutability
To assess whether the synthetic hepcidin-25 peptides of Peptide International and Bachem 
mimic native serum samples in their analytical behavior (so called commutability), according 
to the CLSI C53_P protocol30 we determined whether the synthetic samples followed the 
same trend as the native samples for each couple of "well performing" methods, separately. 
For each couple of "well performing" methods the regression of the difference against 
average was calculated (Bland-Altman plots31) with the 95% confidence band for single 
measurements, using native samples only. Subsequently, the commutability of the synthetic 
sample was assessed by the calculation of the relative differences of its value to the 
regression line in the Bland-Altman plots (normalized SD). Synthetic samples were 
considered not commutable when the normalized SD was > 2, in other words when the 
measurement was outside the 95% confidence band.
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Table 1. Characteristics of methods used for plasma hepcidin measurements.
Principle Method Hepcidin extraction Standard Purchased from Reference
MS HPLC-MS/MS Reversed phase Internal Synthetic Hepcidin-25 [15N,C13] Bachem, in house labeled 10
MS LC-MS/MS WCX Internal Synthetic Hepcidin-25 - -
MS LC-MS/MS WCX magnetic nanoparticles Internal 13C6Phe9,[15N,13C2]Gly20-hepcidin Peptide Int., in house labeled 11
MS LC-MS/MS Reversed Phase Internal Human Hepcidin-25 [13C9,15N1-Phe4] In hosue labeled 14
MS LC-MS/MS Reversed Phase Internal Synthetic Hepcidin-25 [13C2] Peptide Int. 9
MS LC-MS/MS Protein ppt & SPE Internal Synthetic Hepcidin-25 Peptide Int. 8
MS MALDI-TOF MS None Internal Synthetic Hepcidin-25 [15N4,13C6]Argl6 Sigma-Genosys 17
MS MALDI-TOF MS WCX Internal Synthetic Hepcidin-24 Peptide Int. 13,19
MS Q-TOF-LC/MS ACN ppt External Hepcidin-24 heavy isotope -
18
MS SELDI-TOF MS IMAC Internal Synthetic Hepcidin-24 Peptide Int. 15
MS SELDI-TOF MS IMAC External Stable isotope labeled Hepcidin-25 AltaBioscience 12
IC Competitive ELISA None External Synthetic Hepcidin-25 Peptide Int. 19
IC Competitive ELISA None External Synthetic Hepcidin-25 Bachem 20
IC Competitive ELISA None External Synthetic Hepcidin-25 Bachem *
IC Competitive ELISA None External Modified Hepcidin-25 fragment DRG 29
IC Competitive ELISA None External Recombinant Hepcidin-25 In house made 22
IC Competitive RIA None External Synthetic Hepcidin-25 Bachem 23
IC Competitive RIA None External Synthetic Hepcidin-25 Peptide Int. 24
IC Sandwich ELISA None External Synthetic Hepcidin-25 Peptide Int. 25
IC Sandwich ELISA None External Recombinant Hepcidin-25 In hosue made -
IC HBD method None Internal 125l-Hepcidin-25 42 21
MS, Mass spectrometry based; IC, Immunochemical based; HPLC-MS/MS, High Performance Liquid Chromatography; MS/MS, Tandem MS; LC, Liquid Chromatography; 
MALDI, Matrix Assisted Laser Desorption/Ionization; TOF, Tim e of Flight; Q, quadrupole; SELDI, Surface Enhanced Laser Desorption/Ionization; ELISA, Enzyme Linked 
Immunosorbent Assay; HBD, Hepcidin Binding Domain; WCX, W eak Cation Exchange; ppt, protein precipitation; SPE, Solid Phase Extraction; ACN, Acetonitrile; IMAC, 
Immobilized Metal Affinity Chromatography.
Bachem standard: Bachem LTD, St. Helens, UK; Peptide Int., Peptide Int. Inc. Louisville, KY, USA; Sigma-Genosys, Sigma-Genosys, Woodlands, TX, USA; AltaBioscience 
standard, University of Birmingham, Birmingham, UK; DRG standard: DRG Instruments GmbH, Marburg, Germany. * ,Bachem EIA kit (Cat. No S-1337) purchased from 
Bachem in August 2010. Note that the methods are randomly numbered compared to Tables 2-5.
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Harmonization/Standardization
A qualification of a gold standard is that it is measured with optimal precision, i.e. little or no 
variation and this is therefore also the first requirement of an alternative for the gold 
standard. All methods with equal hepcidin values of the same sample will contribute to a 
more optimal precision of their consensus value. The consensus of each sample is the mean 
value of the hepcidin values of those methods that showed good agreement with the x=y 
line in the scatter diagram of each couple. An essential requirement of methods to be 
selected to determine the consensus value, is their very good mutual agreement to increase 
precision and control the noise of the consensus value.
A method specific regression line (algorithm) was constructed from the duplicates of the 
reported native hepcidin results, against the consensus (HEPCON) values. This method 
specific regression line can be used to calculate the consensus value of its own measured 
result and the appropriate confidence interval is calculated using the delta-method.
Results
ANALYTICAL CHARACTERISTICS OF THE METHODS
Table 1 presents the 21 participating methods (11 MS and 10 IC) from in total 16 
laboratories. Mean hepcidin levels with SD measured by the 21 hepcidin methods are shown 
in random order in Table 2. We observed that absolute hepcidin values differed widely 
between samples and the various methods. For example, native samples 1 and 11 were 
measured between 0.0-44.4 nM and 0.08-155.2 nM, respectively. Table 3 shows the 
absolute within- and between-sample SDs, and the within- and between-sample variance 
relative to the total variance for each method. The within- and between-sample SDs differed 
widely between the assays. The contribution of the within-sample variance to the total 
variance is low for 9 MS and 6 IC methods (0.1-7.9 %) and high for 2 MS and 4 IC methods 
(17.7-100.0 %). Notably, the higher the within-sample variance, the lower the probability 
that samples with only small differences can be distinguished.
SELECTION OF "WELL PERFORMING" METHODS FOR FURTHER ANALYSIS
We excluded 6 methods based on the criteria of a within-sample variance of >10% of the 
total variance of this method (Table 3). Of the remaining 15 methods we determined the 
Spearman rank correlations of each combination of two methods (Table 4). Based on the 
results, we excluded 1 additional method (MS(7)) that despite having a significant 
correlation with the other methods, it didn't reach the required coefficient threshold >0.90. 
This restricted our selection to 14 "well performing" methods.
COMMUTABILITY OF SYNTHETIC HEPCIDIN
Figure 1 shows a selection of 4 out of the 98 possible Bland-Altman plots, illustrating 4 
different patterns of analytical behavior of synthetic relative to native samples in the 
comparison of method pairs. The Figure top panels are two examples for which the 
synthetic samples are not commutable to native samples, i.e. results obtained for the 
synthetic samples and native samples are substantially different. The left panels of Figure 1 
are examples with large differences between the two methods.
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Method MS(1) MS(2) MS(3) MS(4) MS(5) MS (6) MS(7) MS (8) MS (9) MS(10)
Samplenr. Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Native
1 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 3.2 (0.3) 0.0 (0.0) 0.5 (0.1) 0.0 (0.0) 1.5 (0.2) 0.0 (0.0) 0.0 (0.0)
2 2.6 (0.1) 5.6 (1.8) 6.2 (0.1) 11.7 (1.5) 4.1 (0.5) 9.4 (1.6) 13.6 (5.7) 8.5 (0.7) 4.4 (0.1) 2.5 (0.6)
3 3.8 (0.1) 4.7 (0.5) 9.2 (0.2) 15.1 (2.0) 5.0 (0.1) 10.7 (0.4) 29.9 (5.1) 11.8 (4.0) 5.8 (0.0) 2.4 (0.8)
4 5.1 (0.1) 7.2 (1.0) 11.6 (0.9) 18.6 (0.4) 6.9 (1.3) 16.9 (3.7) 37.6 (5.6) 12.6 (1.0) 7.8 (0.0) 6.0 (2.2)
5 8.8 (0.1) 12.6 (0.5) 21.7 (1.9) 31.6 (0.1) 12.4 (1.2) 25.3 (1.0) 44.7 (5.9) 24.6 (0.6) 15.3 (0.5) 6.8 (1.0)
6 10.4 (0.1) 14.9 (1.8) 28.3 (1.0) 38.2 (0.2) 18.4 (1.3) 32.2 (3.3) 75.1 (7.6) 28.9 (0.2) 18.3 (0.9) 13.2 (9.0)
7 11.5 (0.0) 14.9 (0.3) 30.6 (0.8) 42.7 (1.1) 24.5 (0.1) 33.3 (1.2) 72.7 (3.1) 36.3 (4.6) 18.9 (1.2) 13.7 (6.8)
8 10.9 (0.2) 17.4 (2.3) 30.7 (2.3) 43.5 (1.5) 21.4 (0.8) 34.7 (2.9) 52.9 (2.7) 43.0 (0.7) 19.6 (0.5) 10.9 (1.0)
9 12.4 (0.0) 20.4 (2.5) 38.4 (0.5) 47.1 (2.1) 31.9 (1.4) 38.5 (0.4) 73.7 (0.3) 39.2 (2.5) 24.6 (0.1) 24.0 (2.8)
10 14.3 (0.1) 22.6 (1.5) 41.1 (0.2) 54.2 (1.2) 33.0 (1.6) 48.7 (5.2) 81.9 (0.5) 46.1 (0.1) 26.1 (1.0) 11.7 (1.5)
11 20.0 (0.4) 29.8 (2.5) 62.4 (0.5) 81.2 (0.5) 48.7 (1.9) 64.7 (0.0) 71.5 (0.8) 72.8 (13.1) 33.0 (9.6) 26.3 (2.8)
Synthetic
PI* 5nM 4.1 (0.3) 4.1 (0.3) 8.1 (0.4) 13.7 (1.2) 5.0 (0.7) 11.5 (0.2) 35.0 (3.6) 8.4 (2.0) 6.0 (0.1) 4.0 (1.1)
12.5nM 10.4 (0.2) 11.7 (0.3) 20.5 (1.3) 29.6 (1.5) 11.5 (0.5) 25.1 (0.4) 66.6 (16.1) 24.4 (1.1) 15.3 (0.1) 15.3 (9.9)
20nM 16.6 (0.3) 18.8 (0.8) 35.0 (0.6) 45.8 (1.0) 18.9 (0.8) 38.2 (0.8) 86.0 (3.6) 41.5 (2.0) 25.3 (0.4) 13.6 (5.1)
B* 3.4nM 2.6 (0.4) 3.2 (0.0) 5.4 (0.0) 8.2 (0.6) 3.0 (0.2) 8.0 (0.1) 20.8 (5.9) 5.4 (0.2) 3.7 (0.0) 1.7 (0.4)
8.6nM 5.0 (0.1) 6.3 (1.3) 10.7 (0.2) 17.5 (0.7) 6.3 (0.5) 13.6 (0.1) 44.2 (10.1) 11.1 (1.9) 7.6 (0.0) 5.0 (0.1)
13.7nM 7.6 (0.3) 9.1 (0.8) 17.8 (0.9) 22.6 (0.3) 9.0 (0.1) 21.5 (0.4) 61.0 (15.9) 20.1 (1.5) 11.8 (0.0) 14.5 (6.9)
Data are expressed in nM. *, Peptide International and Bachem samples are synthetic hepcidin peptides purchased form Peptide Int. (Louisville, KY, USA) and Bachem LTD (St. Helens, UK), respectively, which are spiked 
in blank plasma samples.According the inserts of the companies. Level assignment of the synthetic peptides is achieved by amino acid sequence analysis and purity is checked by HPLC. Native samples are obtained in 
the Radboud University Nijmegen Medical Center, by pooling plasma samples from hospitalized patients.
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Table 2 continued. Mean and standard deviation (SD) of the duplicates of the levels of hepcidin m easured by sam ple by m ethod.
Method M S (ll) IC(1) IC(2) IC(3) IC(4) IC(5) IC(6) IC(7) IC(8) IC(9) IC(10)
Samplenr. Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Native
1 0.000 (0.000) 0.0 (0.0) 0.2 (0.0) 0.0 (0.0) 0.0 (0.0) 0.4 (0.1) 4.3 (1.8) 44.4 (4.0) 2.3 (1.8) 6.2 (0.0) 8.8 (2.0)
2 0.000 (0.000) 1.5 (0.6) 3.2 (0.2) 3.5 (0.0) 5.5 (0.8) 7.1 (0.2) 20.8 (1.6) 40.1 (17.6) 18.5 (1.3) 5.8 (0.9) 10.8 (1.8)
3 0.006 (0.008) 5.2 (0.1) 5.2 (0.5) 4.9 (0.1) 8.1 (0.5) 12.7 (0.2) 26.5 (4.3) 26.5 (9.5) 29.2 (1.8) 6.4 (1.3) 13.5 (4.2)
4 0.014 (0.003) 7.7 (0.4) 7.8 (0.6) 6.1 (0.1) 10.9 (0.7) 19.1 (4.1) 45.8 (1.0) 25.5 (1.4) 45.9 (10.1) 3.8 (0.4) 18.5 (5.8)
5 0.277 (0.367) 16.1 (0.5) 13.0 (0.6) 8.7 (0.6) 21.4 (1.8) 32.7 (0.1) 77.0 (7.8) 31.0 (0.2) 94.7 (21.8) 3.4 (0.0) 52.6 (35.4)
6 0.013 (0.016) 24.1 (0.4) 21.3 (1.9) 11.6 (0.9) 31.8 (0.4) 61.7 (2.1) 98.2 (7.8) 31.0 (7.0) 83.0 (13.4) 4.5 (0.4) 23.8 (8.2)
7 0.018 (0.012) 25.4 (0.4) 23.1 (1.0) 12.4 (1.1) 34.2 (2.0) 52.0 (8.3) 115.0 (30.0) 44.3 (8.4) 73.7 (12.9) 3.4 (0.4) 20.1 (6.3)
8 0.012 (0.009) 30.9 (0.0) 26.1 (1.2) 14.2 (0.8) 36.0 (2.4) 48.4 (8.0) 122.5 (4.4) 46.1 (9.7) 74.2 (4.6) 4.9 (2.5) 64.5 (66.6)
9 0.016 (0.015) 29.1 (1.4) 25.0 (0.7) 14.8 (0.8) 37.1 (1.4) 62.8 (1.1) 117.3 (13.2) 55.2 (6.4) 71.2 (24.1) 5.1 (0.9) 77.4 (68.6)
10 0.019 (0.014) 34.0 (1.3) 23.8 (0.6) 18.1 (0.4) 42.3 (2.5) 45.0 (6.9) 118.0 (18.2) 106.7 (1.5) 62.7 (12.7) 5.9 (0.1) 65.3 (72.4)
11 0.081 (0.079) 50.6 (2.5) 43.9 (1.9) 27.1 (0.0) 56.6 (2.7) 89.1 (0.2) 155.2 (1.0) 43.6 (19.7) 84.6 (16.7) 5.8 (0.0) 35.2 (1.6)
Synthetic
PI* 5nM 0.000 (0.000) 1.5 (0.6) 3.2 (0.2) 3.5 (0.0) 5.5 (0.8) 7.1 (0.2) 20.8 (1.6) 40.1 (17.6) 18.5 (1.3) 5.8 (0.9) 10.8 (1.8)
12.5nM 0.006 (0.008) 5.2 (0.1) 5.2 (0.5) 4.9 (0.1) 8.1 (0.5) 12.7 (0.2) 26.5 (4.3) 26.5 (9.5) 29.2 (1.8) 6.4 (1.3) 13.5 (4.2)
20nM 0.014 (0.003) 7.7 (0.4) 7.8 (0.6) 6.1 (0.1) 10.9 (0.7) 19.1 (4.1) 45.8 (1.0) 25.5 (1.4) 45.9 (10.1) 3.8 (0.4) 18.5 (5.8)
B* 3.4nM 0.277 (0.367) 16.1 (0.5) 13.0 (0.6) 8.7 (0.6) 21.4 (1.8) 32.7 (0.1) 77.0 (7.8) 31.0 (0.2) 94.7 (21.8) 3.4 (0.0) 52.6 (35.4)
8.6nM 0.013 (0.016) 24.1 (0.4) 21.3 (1.9) 11.6 (0.9) 31.8 (0.4) 61.7 (2.1) 98.2 (7.8) 31.0 (7.0) 83.0 (13.4) 4.5 (0.4) 23.8 (8.2)
13.7nM 0.018 (0.012) 25.4 (0.4) 23.1 (1.0) 12.4 (1.1) 34.2 (2.0) 52.0 (8.3) 115.0 (30.0) 44.3 (8.4) 73.7 (12.9) 3.4 (0.4) 20.1 (6.3)
Data are expressed in nM. *, Peptide International and Bachem samples are synthetic hepcidin peptides purchased form Peptide Int. (Louisville, KY, USA) and Bachem LTD (St. Helens, UK), respectively, which are spiked in blank plasma 
samples.According the inserts of the companies. Level assignment o f the synthetic peptides is achieved by amino acid sequence analysis and purity is checked by HPLC. Native samples are obtained in the Radboud University Nijmegen Medical 
Center, by pooling plasma samples from hospitalized patients.
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Figure 2 shows the relative difference (in normalized SD) of the value of the synthetic sample 
to the regression line in the Bland-Altman plots, that ranges from less than two for the 
lowest concentration of the Peptide International and Bachem synthetic samples, to over 9 
for the highest Peptide International synthetic samples. For the majority of the method 
couples in the Bland-Altman plots the synthetic hepcidin samples were situated outside the 
95% confidence interval (CI) of the regression line of the native samples, i.e. n=76 and n=73 
from the total of n=98 for Peptide International and Bachem, respectively. Normalized SDs 
increase for both synthetic peptides with increasing concentrations. Note that the Bachem 
synthetic samples tend to have lower normalized SDs compared to the Peptide International 
synthetic samples.
HARMONIZATION BY NATIVE SAMPLES
Fourteen method couples, MS-MS (n=6), IC-IC (n=2) and MS-IC (n=6), showed moderate 
agreement for the x=y lines. Two MS methods (6 & 8) were found to have a very good 
agreement between the x=y lines (Figure 3) and were used to calculate the hepcidin 
consensus (HEPCON) value.
The algorithms designed based on the HEPCON consensus values could be used to 
recalculate a single method specific hepcidin value to the HEPCON value and vice versa 
(Table 5). For example, methods MS1 and IC6 measure 8.8 nM and 77.0 nM for a specific 
sample, respectively. Using the algorithm this results in HEPCON values of 26.3 nM and 29.8 
nM, respectively. These algorithms to calculate method specific hepcidin values from the 
HEPCON succeed to explain between 87 and 99 % of the variance (R-square). Note that 
these algorithms may be less reliable in the low and high hepcidin concentration range.
Table 3. The total between- and within-sample standard deviation (SD) of the methods and
the contribution of the between- and within-sample variance to the total variance.
Method Total SD Between-sample SD Within-sample SD
Variance (%) 
Between-sample Within-sample
MS(1) 5.8 5.8 0.2 99.9 0.1
MS(2) 8.9 8.8 1.6 96.8 3.2
MS(3) 18.3 18.2 0.9 99.7 0.3
MS(4) 22.4 22.4 1.2 99.7 0.3
MS(5) 15.0 15.0 1.1 99.4 0.6
MS(6) 18.8 18.6 2.4 98.3 1.7
MS(7) 27.7 27.4 4.3 97.6 2.4
MS(8) 21.0 20.6 4.4 95.6 4.4
MS(9) 10.5 10.1 2.9 92.1 7.9
MS(10) 8.9 8.1 3.8 82.3 17.7
MS(11) 0.1 0.0 0.1 1.1 98.9
IC(1) 15.8 15.8 1. 0 99 .6 0. 4
IC(2) 13.0 13.0 1.0 99.4 0.6
IC(3) 7.6 7.6 0.6 99.4 0.6
IC(4) 17.9 17.8 1.7 99.1 0.9
IC(5) 27.6 27.3 4.3 97.6 2.5
IC(6) 50.8 49.4 12.0 94.4 5.6
IC(7) 23.5 21.4 9.8 82.6 17.4
IC(8) 31.5 28.5 13.4 81.9 18.1
IC(9) 1.3 0.9 1.0 44.8 55.2
IC(10) 36.7 0.0 36.7 0.0 100.0
Variance components of each method are estimated by a linear mixed model using the data of the native 
samples. SD, absolute error; Between-sample, segment due to variation between samples; Within-sample, 
segment due to repeated measurements; MS, Mass Spectrometry based; IC, Immunochemical based. Data are 
expressed in nM. The within-sample variance > 10 % of the total variance are indicated in bold. Note that the 
methods are randomly numbered within the type of platform compared to table 1.
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Table 4. Spearman's correlation coefficients between the 15 methods with a within-sample 
variance < 10 % of the total variance.
Method MS(1) MS(2) MS(3) MS(4) MS(5) MS(6) MS(7) MS(8) MS(9) IC(1) IC(2) IC(3) IC(4) IC(5)
MS(2) 0.96
MS(3) 0.98 0.98
MS(4) 0.98 0.98 0.99
MS(5) 0.96 0.96 0.98 0.98
MS(6) 0.98 0.98 0.99 0.99 0.98
Ms (7) 0.89 0.85 0.87 0.87 0.85 0.88
MS(8) 0.96 0.96 0.97 0.98 0.97 0.96 0.84
MS(9) 0.99 0.97 0.99 0.99 0.97 0.99 0.89 0.97
IC(1) 0.92 0.94 0.96 0.96 0.97 0.95 0.80 0.96 0.95
IC(2) 0.92 0.95 0.95 0.95 0.97 0.94 0.78 0.96 0.93 0.98
IC(3) 0.99 0.98 0.98 0.99 0.97 0.99 0.88 0.97 0.99 0.94 0.94
IC(4) 0.93 0.96 0.97 0.97 0.98 0.96 0.80 0.96 0.95 0.98 0.97 0.95
IC(5) 0.90 0.93 0.93 0.93 0.94 0.93 0.78 0.91 0.91 0.95 0.96 0.91 0.96
IC(6) 0.92 0.94 0.95 0.95 0.97 0.94 0.79 0.94 0.94 0.97 0.97 0.94 0.98 0.96
In bold the method with Spearman's correlations < 0.90 with the other methods. MS, Mass Spectrometry 
based; IC, Immunochemical based.
Figure 2 shows normalized SDs ranging from <2 for the lowest concentration of the Peptide 
International and Bachem synthetic samples, to nearly 9 for the highest Peptide 
International synthetic samples. Normalized SDs increase for both synthetic peptides with 
increasing concentrations. The Bachem synthetic samples show lower normalized SDs 
compared to the Peptide International synthetic samples, due to the lower concentrations.
Table 5A. The algorithm to calculate the estimated hepcidin value from the HEPCON value, using a 
linear regression model on the native samples only.
Method SEM RSquare
IC1 Y = -4.37 + 0.78 * HEPCON 0.73 0.92
IC2 Y = -2.55 + 0.64 * HEPCON 0.55 0.93
IC3 Y = 0.28 + 0.38 * HEPCON 0.18 0.98
IC4 Y = -2.60 + 0.89 * HEPCON 0.82 0.92
IC5 Y = -2.04 + 1.30 * HEPCON 1.78 0.83
IC6 Y = 3.14 + 2.49 * HEPCON 2.89 0.87
MS1 Y = 0.99 + 0.30 * HEPCON 0.24 0.93
MS2 Y = 0.56 + 0.45 * HEPCON 0.29 0.96
MS3 Y = -1.07 + 0.91 * HEPCON 0.36 0.98
MS4 Y = 2.01 + 1.13 * HEPCON 0.41 0.99
MS5 Y = -3.12 + 0.72 * HEPCON 0.56 0.94
MS6 Y = 1.59 + 0.93 * HEPCON 0.37 0.98
MS8 Y = -1.59 + 1.07 * HEPCON 0.37 0.99
MS9 Y = 1.17 + 0.52 * HEPCON 0.51 0.90
MS, Mass Spectrometry based; IC, Immunochemical based. HEPCON, average of MS6 and MS8; SEM, standard 
error of the mean.
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Table 5B. The algorithm to calculate the estimated HEPCON value from the hepcidin value, using a 
linear regression model of Y on HEPCON based on the native samples only.
Method SEM
IC l HEPCON = S.S9 + 1.28 * Y 0.93
IC2 HEPCON = 3.96 + 1.S6 * Y 0.86
ICS HEPCON = -0.74 + 2.63 * Y 0.48
IC4 HEPCON = 2.91 + 1.12 * Y 0.91
ICS HEPCON = 1.S8 + 0.77 * Y 1.37
IC6 HEPCON = -1.26 + 0.40 * Y 1.16
MS1 HEPCON = -3.3S + 3.37 * Y 0.81
MS2 HEPCON = -1.2S + 2.24 * Y 0.6S
MSS HEPCON = 1.17 + 1.10 * Y 0.39
MS4 HEPCON = -1.78 + 0.89 * Y 0.36
MSS HEPCON = 4.33 + 1.39 * Y 0.77
MS6 HEPCON = -1.71 + 1.07 * Y 0.39
MS8 HEPCON = 1.49 + 0.94 * Y 0.34
MS9 HEPCON = -2.27 + 1.94 * Y 0.99
MS, Mass Spectrometry based; IC, Immunochemical based. SEM, standard error of the mean. This algorithm is 
the reverse of the one presented in the previous table.
Figure 1. Four examples of 98 Bland-Altman plots for the comparison of two methods with the 
regression lines (thick solid line) using the native samples (closed circles) only. The dashed lines 
indicate the 95% confidence band. The horizontal line at 0 refers to no difference between methods. 
The squares indicate the synthetic hepcidin of Peptide Int. and the stars indicate the synthetic 
hepcidin of Bachem. The left panels are two examples with large differences between the two 
methods. The top panels are two examples for which the synthetic samples are not commutable.
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Discussion
We confirmed the observations of the hepcidin round robin 1 that hepcidin values differ 
widely between plasma hepcidin methods.26 We, moreover, observed large differences in 
SD, but the contribution of the within-sample variation to the total variation to be similar 
for the majority of the methods. We found the synthetic hepcidin samples not to be 
commutable, thus not suitable for harmonization purposes. As an alternative, we used 
native samples for harmonization, and constructed algorithms that allow analytically well 
performing methods to compute values obtained by each if the methods into international 
hepcidin consensus (HEPCON) values and vice versa.
The observations of widely differing hepcidin values between methods corroborate those 
obtained in our first round robin for hepcidin methods.26 In fact, this observation was the 
main reason to set up the harmonization study. These differences might be attributed to 
differences in the values the companies assign to the internal and external standards used 
by the different methods, to impurities in these standards or to loss of the standard during 
storage, e.g. by aggregation28,32 or sticking of the synthetic hepcidins to the tubes. Hence, 
studies on the optimal handling and storage conditions of synthetic hepcidin standards are 
warranted to allow the formulation of recommendations on this point. Moreover accurate 
value assignment of the synthetic peptides could also contribute to bringing the values of 
the various methods together. This could be achieved by state of the art techniques of 
peptide quantification, such as amino-acid analysis, which however also have their analytical 
uncertainties. Alternatively, stable isotopes can be send out from reference laboratories to 
calibrate the standards.
We found the majority of methods to have a relatively low contribution (< 10%) of the 
within-sample variation to the total variation, implying that these method have a good 
ability to distinguish samples of different hepcidin concentrations. Methods and their 
corresponding laboratories that showed a relatively large within-sample variation (> 10 %) or 
a relatively low correlation with the other methods were encouraged to improve the 
precision and accuracy of their method.
We found the inter-method behavior of both synthetic samples to be different from that of 
pooled native patient plasma for the large majority of the method couples. Even in the low 
concentration range, synthetic samples of both Bachem and Peptide International behaved 
differently from native samples. This difference in inter-method behavior between synthetic 
and native samples increases with increasing hepcidin concentrations. Thus, the low added 
concentrations of Bachem did not result in false judgment of the commutability. These 
observations imply that the synthetic samples are not commutable to the native samples. 
These artificial samples are therefore not suitable for measurement of inter-method level 
variability, precluding the exploitation of these synthetic samples as materials for 
harmonization purposes, i.e. for equalizing the levels of hepcidin of the different methods.32 
This non-commutability of the synthetic hepcidin samples can be caused by a matrix 
alteration or by a nonnative analyte.34-36 In the case of hepcidin: i) the structure of the 
native hepcidin might well be different from the synthetic hepcidin, e.g. because of 
thermodynamic processes that differ for the in vitro and in vivo production of hepcidin,32,33 
and ii) in vitro addition of a synthetic or native hepcidin peptide to a plasma might cause a 
different binding to plasma proteins, such as a-2 macroglobulin or albumin38 than the in vivo 
secreted hepcidin. Thus even when we could succeed to make a synthetic or recombinant 
hepcidin that has a structure identical to native hepcidin, and spike it to plasma, it is unclear 
if it behaves similar to the hepcidin secreted in vivo.
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Since the synthetic samples appeared not be useful for harmonization we used native 
samples and constructed algorithms which allow computing hepcidin consensus (HEPCON) 
values for the results obtained by the various methods and vice versa. In the absence of an 
IFCC validated reference method,39 we selected 2 methods for the definition of consensus 
values, that showed a good precision and correlation with the majority of other methods as 
criteria, and which gave hepcidin results for the native samples that are (almost) equal. Any 
of the methods could have passed to be used as an consensus because of low within sample 
variations. However, to increase the precision and control the noise of the consensus value, 
we averaged those methods that produced "identical" results (only 2). Whether this 
selection results in consensus values which reflect true values is unknown. Furthermore, 
these methods are not necessarily the most precise methods. Nevertheless, they allow us to 
generate algorithms by which international hepcidin consensus values can be obtained that 
can be compared worldwide. Here, it should be noted that the better the precision of the 
hepcidin method the better the precision of the calculated HEPCON values.
Altogether, calculation of originally obtained values in HEPCON values add to harmonization 
of the methods in the absence of a reference method and calibrator, and may contribute to 
i) definition of generally accepted and usable reference intervals, ii) application of consistent 
clinical decision limits for medical care and best practice guidelines, and iii) pooling and 
comparison of data from various studies to facilitate medical research and research 
translation.
Since the proposed algorithms are susceptible to changes causes by adaptations to the 
methodologies, the "hepcidin community" should further work on the development of 
commutable calibrators and reference methods. Meanwhile, we intend to regularly update 
the algorithms by the organization of a bi-annual round robins.
In conclusion, until commutable materials for harmonization are defined, harmonization can 
be achieved by exploiting specific algorithms allowing each lab to report in HEPCON (version 
1) values. This study is the first step towards harmonization of plasma hepcidin methods and 
facilitates the definition of clinical decision limits.
3.4 nM 5 nM 8.6 nM 12.5 nM 13.7 nM 20 nM
SPIKE B SPIKE PI SPIKE B SPIKE PI SPIKE B SPIKE PI
Figure 2. The normalized SD of the synthetic samples relative to the regression line in the 98 Bland- 
Altman plots. Spikes were considered not commutable when the normalized SD > 2. The synthetic 
samples consist of hepcidin purchased from the Peptide Int. (Spike PI) and hepcidin purchased from 
Bachem (Spike B), each spiked in 3 different concentrations to the native blank plasma.
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Figure 3. Scatterplot of the 2 methods selected for the hepcidin consensus.
(-) is X-Y line; (*), native samples
Acknowledgements
We thank the hepcidin technicians Erwin Wiegerinck and Coby Laarakkers for their technical 
assistance and the valuable discussions on explanations for both differences in analytical 
characteristics between methods and non commutability of the synthetic samples. We thank 
Siem Klaver for his support in the collection and logistics of the study and Herman Steigstra 
for his help in the initial stage of this study.
On behalf of the participants of the Round Robin-2 team:
Sandro Altamura1, Damon S. Anderson2, Sukhvinder S. Bansal3, Pierre Brissot4, Mark Busbridge5, 
Anthony M. Butterfield6, Keegan Cooke7, David Crockett8, Ivana De Domenico9, Mark Fleming2,
11 3 12 9 13Anneke J. Geurts-Moespot , Robert C. Hider , Alfred Janetzko , Jerry Kaplan , Uwe Kobold , Vasiliki 
Koliaraki14, Avgi Mamalaki14, Martina Muckenthaler1, Anthony T. Murphy6, Gordana Olbina10, Ralf 
Roeddiger13, Barbra Sasu7, Naohisa Tomosugi15, Olivier Tribut4, Chris Tselepis16, Douglas G. Ward16, 
Mark Westerman10.
1Kinderklinik, Heidelberg, Germany
2Department of Pathology, Children's hospital Boston, Boston, MA, USA
3Pharmaceutical Sciences Division, King's College London, London, UK
4Laboratoire de Pharmacologie, Hopital Pontchaillou, Rennes, France
5Department of Clinical Chemistry, Imperial College HealthCare NHS Trust, Hammersmith Hospital 
Campus, London, UK
6Lilly Research Laboratories, Lilly Corp. Center, Indianapolis, IN, USA
7Amgen Inc., Thousand Oaks, CA, USA
8ARUP Laboratories, Salt Lake City, UT, USA
9University of Utah, Salt Lake City, UT, USA
“ Intrinsic Life Sciences, La Jolla, CA, USA
“ Department of Laboratory Medicine -  Laboratory of Genetic Endocrine and Metabolic diseases, 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
12DRG Instruments GmbH, Marburg, Germany
88
Chapter 5
13Roche Diagnostics GmbH, Penzberg, Germany
14Laboratory of Molecular Biology & Immunobiotechnology, Department of Biochemistry, Hellenic
Pasteur Institute, Athens, Greece
15Division of Advanced Medicine, Medical Research Institute/Division of Nephrology, Kanazawa
Medical University, Ishikawa, Japan
16CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, UK
Reference List
1. Kroot JJC, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic 
implications. Clinical Chemistry 2011, in press.
2. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-33.
3. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol 
2011;54:173-81.
4. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver- 
specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is 
overexpressed during iron overload. J Biol Chem 2001;276:7811-9.
5. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I et al. The gene encoding the iron 
regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 
2002;110:1037-44.
6. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM et al. Hepcidin regulates 
cellular iron efflux by binding to ferroportin and inducing its internalization. Science 
2004;306:2090-3.
7. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin 
measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 
2007;53:620-8.
8. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and 
mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007;110:1048- 
54.
9. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of 
bioactive peptides in biological matrices using liquid chromatography/selected reaction 
monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass 
Spectrom 2007;21:4033-8.
10. Kobold U, Dulffer T, Dangl M, Escherich A, Kubbies M, Roddiger R, Wright JA. Quantification of 
hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry. Clin 
Chem 2008;54:1584-6.
11. Bansal SS, Abbate V, Bomford A, Halket JM, Macdougall IC, Thein SL, Hider RC. Quantitation of 
hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass 
spectrometer. Rapid Commun Mass Spectrom 2010;24:1251-9.
12. Ward DG, Roberts K, Stonelake P, Goon P, Zampronio CG, Martin A et al. SELDI-TOF-MS 
determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an 
internal standard. Proteome Sci 2008;6:28.
13. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H. Advances in 
quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 
2008;3:e2706.
14. Li H, Rose MJ, Tran L, Zhang J, Miranda LP, James CA, Sasu BJ. Development of a method for the 
sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J 
Pharmacol Toxicol Methods 2009;59:171-80.
15. Altamura S, Kiss J, Blattmann C, Gilles W, Muckenthaler MU. SELDI-TOF MS detection of urinary 
hepcidin. Biochimie 2009;91:1335-8.
16. Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A et al. Evaluation of 
hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J 
Biomed Biotechnol 2010;2010:329646.
89
Harmonization of hepcidin methods
17. Anderson DS, Heeney MM, Roth U, Menzel C, Fleming MD, Steen H. High-throughput matrix- 
assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification 
of hepcidin in human urine. Anal Chem 2010;82:1551-5.
18. Crockett DK, Kushnir MM, Phillips JD, Rockwood AL. Time-of-flight mass spectrometry analysis of 
the ferroportin-hepcidin binding domain complex for accurate mass confirmation of bioactive 
hepcidin 25. Clin Chim Acta 2010;411:453-5.
19. Kroot JJC, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE et al. 
Immunochemical and Mass-Spectrometry-Based Serum Hepcidin Assays for Iron Metabolism 
Disorders. Clin Chem 2010;56:1570-9.
20. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. 
Blood 2008;112:4292-7.
21. De Domenico I, Nemeth E, Nelson JM, Phillips JD, Ajioka RS, Kay MS et al. The hepcidin-binding 
site on ferroportin is evolutionarily conserved. Cell Metab 2008;8:146-56.
22. Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA et al. A novel 
immunological assay for hepcidin quantification in human serum. Plos One 2009;4:e4581.
23. Busbridge M, Griffiths C, Ashby D, Gale D, Jayantha A, Sanwaiya A, Chapman RS. Development of 
a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci 2009;66:150-7.
24. Grebenchtchikov N, Geurts-Moespot AJ, Kroot JJ, den HM, Tjalsma H, Swinkels DW, Sweep FG. 
High-sensitive radioimmunoassay for human serum hepcidin. Br J Haematol 2009;146:317-25.
25. Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, Wroblewski VJ, Konrad RJ. A Dual­
Monoclonal Sandwich ELISA Specific for Hepcidin-25. Clin Chem 2010;56:1725-32.
26. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D et al. Results of the first 
international round robin for the quantification of urinary and plasma hepcidin assays: need for 
standardization. Haematologica 2009;94:1748-52.
27. van Dijk BA, Kemna EH, Tjalsma H, Klaver SM, Wiegerinck ET, Goossens JP et al. Effect of the new 
HJV-L165X mutation on penetrance of HFE. Blood 2007;109:5525-6.
28. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide 
hormone with antimicrobial activity that is involved in iron uptake and hereditary 
hemochromatosis. J Biol Chem 2002;277:37597-603.
29. Schwarz P, Strnad P, von FG, Janetzko A, Krayenbuhl P, Adler G, Kulaksiz H. A novel monoclonal 
antibody immunoassay for the detection of human serum hepcidin. J Gastroenterol 2010.
30. CLSI. Characterization and Qualification of Commutable Reference Materials for Laboratory 
Medicine;Proposed Guideline. CLSI document C53-P. Wayne, PA: Clinical and Laboratory 
Standards Institute; 2008.
31. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med 
Res 1999;8:135-60.
32. Jordan JB, Poppe L, Haniu M, Arvedson T, Syed R, Li V et al. Hepcidin revisited, disulfide 
connectivity, dynamics, and structure. J Biol Chem 2009;284:24155-67.
33. Miller WG, Myers GL, Rej R. Why commutability matters. Clin Chem 2006;52:553-4.
34. Rej R, Jenny RW, Bretaudiere JP. Quality control in clinical chemistry: characterization of 
reference materials. Talanta 1984;31:851-62.
35. Miller WG. Specimen materials, target values and commutability for external quality assessment 
(proficiency testing) schemes. Clin Chim Acta 2003;327:25-37.
36. Franzini C, Ceriotti F. Impact of reference materials on accuracy in clinical chemistry. Clin 
Biochem 1998;31:449-57.
37. Aschi M, Bozzi A, Di BR, Petruzzelli R. The role of disulfide bonds and N-terminus in the structural 
properties of hepcidins: insights from molecular dynamics simulations. Biopolymers 
2010;93:917-26.
38. Peslova G, Petrak J, Kuzelova K, Hrdy I, Halada P, Kuchel PW et al. Hepcidin, the hormone of iron 
metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood 2009;113:6225-36.
39. Groche D, Hoeno W, Hoss G, Vogt B, Herrmann Z, Witzigmann A. Standardization of two 
immunological HbA1c routine assays according to the new IFCC reference method. Clin Lab 
2003;49:657-61.
90
e Regulation of serum hepcidin levels in Sickle Cell Disease
Joyce J.C. Kroot,1 Coby M.M. Laarakkers,1 Erwin H.J.M. Kemna,1 Bart J. Biemond,2 Dorine W.
Swinkels,1
departm ent of Clinical Chemistry, Radboud University Nijmegen Medical Center, Nijmegen, The 
Netherlands; 2Department of Hematology, Amsterdam Medical Center, Amsterdam, The
Netherlands.
This chapter is published in Haematologica 2009;94(6):885-7
Hepcidin in Sickle Cell Disease
The peptide hormone hepcidin exerts its function by binding to the transmembrane cellular 
iron exporter ferroportin and inducing its internalization and degradation, resulting in 
decreased intestinal iron uptake and iron retention in the reticulo-endothelial (RE) 
macrophages. Inflammatory cytokines and iron loading increase hepcidin production, while 
increased bone marrow activity, and anemia suppress hepcidin synthesis.1,2 However, most 
of the evidence of these regulatory processes is obtained by molecular in vitro work and 
mice models, and much is still unknown about how these different stimuli interact in man. 
Sickle cell disease (SCD) patients are characterized by chronic hemolytic anemia, increased 
erythropoiesis and a chronic inflammatory state with endothelial activation and enhanced 
red cell and leukocyte adhesion. Sickle cell patients have iron overload due to chronic blood 
transfusions in the treatment or prevention of the severe sickle cell-related complications 
such as stroke.3 SCD has been associated with low urinary hepcidin levels in children.4 
However, serum hepcidin 25-amino acid isoform (hepcidin-25) levels, which are directly 
responsible for the biological effect, have not been documented and factors that contribute 
to hepcidin regulation in this disease have not been assessed.
Samples were collected from adult steady state SCD patients5 with various hemoglobin (Hb) 
genotypes (9 HbSS, 3 HbSbO-thalassemia and 4 HbSC, Table 1) between February 2005 and 
February 2006, and stored in polypropylene tubes at -80°C until analysis. Patients received 
no transfusions or chelation therapy for two months prior to sampling. Race matched 
controls were heterozygous for HbS or C.5 Serum and urinary hepcidin-25 measurements 
were performed in November and December 2007 by use of surface enhanced laser 
desorption ionization-time of flight mass spectrometry (SELDI-TOF MS) as previously 
described.6,7 The hepcidin regulators' inflammation, iron store and erythropoiesis (reflected 
in the serum markers C-reactive protein (CRP), ferritin and soluble transferrin receptor 
(sTfR), respectively) were assessed to delineate the regulatory pathways of hepcidin.8 
Approval for the study was obtained from the Medical Ethics Committee of the Academic 
Medical Center in Amsterdam.
We found the various serum parameters to vary widely within this population (Table 1). Of 
note is the pattern of the serum iron parameters, which shows highly variable ferritin levels, 
not simply related to the transfusion history and in the presence of normal transferrin 
saturation (TS). This suggests an iron distribution pattern of the anemia of chronic disease, 
with relatively more iron in the RE system.
Serum hepcidin-25 levels were below the lower limit of detection (LLOD <0.5 nM) in 5 SCD 
patients, while in the rest, the levels were between 1 and 10 nM, which is considered to be 
the normal range (Table 1). The median serum and urine hepcidin-25 levels were similar for 
patients and controls (p>0.2), but hepcidin-25/ferritin ratio's as a measure of 
appropriateness of hepatocyte-produced hepcidin for the iron burden,4 were significantly 
lower for patients (p<0.01) (Table 1). However, as ferritin in SCD might be increased by 
inflammation and iron loading of RE cells by transfusions, this ratio might not be suitable in 
the evaluation of the adequacy of hepcidin in response to hepatocytes iron loading.9 
Results confirm that erythropoiesis down-regulates hepcidin-25, i.e. when only sTfR is 
increased, serum hepcidin-25 levels are in the lower normal range or even not detectable 
(<LLOD-3.6 nM; patients 2, 4, 5, 13-16). In cases where next to a substantially increased sTfR 
inflammation and/or high iron stores are also present, serum hepcidin-25 levels are in the 
normal range (1.2 - 9.5 nM; patients 1, 3, 6, 8-12) confirming the induction of hepcidin by 
inflammation and elevated iron stores in sickle cell patients. Interestingly, in patient 7 the 
low hepcidin-25 level due to increased erythropoiesis (highly elevated sTfR) is not
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Table 1. Characteristics of study populations of adult sickle cell disease patients in steady state of their disease.
Gender Age
Transfused
PCU
Genotype BMI Hb MCV ALT Ferritin TS CRP sTfR Reticulocytes Hepcidin-25
Hepcidin-
25/Ferritin
Serum Urine Serum Urine
(M/F)
(Year
s)
(n) (kg/m2)
(mmol/
L) (fl)
(U/L) (Hg/L) (%) (mg/L) (mg/L) (°/o o) (nmol/L)
(nmol/ 
mmol cr)
(nmol/
Hg)
(pmol/
mmol
cr.^g)
1 F 24 32 SS# 31.9 5.9 92.2 81 4470 39.5 50 7.79 11.00 5.5 1.7 1.2 0.4
2 M 22 15 SS# 19.4 6.0 - 21 213 71.7 5 8.93 -- <LLOD 0.1 2.3 <0.5
3 F 52 16 SS 23.9 5.4 118.01 23 2051 44.4 8 5.36 10.80 9.5 2.5 4.6 1.2
4 F 45 67 SS# 18.9 4.6 85.8 16 108 24.1 <5 5.85 8.80 <LLOD 0.1 4.6 <0.9
5 F 18 2 SS# 21.1 6.0 96.2 16 140 42.6 <5 4.85 10.00 <LLOD 0.1 3.6 <0.7
6 F 22 5 SS# 21.9 5.2 93.1 14 438 39.6 <5 7.69 19.20 1.5 0.3 3.4 0.7
7 F 33 51 SS 19.8 4.0 90.1 26 210 41.9 10 10.40 17.50 <LLOD 0.1 2.4 <0.5
8 F 45 24 SS 18.0 6.1 99.9 68 739 23.3 <5 5.81 7.50 5.4 1.4 7.3 1.9
9 F 46 11 SS 31.3 5.2 125.01 10 293 31.2 12 6.14 13.10 2.4 0.4 8.2 1.4
10 F 19 8 sp° 22.5 5.4 64.2 52 180 25.5 10 6.87 8.30 1.2 0.5 6.7 2.8
11 F 41 43 S(30# 19.3 4.9 68.9 49 826 42.0 10 5.50 7.80 7.6 0.6 9.2 0.7
12 F 33 30 sp° 24.4 6.0 65.5 7 392 21.8 6 7.96 6.30 1.2 0.5 3.1 1.3
13 F 24 n.a. sc 21.2 5.9 74.7 7 40 23.5 <5 4.03 3.00 <LLOD 0.1 12.5 <2.5
14 32 19 sc 27.6 8.6 85.7 26 91 32.8 <5 2.72 2.70 1.4 0.1 15.4 1.1
15 F 29 4 sc 22.8 6.6 73.1 13 65 21.6 <5 2.23 1.60 3.6 0.5 55.4 7.7
16 F 40 n.a. sc 24.2 7.3 71.1 6 49 18.5 <5 3.15 1.60 1.7 0.2 37.4 4.1
Med. n.a. 33 18 n.a. 22.2 5.9 85.8 19 212 32.0 10 5.83 8.30 1.5 0.4 5.7 1.2
(Range)
(18-
52)
(0-67)
(18.0-
31.9)
(4.0-8.6)
(64.2-
125.0)
(6-
81)
(40-4470)
(18.5-
71.7)
(5-50)
(2.23-
10.40)
(1.60-19.30) (cO.5-9.5) (0.1-1.7)
(1.2-
55.4)
(0.4-
7.7)
17 M 27 n.a. AS 26.4 7.8 93.0 16 219 58.5 <5 1.32 0.80 4.6 1.5 21.0 6.8
18 F 37 n.a. AS 36.3 7.2 65.3 18 66 19.4 22 1.21 1.10 6.0 0.1 90.9 1.5
19 F 61 n.a. AS 31.2 9.0 81.0 46 132 32.1 <5 1.32 1.00 3.9 2.7 29.6 20.5
20 M 42 n.a. AS 22.9 8.9 78.5 17 100 19.4 <5 1.40 0.90 5.8 1.4 58.0 14.0
21 F 27 n.a. AC 21.8 8.5 81.2 19 23 27.3 <5 0.85 0.70 1.4 0.2 60.9 8.7
22 F 38 n.a. AS 23.3 9.4 76.7 19 20 41.8 <5 2.27 2.20 0.7 0.3 35.0 15.0
23 F 25 n.a. AS 26.9 8.6 85.4 6 79 36.7 <5 0.76 1.70 1.8 1.5 22.8 19.0
Med. n.a. 37 n.a. n.a. 26.4 8.6 81.0 18 79 32.1 5 1.32 1.00 3.9 1.4 35.0 14.0
(Range)
(25-
61)
(21.8-
36.3)
(7.2-9.4)
(65.3-
93.0)
(6-
46)
(20-219)
(19.4-
58.5)
(5-22)
(0.76-
2.27)
(0.70-2.20) (0.7-6.0) (0.1-2.7)
(21.0-
90.9)
(1.5-
20.5)
1, patient 3 and 9 receive maintenance therapy with hydroxyurea; # ,patients with co-inherited b-thalassemia; A,these controls are race matched carriers and do not have anemia,enhanced hemolysis or 
inflammation; — indicates lab results are not available; n.a.not applicable; LLOD: lower limit of detection (0.5 nM).CRP is set <5 mg/L when there is no indication of inflammation. Reticulocytes are expressed as the 
% reticulocytes of the population of red blood cells and reticulocytes.PCU, packed cell units; BMI: body mass index; Hb: hemoglobin;MCV: mean corpuscular volum e;ALT: alanine am inotransferase;TS: transferrin 
saturation; CRP: C-reactive protein; sTfR: soluble transferrin receptoras a direct measure of the total transferrin receptor in the body and reflects both the cellular need for iron and the rate of erythropoiesis; cr: 
creatinine.Reference range Caucasian controls hepcidin-25 (n=24),serum 0.5-13.9 nM and urine 0.01-10.6 nmol/mmol creatinine (www.hepcidinanalysis.com ); MCV 80-98 fL; serum TS fem ale 15-50%,TS male 20- 
50%; ferritin fem ale premenopasual 6-80 pg/L; ferritin fem ale postmenopausal 6-190 pg/L; ferritin male 15-280 pg/L; sTFR 0.76-1.76 mg/L.
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compensated by low grade inflammation (CRP of 10 mg/L) and a slightly elevated iron store 
(ferritin of 210 ng/L), resulting in undetectable serum hepcidin-25 levels.
While this is a small study, the results only describe the qualitative contribution of the 
various parameters to hepcidin-25 levels. Nevertheless, Spearman's correlation analysis 
showed that serum hepcidin-25 levels were significantly correlated with urine hepcidin-25,
log ferritin, Body Mass Index (BMI) 
1D-F) and hemoglobin.
10 (Figure 1A-C) and age, but not with CRP, sTfR, TS (Figure
Figure 1. Spearman's correlation analysis of serum hepcidin-25 with (A) urine hepcidin-25 (B) Log 
Ferritin (C) BMI (D) CRP (E) sTfR, F) TS. Data represent the whole study population of 16 SCD 
patients (HbSS, HbSb0-thalassemia and HbSC) (triangle) and 7 controls (square). BMI: body mass 
index; CRP: C-reactive protein; sTfR: soluble transferrin receptor; TS: transferrin saturation.
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In conclusion, this proof of principle study in a heterogeneous group of SCD patients 
indicates that: (i) previous results obtained in vitro and mice studies of hepcidin-25 
suppression by increased erythropoietic activity that is counterbalanced by iron stores and 
(low grade) inflammation are also valid in man; (ii) larger studies are needed to determine 
the quantitative contribution of various factors to hepcidin-25 regulation in this disease. The 
insights gained in this study could be clinically beneficial in the identification and treatment 
of patients most at risk of iron mediated tissue damage.
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Hepcidin during inflammation in a patient with HFE-hemochromatosis
Abstract
It is currently unknown if the increase of the hepatic iron regulatory hormone hepcidin 
during inflammation in man depends on an intact HFE-protein. Here we describe the 
temporal relationship of serum hepcidin, serum iron and cytokines in a patient with HFE- 
related (C282Y homozygous) hereditary hemochromatosis who was treated for an auto- 
inflammatory condition, i.e. variant Schnitzler's syndrome, with the potent anti­
inflammatory cytokine interleukin-1 receptor antagonist (IL-1ra, anakinra). The patient had 
bouts of fever with peaking serum IL-6 concentrations followed by peaking serum hepcidin 
levels, while serum iron was low. Upon treatment, these peaks disappeared and hepcidin 
levels became non-detectable, consistent with HFE deficiency. In conclusion, this in vivo 
human model: i) supports the importance of an HFE-independ IL-6-hepcidin axis in the 
development of hypoferremia and anemia of inflammation; and ii) suggests that chronic 
inflammation protects patients with HFE-related hereditary hemochromatosis from iron 
accumulation.
Introduction
One of the critical host defense strategies after infection is to withhold iron from the 
invading pathogen by redistribution of iron out of the circulation into macrophages and 
decrease of iron absorption by enterocytes.1,2 This inflammation-associated reaction is 
mediated primarily by the hepatocellular peptide hormone hepcidin.3,4 Hepatic hepcidin 
production is under the control of various physiological stimuli, i.e it is down-regulated by 
low body iron status and erythropoietic activity and increased by pro-inflammation 
cytokines, particularly interleukin-6 (IL-6).5,6
Patients with HFE-gene related (C282Y-homozygous) hereditary hemochromatosis (HH) have 
an impaired hepcidin gene expression with decreased, although not uniformly low, serum 
hepcidin levels.7 Experiments in HFE-knock out (KO) mice show that, in spite of this positive 
regulatory action of HFE protein on basal hepcidin levels, HFE-protein is not required for 
hepcidin upregulation during inflammation.5,8,9 One study, however, showed a blunted 
hepcidin response to inflammatory stimuli in the KO-mice.10 Thus, with respect to hepcidin 
regulation at least two distinguishable pathways are operational: one which is HFE-protein 
dependent and one engaged after pro-inflammatory stimuli. To the best of our knowledge, 
these mouse data have not yet been confirmed by observations in humans. Here we 
describe the temporal relationships of serum hepcidin, serum iron and inflammatory 
cytokines, in a C282Y homozygous HH patient who was treated for an auto-inflammatory 
condition, i.e. variant Schnitzler's syndrome,11 with the potent anti-inflammatory cytokine 
interleukin-1 receptor antagonist (anakinra).12 We demonstrate the existence of an HFE- 
independent cytokine-hepcidin axis in the development of hypoferremia and anemia of 
inflammation. Our observations further suggest that chronic inflammation countermands 
iron accumulation in C282Y-homozygotes.
CASE DESCRIPTION
The patient, a 53-year old man, started having complaints in 1991, at the age of 36 years. 
From that time he experienced periodically malaise, myalgia, spiking fever, arthralgia, painful 
swelling and redness of eye lids. At first examination his spleen was slightly enlarged and 
laboratory analysis showed a marked IgG type-K monoclonal gammopathy of 21 g/L. Under 
the suspicion of malignant lymphoma, a splenectomy was performed with biopsy of liver and 
intraabdominal lymph nodes. No malignancy could be detected. Unexpectedly, on histology
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spleen and liver showed signs of hemosiderosis. More specifically, in the absence of fibrosis 
and cirrhosis, Perls' stain was generalized and strongly positive in hepatocytes and also 
present in some foci of Kupffer cells. At that time ferritin was 1540 pg/L (normal <280 pg/L) 
and the transferrin saturation (TS) 45%. In the late 1990s, HFE-gene analysis disclosed 
homozygosity for the C282Y mutation in the patient and his brother. This confirmed the 
diagnosis of HFE-related HH.
Over the following year, the patient was treated with 30 phlebotomies of 500 mL each to a 
final ferritin level of 24 pg/L (TS of 9.8%). Because the original physical complaints of 
arthralgia and periodic fever persisted, prednisone was started in a maintenance dose of 15 
mg/day. Nevertheless, there were various short-lasting bouts of fever, arthralgia, red 
swollen eyes and auricles. In the late 1990s progressive deafness developed. The monoclonal 
gammopathy remained stable. From 1993 to 2007, the patient received a further 15 
phlebotomies of 500 mL each. Serum ferritin levels, TS and CRP in this time interval, varied 
between 36 and 540 0g/L, 11.4 and 106%, and 26 and 81 mg/L, respectively. Although these 
data appeared to be too incomplete to draw conclusions about a temporal relationship 
between inflammation episodes and iron parameters, it is clear that the patient was not 
always in an inflammatory state.
In 2007, at the age of 52 years, the physical complaints became progressively worse, and 
consisted of malaise, arthralgia, chills, fever, and short lasting generalized urticae. Clinical re­
evaluation in 2008 showed, in spite of the invariably high (20-25 g/L) monoclonal 
gammopathy and high number (10-15%) of bone-marrow plasma cells, no other signs of 
malignant multiple myeloma. The bouts of fever were accompanied by IL-6 peaks followed 
by increased hepcidin-concentrations (Figure 1, panels A and B).
Based on the occurrence of chills with spiking fever and urticae in the presence of IgG-K 
gammopathy, the diagnosis of variant Schnitzler's syndrome was considered and it was 
decided to treat the patient with interleukin-1 receptor antagonist (IL-lra; anakinra; 1st dose 
300 mg i.v., followed by six days 100 mg s.c.).11,12 Serum ferritin levels were around 200 Sg/L 
in the days before treatment, stayed between 200 and 250 pg/L during treatment and 
decreased thereafter to 140, 80 and 22 pg/L, at days 13, 17 and 36, respectively. 
Immediately after the start of IL-1ra all complaints disappeared. The treatment abrogated 
c.q. prevented the pattern of peaking fever in the following days and IL-6 and CRP 
normalized (Figure 1, panel A). Interestingly, serum hepcidin, clearly detectable in spite of 
the HFE-gene defect during the febrile inflammatory episode, decreased rapidly after start of 
IL-1ra whereas serum iron increased(Figure 1, panels B and C). IL-ip levels remained below 
20 pg/mL before and after IL-1ra treatment (data not shown). The moderately increased IL- 
18 levels were not clearly affected by IL-1ra treatment (data not shown).
Design and Methods
Serum iron parameters and CRP were determined by standard laboratory analysis. Cytokines 
and hepcidin were assayed in one run in serum stored at -80°C. Cytokines were measured 
using a multiplex Luminex assay.13 Hepcidin was measured as described previously.14 Lower 
limit of detection was 0.5 nmol/L. Hepcidin range in healthy volunteers (n=24) 0.5-13.9 
nmol/L, median 4.2 nmol/L; in untreated C282Y homozygotes (n=22) <0.5-4.8 nmol/L, 
median 1.9 nmol/L; in C282Y homozygotes (n=4) in maintenance phase of phlebotomy (15 
samples) <0.5-2.5 nmol/L.7 The study was carried out in accordance with applicable Dutch 
regulations concerning IRB review and informed consent.
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Results and Discussion
We describe the first human in vivo 
observation of serum iron parameters, 
including hepcidin, in a patient with an 
aberrant HFE-protein and inflammation, 
before and after anti-inflammatory 
treatment. The patient presented with a 
combination of Schnitzler's syndrome and 
C282Y homozygosity of the HFE-gene 
under a regime of maintenance 
phlebotomies, and was subsequently 
treated with anti-inflammatory anti-IL-lra. 
Schnitzler's syndrome is a rare disabling 
auto-inflammatory disease. It is 
characterized by varying degrees of 
recurrent bouts of unexplained fever, 
arthralgia or arthritis, bone pain, 
lymphadenopathy, hepato- or
splenomegaly, leukocytosis, and elevated 
erythrocyte sedimentation rate 
accompanied by an urticarial rash in the 
presence of a monoclononal IgG or IgM 
gammopathy. The complaints respond 
well to treatment with IL-lra.12 
A biochemically penetrating C282Y 
homozygous patient is typically 
characterized by elevations of both serum 
ferritin and serum iron levels.15 In the 
patient presented herein the ongoing and 
periodically exacerbating inflammation 
increased serum ferritin levels and 
lowered TS, at times leading to a pattern 
of serum iron indices less pathognomonic 
for HH.Thus, the iron status in the patient 
might be understood from a combination 
of HH treated with phlebotomies, and 
both sequestering of iron in the reticulo­
endothelial (RE) macrophages and 
reduced intestinal iron uptake due to 
inflammation induced elevated hepcidin 
levels.
The bouts of fever and IL-6 peaks in the 
patient were followed by peaks of serum 
hepcidin. Hepcidin serum concentrations 
before treatment in our patient ranged
Figure 1. Laboratory measurements before 
and after treatment. Body temperature, CRP 
and IL-6 levels (panel A), serum hepcidin 
(panel B), iron and transferrin saturation 
(panel C) were measured in an iron deplete 
C282Y homozygous patient with an auto- 
inflammatory condition, i.e. variant 
Schnitzler's syndrome, before, during and 
after treatment with the potent anti­
inflammatory cytokine interleukin-1 receptor 
antagonist (IL-1ra, anakinra). The period of IL- 
1ra treatment is indicated in grey.
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from 2.9 to 11.2 nmol/L, high for an C282Y homozygote in the maintenance phase of 
phlebotomy.7 Normalization of IL-6, triggered by IL-1ra treatment, led to undetectable 
hepcidin and higher serum iron levels. These findings confirm the (temporal) relations, 
observed by us in an in vivo model of LPS induced inflammation,6 and by Kawabata et al. in 
an IL-6 overproducing patient with multicentric Castleman's disease treated with IL-6 
receptor antibodies.16 In addition to this, IL-1ra may directly inhibit IL-1 dependent hepcidin 
production through the blockade of the IL-1 receptor.5
At first glance, our data seem to contrast with the observation that in C282Y homozygotes 
the total body iron does not correlate with the momentary IL-6 and CRP levels.17 The latter 
report however can be criticized because of the different kinetics of IL-6, CRP and body iron. 
On the other hand, our observations of a patient with a defect of the HFE protein that can 
still respond to inflammatory stimuli by increasing hepcidin levels are in agreement to those 
described for patients with deficiency of the TfR2 protein.18 Interestingly, HFE and TfR2 
proteins have been found to interact in a common signal transduction pathway to 
hepcidin.19 From our observation it is clear that C282Y homozygosity and/or iron deficient 
anemia do not abrogate cytokine induced hepcidin production. However, in the absence of 
appropriate controls for this natural biological model as provided by the described patient, 
no conclusions can be made as to whether the level achieved in the patient is of the same 
level seen in humans without HFE-related HH. Nevertheless, the retained ability of C282Y 
homozygotes to increase hepcidin production upon inflammatory stimuli, and thus, 
according to the hepcidin mode of action,20 to redistribute iron out of the bloodstream into 
RE macrophages, might be advantageous in the setting of infection by extracellular 
pathogens, but on the other hand might also increase hepatic damage through iron-induced 
mesenchymal activation.21
In conclusion, our in vivo human model of a C282Y homozygous patient with an auto- 
inflammatory disease treated with IL-1ra supports the importance of an HFE-independent 
cytokine-hepcidin axis in the development of hypoferremia and anemia of inflammation. 
These findings on the cross-talk between pathways regulating hepcidin provides indirect 
information on the iron availability to certain pathogens relevant in critical host defense 
strategies.2,22-24 It furthermore suggests that chronic inflammation may reduce iron stores in 
C282Y homozygotes, contributing to the variable penetrance of the C282Y mutation.
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Hepcidin as a predictive marker of anemia after sepsis
Abstract
Introduction: Anemia is a frequently encountered problem during inflammation. Hepcidin is 
an interleukin-6 (IL-6)-induced key modulator of inflammation-associated anemia. Human 
sepsis is a prototypical inflammatory syndrome, often complicated by the development of 
anemia. However, the association between inflammation, hepcidin release and anemia has 
not been demonstrated in this group of patients. Therefore, we explored the association 
between hepcidin and sepsis-associated anemia.
Methods: 92 consecutive patients were enrolled after presentation on the emergency ward 
of a university hospital with sepsis, indicated by the presence of a proven or suspected 
infection and > 2 extended systemic inflammatory response syndrome (SIRS) criteria. Blood 
was drawn at day 1, 2 and 3 after admission for the measurement of IL-6 and hepcidin-25. IL- 
6 levels were correlated with hepcidin concentrations. Hemoglobin levels and data of blood 
transfusions during 14 days after hospitalisation were retrieved and the rate of hemoglobin 
decrease was correlated to hepcidin levels.
Results: 53 men and 39 women with a mean age of 53.3 ± 1.8 yrs were included. Hepcidin 
levels were highest at admission (median[IQR]): 17.9[10.1 to 28.4]nmol/l and decreased to 
normal levels in most patients within 3 days (9.5[3.4 to 17.9]nmol/l). Hepcidin levels 
increased with the number of extended SIRS criteria (P = 0.0005). Highest IL-6 levels were 
measured at admission (125.0[46.3 to 330.0]pg/ml) and log-transformed IL-6 levels 
significantly correlated with hepcidin levels at admission (r = 0.28, P = 0.015), day 2 (r = 0.51, 
P < 0.0001) and day 3 (r = 0.46, P < 0.0001). Twelve patients received one or more blood 
transfusions during the first 2 weeks of admission, not related to active bleeding. These 
patients had borderline significant higher hepcidin level at admission compared to non­
transfused patients (26.9 [17.2 to 53.9] vs 17.9[9.9 to 28.8]nmol/l, P = 0.052). IL-6 
concentrations did not differ between both groups. Correlation analyses showed significant 
associations between hepcidin levels on day 2 and 3 and the rate of decrease in hemoglobin 
(Spearman's r ranging from -0.32, P = 0.03 to -0.37, P = 0.016, respectively).
Conclusions: These data suggest that hepcidin-25 may be an important modulator of anemia 
in septic patients with systemic inflammation.
Introduction
Inflammation-associated anemia represents an important and highly prevalent clinical 
problem. In 2000, Krause et al. described a peptide that was later called 'hepcidin' based on 
its hepatic expression and antimicrobial activity.1,2 This p-defensin-like peptide was found to 
be a principle regulator of systemic iron homeostasis. In concordance with this dual function, 
its expression is modulated by systemic iron requirements and inflammatory stimuli, as it is 
induced by cytokines such as IL-6.3 Its role in the development of anemia was first suggested 
in 2001.4 Since then it has been demonstrated that hepcidin is a central modulator of 
inflammation-associated anemia, not only by controlling the expression of ferroportin on 
intestinal cells and macrophages,5 but also via a direct inhibitory effect of hepcidin on 
erythropoiesis.6 In humans, increased concentrations of hepcidin were detected in patients 
with chronic infections and severe inflammatory diseases.7 The association of increased 
concentrations of hepcidin with anemia has been determined in patients suffering from 
chronic inflammation,8 chronic kidney disease,9 and cancer.10 In addition, acute systemic 
inflammation evoked by experimental endotoxemia in humans resulted in an increase in 
hepcidin release, associated with a decrease in serum iron.11 Nevertheless, the association
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between the innate immune response, hepcidin release and consequent decrease in 
hemoglobin (Hb) has not been established in patients with an acute systemic inflammation. 
Human sepsis is a prototypical acute inflammatory syndrome frequently complicated by the 
development of anemia. As the incidence of sepsis is high,12 determination of this putative 
pathway of the development of anemia is of clinical importance. Therefore, we explored the 
correlation between IL-6 and hepcidin, and the subsequent rate of Hb decrease and number 
of blood transfusions received in septic patients.
Materials and Methods
SUBJECTS AND SAMPLING
This is an explorative observational study in which data of the subjects were retrieved from a 
prospectively aggregated database of patients with sepsis. Following Dutch law, the local 
Institutional Review Board of Arnhem-Nijmegen indicated that no formal approval was 
required for this study. Patients were informed, but no written consent was necessary. 
Ninety-two consecutive septic patients were enrolled after presentation on the emergency 
ward and subsequent hospital admission. Sepsis was defined by the presence of two or more 
extended criteria for systemic inflammation (body temperature >38.3 or < 36°C, acutely 
altered mental status, shivering, heart rate >90 bpm, systolic blood pressure <90 mmHg or 
mean arterial pressure < 65 mmHg, respiratory rate >20 breaths/min, hyperglycemia in 
absence of diabetes) and a proven or suspected source of infection.13 The total number of 
extended systemic inflammatory response syndrome (SIRS) scores were calculated. Patients 
were given usual care according to the guidelines of the Surviving Sepsis Campaign.14 Blood 
was drawn at day one, two and three of admission for the measurement of IL-6 and 
hepcidin-25. Hb measurements were not taken as part of a protocol, but Hb levels that were 
determined as part of standard hospital care during the first 14 days after hospital admission 
were retrieved and used for further analysis, Hemoglobin levels were checked regularly, but 
not every day in every patient. Also the accompanying indices of mean corpuscular volume 
(MCV), mean cell Hb (MCH), and red cell distribution width (RDW) were analyzed. Blood 
transfusions during hospital stay were recorded. We hypothesized that the effect of 
sustained elevated levels of hepcidin could be first seen in the Hb level after a period of 7 to 
14 days. This was based on the assumption that erythrocytes circulate for approximately 120 
days. If erythropoiesis would be abrogated by hypoferremia due to an increased hepcidin 
level, it would therefore take approximately 12 days to reduce the Hb levels by 10%. A 
decrease of 10% was considered a clinically relevant and reliably detectable difference. 
However, due to a possible direct inhibitory effect of hepcidin on erythropoiesis, and a 
reduced erythrocyte half-life during inflammation, a detectable reduction of Hb from day 
seven onwards was anticipated.
LABORATORY MEASUREMENTS
IL-6 levels were measured on an Immulite 2500 (Siemens, Breda, The Netherlands), based on 
a solid-phase, enzymelabelled, chemiluminescent sequential immunometric method. Serum 
hepcidin-25 measurements were performed by a combination of weak cation exchange 
chromatography and time-of-flight mass spectrometry (TOF-MS), using a Microflex LT 
matrix-enhanced laser desorption/ionisation TOF-MS platform (Bruker Daltonics, Bremen, 
Germany). An internal standard (synthetic hepcidin-24; Peptide International Inc., Louisville, 
KT, USA) was used for quantification.15,16
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CALCULATIONS AND STATISTICAL ANALYSIS
Log-transformed IL-6 concentrations were correlated with hepcidin-25 concentrations using 
Pearson's correlation coefficient. Hepcidin-25 was correlated with the rate of decrease of Hb 
between day 1 and 14, using Spearman's correlation coefficient. The rate of decrease of Hb 
was calculated per patient by linear regression using all available Hb measurements. If Hb 
levels were not measured at days 7 to 14, or if patients received a blood transfusion during 
their stay, they were excluded from this analysis. Hepcidin levels at admission (prior to any 
transfusion) of patients who received a blood transfusion during the first 14 days of 
hospitalization were compared with patients who did not.
To test whether the presence of comorbidity affected the rate of Hb decrease, we divided 
different forms of comorbidity into eight categories (chronic kidney disease, hematologic, 
malignancy, pulmonary, rheumatic/autoimmune, cardiologic, urologic, and other) and 
performed a step-wise multi-variate analysis in which hepcidin levels and the eight 
categories of comorbidity were added to the model. If a comorbidity was found to 
significantly attribute to the prediction of Hb decrease, it was left in the model, but 
otherwise discarded. Data are expressed as mean ± standard error of the mean or median 
(25th to 75th percentile) depending on their distribution. Correlations were expressed as 
Spearman's correlation coefficient, except for the correlations between hepcidin and log- 
transformed IL-6 concentrations that were expressed as Pearson's r.
Paired observations over time were tested with Wilcoxon matched-pairs test and unpaired 
observations with a Mann-Whitney test.
Results
DEMOGRAPHIC DATA
Demographic data of the subjects are displayed in Table 1. Two patients died during 
hospitalization. Blood culture results are presented in Table 2. Twenty percent of the 
patients had a positive blood culture. This relatively low percentage is probably due to the 
fact that in most cases the general practitioner had already initiated antimicrobial therapy 
before admission to the hospital.
IL-6 AND HEPCIDIN
IL-6 was highest at admission (125.0 (46.3 to 330.0) pg/ml), and decreased on day two (37.2 
(16.8 to 112.8) pg/ml) and day three (19.5 (7.4 to 55.7) pg/ml). A similar pattern was 
observed for hepcidin levels, being highest at admission (17.9 (10.1 to 28.4) nmol/l) and 
declining to 9.5 (3.4 to 17.9) nmol/l on day three, which is still increased compared with 
control values. Log-transformed IL-6 levels correlated significantly with hepcidin levels on 
admission, day two and day three, (Pearson's r = 0.28, P = 0.015; r = 0.512, P< 0.0001; r =
0.458, P< 0.0001, respectively; Figure 1a). Also, the number of extended SIRS criteria present 
correlated with hepcidin levels (Figure 1b).
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Table 1. Demographic data of the subjects Table 2. Blood culture results
Number (%) Organisms and culture sites Number
Total 92 (100) of patients
Male/Female 53/39 (58/42) Organisms
Age (years) 53.3 ± 1.8 Aeromonas species 1
ICU admissions 3 (3) Candida species 2
Deaths 2 (2) Citrobacter species 1
Median hospital length of stay (days) 6 (4-11) Corynebacterium jeikeium 1
Number of SIRS criteria present 2.5 ± 0.9 Coxiella species 4
Number of patients transfused 12 (13) Enterobacter species 1
Site of infection Enterococcus species 5
Lung 28 (30) Escherichia coli 10
Abdomen 12 (13) Haemophilus influenzae 1
Urinary tract 24 (26) Klebsiella species 2
Skin / soft tissue 4 (4) Morganella species 1
Bone / joint 3 (3) Pseudomonas species 3
Blood 2 (2) Salmonella species 1
Cerebral 1 (1) Staphylococcus species 2
Other 3 (3) Streptococcus species 3
Unknown 9 (10) Viral infection (positive serological test) 6
No infectious focus 6 (7) No pathogen cultured 50
Comorbidity Sites
None 36 (39) Blood 18
Chronic kidney disease 13 (14) Urine 18
Hematologic disease 7 (8) Other 4
Malignancy 8 (9) Multiple organisms 2
Lung disease 6 (7) Multiple sites 2
Rheumatic / autoimmune disease 2 (2) 
Cardial disease 1 (1)
Urological disease 5 (5)
_____Other__________________ 14 (15)_____
Data are expressed as absolute numbers and 
percentages of total, mean ± standard error of the mean 
or median (25th to 75th percentile). Multivariate analysis 
demonstrated that comorbidities were not 
independently associated with hemoglobin decrease.
SIRS, systemic inflammatory response syndrome.
HEPCIDIN AND HEMOGLOBIN
Hb was 12.0 (11.2 to 13.4) g/dl at admission and decreased to an average of 11.3 (10.3 to 
12.8) g/dl at day 7 to 14 (P = 0.004) in patients who did not receive a blood transfusion. 
During hospitalization the Hb levels decreased at least 0.8 g/dl in 69 (86%) of 80 patients 
who did not receive a blood transfusion. There was no correlation between hepcidin levels 
and Hb levels at admission (r = 0.21, P = 0.07). Hepcidin levels on day one of admission did 
not correlate with the rate of decrease in Hb (r = -0.13, P = 0.39). Hepcidin on day two and 
day three significantly correlated with the rate of decrease of Hb (r = -0.32, P = 0.03 and r = -
0.37, P = 0.016; Figure 1c).
Twelve patients received one or more blood transfusions during the first two weeks of 
admission, not related to active bleeding. These patients had borderline significant higher 
hepcidin level at admission (preceding any blood transfusion) compared with non-transfused 
patients (26.9 (17.2 to 53.9) vs 17.9 (9.9 to 28.8)nmol/l, P = 0.052; Figure 1d).
MCV slightly increased during hospital admission from 86.0 (84.0 to 90.0) to an average of 
88.5 (85.7 to 92.6) fl at day 7 to 14 (P = 0.011). RDW increased from 13.9 (13.1 to 15.4) to an 
average of 15.9 (14.2 to 17.0)% (P = 0.002). MCH remained unchanged during 14 days of 
follow up (from 1.84 (1.75 to 1.90) fmol to an average of 1.82 (1.76 to 1.90) fmol at day 7 to 
14 (P = 0.39)). None of the changes in red cell indices correlated with the hepcidin levels on 
days one to three.
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Ln IL-6 (pg/mL)
Hepcidin (nmol/L)
Nr. extended SIRS criteria present
Number of packed red cells transfused
Figure 1. Association between IL-6, hepcidin and hemoglobin decrease.
(a) H umoral relation between inflammation and hepcidin levels: Pearson's correlation between the 
natural logarithm (Ln) of IL-6 and hepcidin-25 on day 2 (black diamonds, uninterrupted line), and day
3 (grey dots, dashed line. The correlation on day 1 (r = 0.28, P = 0.015), was omitted for reasons of 
clarity. The median reference level of serum hepcidin-25 is 4.2 nM, range 0.5 to 13.9 nM [15]. (b) 
Clinical relation between inflammation and hepcidin levels: hepcidin-25 levels according to the 
number of extended systemic inflammatory response syndrome (SIRS) criteria at presentation at the 
emergency ward [13]. Differences were tested with Kruskal-Wallis. (c) Spearman's correlation 
between rate of hemoglobin (Hb) decrease and hepcidin-25 concentration on day 2 (black dots, 
uninterrupted line) and day 3 (open triangles, dashed line). The rate of decrease was only calculated 
in patients that did not receive a blood transfusion and of whom Hb was measured at least once 
between day 7 and 14 of hospital admission (n = 44). (d) Relation between hepcidin-25 levels at 
admission and the number of blood transfusions received during 14 days of follow up. Boxes 
represent median and interquartile range, whiskers represent 5th and 95th percentile. Difference 
between transfused and non-transfused patients was tested with a Mann Whitney test.
Discussion
In the present study, three novel findings emerged. This is the first study to show that: 
hepcidin-25 is increased during human sepsis; in septic patients the degree of inflammation, 
indicated by IL-6 levels and number of SIRS criteria present, is associated with the elevated 
concentrations of hepcidin; and persistently increased levels of hepcidin-25 at day two and 
day three after admission are associated with a decrease in Hb during hospitalization. 
Naturally, in patients who received a transfusion, the effect of hepcidin on Hb could not be
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determined and these patients were excluded from this part of the analysis. In a separate 
analysis, we showed that transfused patients showed a trend towards higher hepcidin levels 
than those who were not. These findings combined suggest that the observed association 
between elevated hepcidin and a decrease in Hb is likely to be an underestimation.
This study does not necessarily indicate a causal relation between elevated hepcidin and Hb 
decrease in septic patients. However, the causal relation of the induction of hepcidin by IL-6 
and the development of anemia by sustaining elevated hepcidin levels has been shown by 
others in separate experiments .3,5,6,1? This study is the first to address the combined 
measurement of hepcidin, IL-6 and Hb levels in patients and shows that hepcidin probably 
plays a role in sepsis-associated anemia. One may argue that the correlation between 
inflammation, hepcidin and anemia is an epiphenomenon, because more severely affected 
patients release higher levels of inflammatory parameters and also receive more fluids 
during their volume resuscitation, resulting in the more pronounced decrease in Hb. This 
appears not to be the case, because hepcidin concentrations at admission did not predict 
the decrease in Hb, in contrast to more prolonged elevations in hepcidin during the first 
three days. Moreover, the decrease in Hb was determined over 14 days, a period in which 
the effects of volume resuscitation should have diminished. Nevertheless, it is important 
that in addition to the physiological role of hepcidin, several other factors that lead to 
anemia during infection have been described, such as iatrogenic blood loss, inhibition of
18 18 19erythropoietin production, blunted erythropoietic response, , and a decreased lifespan 
of erythrocytes, mediated by increased adherence to the vascular wall and phagocytosis by 
macrophages.20 In addition, in these patients the presence of different comorbidities and the 
severity of the disease could have influenced the development of anemia. However, we 
were not able to express these variables in size and number, and therefore could not include 
these parameters as a continuous variable into a multivariate regression analysis. This may 
explain the relatively low correlation coefficients we found between hepcidin and Hb 
decrease.
There are two known ways that hepcidin can result in inflammation-associated anemia. First, 
hepcidin can abrograte erythroid colony formation in situations where erythropoietin 
concentrations are reduced, as is the case during sepsis.6 Furthermore, inflammation leads 
to sequestration of iron in cells resulting in a blocked transport of iron to the bone marrow. 
Considering the fact that the lifespan of erythrocytes of approximately 120 days might be 
shortened due to inflammation and the fact that hepcidin suppresses erythropoiesis itself, 
we hypothesized that if hepcidin is upregulated by inflammation and thereby suppresses 
serum iron levels, a measurable effect on Hb level was expected from seven days onwards 
after the diagnosis of sepsis. Furthermore, we anticipated a swift decrease in inflammation 
in treated septic patients. For these reasons we determined IL-6 and hepcidin levels for 
three days and the rate of Hb decrease within 7 to 14 days.
We were not able to demonstrate a relation of Hb decrease with a change in MCV, MCH, or 
RDW. This does not invalidate the hypothesis that increased hepcidin attributes to the 
development of anemia in these patients. It was previously shown that erythrocyte 
progenitor cells carry iron transporter ferroportin1B on their cell membrane.21 During 
inflammation systemically elevated hepcidin down-regulates ferroportin on these cells, 
thereby preventing a loss of intracellular iron and the microcytic anemia that is seen in iron- 
deficiency anemia. Therefore, inflammation-associated anemia is not typically microcytic.22 
Moreover, the observed effect of hepcidin on the development on anemia may have been
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mediated by a direct inhibitory effect on erythropoiesis, rather than by blocking iron 
transport to the bone marrow by sequestration.
Interestingly, hepcidin at day one did not predict the rate of Hb decrease. Probably 
persistently elevated hepcidin levels are necessary to exert a relevant effect on Hb 
concentrations. The association we found may be an underestimation, because the patients 
in this study were already anemic at the time of presentation to the emergency ward and 
likewise it is possible that before presentation hepcidin levels were even more pronounced. 
Nevertheless, although statistically significant, the observed association between hepcidin 
and Hb levels is modest, indicating that other previously mentioned factors that influence Hb 
are likely to play a role.
Conclusion
Anemia during acute systemic inflammation evoked by sepsis is a frequently encountered 
clinical problem. Up to now, human data concerning the effect of hepcidin release on the 
development of anemia during sepsis were absent. Our study demonstrates that 
inflammation in septic patients is associated with increased hepcidin-25 concentrations. 
Moreover, the elevated hepcidin concentrations observed in early sepsis negatively 
correlated with Hb levels during the hospital stay of these patients. These human in vivo 
correlations suggest that hepcidin release is a modulator of anemia in septic patients with 
systemic inflammation.
KEY MESSAGES
• IL-6 concentrations and number of SIRS criteria present in septic patients are associated 
with
increased hepcidin-25 concentrations.
• The increase in hepcidin concentrations observed in early sepsis correlates with the 
decrease in Hb
levels during their hospital stay and patients with higher hepcidin concentrations tend to
need more
blood transfusions.
• The inflammation-hepcidin release-anemia pathway is present in patients with sepsis.
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Serum hepcidin in metabolic syndrome
To the editor:
Valenti et al. report increased MCP-1 and hepcidin-25 levels in patients with non alcoholic 
fatty liver disease (NAFLD) along with metabolic alterations and found them to be an 
independent predictor of the presence of carotid plaques, indicating an advanced 
atherosclerotic process.1
We performed a case-control study on hepcidin levels in a differently defined population 
with the metabolic syndrome (MetS). Patients and controls were drawn from the Nijmegen 
Biomedical Study (NBS), a population-based survey among 22,454 randomly selected 
inhabitants from the city of Nijmegen, The Netherlands.2 We evaluated the presence of 
MetS by means of a self-administrated questionnaire among the 6,468 responders. Cases 
had to report hypertension, hypercholesterolemia, and diabetes diagnosed by a physician 
and a BMI > 30 kg/m2 (n=16); per case we selected 2 sex- and age-matched controls with a 
BMI between 20-25 kg/m2, who did not report hypertension, hypercholesterolemia or 
diabetes. We measured serum hepcidin levels by our mass spectrometry-based assay, that is 
able to separately quantify the 25 amino acid (aa) hepcidin-25 and the smaller hepcidin 
isoform of 20 aa (hepcidin-20).3
We found levels of hepcidin-25 in MetS patients to be significantly higher than those of 
controls (median 6.1 nM vs. 4.9 nM; p <0.05) (Table 1, Fig. 1 - 
http://www.hepcidinanalysis.com/documents/Figure1ATVBlettertoeditor_Krootetal2011.pd 
f). Of note, in addition to hepcidin-25, also hepcidin-20 levels of the MetS patients were 
elevated compared to controls (median 1.5 nM vs. 1.1 nM; p < 0.01) (Table 1, Fig. 1 - 
http://www.hepcidinanalysis.com/documents/Figure1ATVBlettertoeditor_Krootetal2011.pd 
f). The biological significance of hepcidin-20 in serum is unknown. It appears not to be 
involved in iron metabolism,4,5 although it may have antimicrobial activity.6 
Previous studies showed an increased risk for atherovascular diseases in MetS,7,8 however 
the cause of this increased risk is not known yet. Our results of increased hepcidin levels in 
patients with MetS, in combination with the relation of increased hepcidin levels with 
atherosclerosis reported by Valenti et al.,1 might implicate serum hepcidin as a determinant 
for the increased prevalence of atherosclerosis in patients with MetS.
These observations indirectly add to the evidence for the hypothesis that elevated hepcidin 
levels may contribute to the development of atherosclerotic vascular disease, probably by 
causing macrophages to sequester iron, increasing oxidative stress and inducing their 
transformation into foam cells.9,10 Furthermore, our data in conjunction with those reported 
by Valenti et al. suggest that anti-hepcidin therapy might be beneficial in the prevention of 
atherosclerotic plaque forming in these patients.1,11
Table 1. Characteristics and hepcidin levels of the study population.
Cases (n=16) Controls (N=32) p-value
Mean (sd Median Mean (sd) Median
Age (years) 6B.B (7.8 64.9 6B.4 (7.9) 64.9 0.98
BMI (kg/m2) BB.2 (2.5) B2.8 2B.1 (1.B) 2B.4 <0.001
Transferrin saturation (%) 28.6 (6.5) 28.2 27.9 (8.B) 29.0 0.B8
Ferritin (^g/L) 199 (101) 210 1B1 (82) 120 <0.01
ALAT (U/L) 18 (12) 14 11 (6) 11 <0.01
hsCRP (mg/L) 2.64(2.17 2.28 1.19 (1.24) 0.83 <0.01
Hepcidin-25 (nmol/L) 6.6 (2.6 4.9 5.0 (2.6) 4.9 <0.05
Hepcidin-20 (nmol/L) 1.5 (0.5) 1.5 1.1 (0.B) 1.1 <0.01
Hepcidin total (nmol/L) 8.1 (2.8 7.4 6.1 (2.7) 6.6 <0.05
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Figure 1. Hepcidin levels in controls and cases (A) hepcidin-25, (B) hepcidin-20 and (C) total 
hepcidin. Lines indicate means.
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Summary, conclusions & Perspectives
Iron is required for the function of oxygen-binding molecules, mainly hemoglobin and 
myoglobin, and iron-containing enzymes, including the cytochrome system in mitochondria. 
Without iron, cells lose their capacity for electron transport and energy metabolism. 
However, iron can also cause damage. To maintain systemic iron homeostasis, 
communication between cells that absorb iron from the diet (duodenal enterocytes), 
consume iron (mainly erythroid precursors) and store iron (hepatocytes and tissue 
macrophages) is crucial.
The iron regulatory peptide hormone hepcidin has been demonstrated to play a central role 
in regulating dietary iron absorption and body iron distribution, by its interaction with the 
cellular iron exporter ferroportin, present on enterocytes, hepatocytes and macrophages. 
As a result, internalization and degradation of ferroportin prevents iron release into the 
circulation. Hepcidin consists of 3 isoforms. Besides the 25 amino acid (aa) form, additional 
amino-terminal processing events result in two smaller hepcidin forms of 22 and 20 aa. It is 
currently unknown if the smaller forms reflect either a specific or a-specific catabolism of 
hepcidin-25. Alternatively, hepcidin-20 and 22 isoforms may be directly generated from the 
(pre-)pro-hormone. Interestingly, the two smaller isoforms only occur in serum in diseases 
with either elevated concentrations of hepcidin-25, and/or prolonged circulation time.
To date, various mass spectrometry and immunochemical methods have been developed for 
its quantification in serum and urine. These newly developed methods made it possible to 
perform human studies and revealed that serum hepcidin concentrations are increased in 
infections, inflammatory conditions (rheumatic diseases, chronic kidney disease), and 
decreased in iron deficiency, hereditary hemochromatosis and the iron loading anemia's 
(thalassemia). Additionally, hepcidin is currently being investigated as a therapeutic target 
for inflammatory diseases and replacement therapy in iron loading diseases, necessitating 
hepcidin as a read out parameter.
The major aim of this thesis was the comparison, standardization and harmonization of 
hepcidin methods, and to establish the clinical utility of hepcidin.
Chapter 2 reports the development of a competitive (c-)ELISA approach for hepcidin 
quantification in serum and comparison of this newly developed assays with our validated 
weak cation exchange time-of-flight mass spectrometry (WCX-TOF-MS) approach. This study 
increased our insights of their relative analytical strengths and clinical utility. We found that 
(a) the relative differences in median hepcidin concentrations in various diseases to be 
similar, although the absolute concentrations differed; (b ) hepcidin isoforms in diseases such 
as chronic kidney disease, contributed to differences in hepcidin concentrations between 
methods since the ELISA could only measure the total of the hepcidin isoforms, whereas the 
MS method enables to distinguish between the isoforms; and (c) hepcidin concentrations 
measured by the c-ELISA correlated with ferritin concentrations <60 ng/L, and is suitable for 
distinguishing between iron deficiency anemia (IDA) and the combination of IDA and anemia 
of chronic disease. We concluded that c-ELISA is the method of choice for the large-scale 
quantification of serum hepcidin concentrations, because of its low limit of detection, low 
cost, and high-throughput. Because of its specificity for bioactive hepcidin-25, WCX-TOF-MS 
can be regarded as a valuable special-purpose assay for disorders with variable 
concentrations of hepcidin isoforms, such as chronic kidney disease.
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Utility of hepcidin methods in the clinic depends on the analytical strengths and 
reproducibility of a method. In Chapter 3 we sought to assess the within-subject variability 
and between-subject variability of hepcidin in healthy controls by TOF-MS at four different 
time points during the day. During that day we found urine levels remain to be similar during 
the course of the morning and to increase significantly during the afternoon, whereas serum 
levels increased significantly throughout both the morning and afternoon. Furthermore, in 
serum the (pre)analytical variability was smaller than the between-subject and within- 
day/within-subject variability compared with urine variability. Based on these results, we 
recommend standardizing for sampling time and to measure serum hepcidin to minimize 
variability in future studies.
Differences in methodology and analytical performance hinder the comparability of data. As 
a first step towards method harmonization, in Chapter 4 we compared several methods by 
sending out samples to laboratories in the world (round robin) with hepcidin methods. First, 
we determined the absolute hepcidin concentrations and found them to be widely different 
between the methods. Furthermore, we determined the analytical strengths and 
reproducibility of the methods, and found them to be similar for most methods. We 
revealed that the analytical variation as percentage of the total variance is low for all 
methods. We conclude that all methods are suitable to distinguish hepcidin levels of 
different samples. From this study, to obtain further harmonization, we recommend to (i) 
introduce an internal standard for all methods used for clinical studies; (ii) reach consensus 
on level assignment and level adjustment of the calibrators used in every procedure; (iii) 
produce a calibrator that mimics patient sera; and (iv) regularly test shared samples and/or 
calibrators that are commutable and have been value assigned for quality control.
We followed up the latter two items as first steps towards the world wide harmonization of 
serum hepcidin methods. To this end we set up second Round Robin for hepcidin methods, 
which is described in Chapter 5. We investigated i) the analytical performance of the 
participating methods, ii) whether synthetic samples mimic native samples (commutability), 
and iii) the harmonization of methods on synthetic samples when commutable or on a 
hepcidin consensus value (HEPCON) of native samples when not commutable. We found the 
methods to differ widely in absolute values and 14 methods to show acceptable within- 
sample variation (< 10%) and mutual correlation (> 0.90). Furthermore, we found the 
synthetic hepcidin samples not to be commutable with native hepcidin and conclude these 
samples not to be suitable for harmonization purposes. The above mentioned 14 methods 
then were investigated for their suitability to determine the consensus value based on the 
agreement of the x=y lines of all method couples. The mean of only two methods showed 
consensus values with high precision and low noise. Subsequently, method specific 
regression lines (algorithms) were constructed of measured native samples with the 
consensus. These algorithms allow the participants to calculate the hepcidin consensus 
(HEPCON) values (and 95% CI) from the measurements of their method and vice versa. 
Altogether, calculation of originally obtained values in HEPCON values add to harmonization 
of the methods in the absence of a reference method and calibrator. This harmonization 
then allows: i) the definition of generally accepted and usable reference intervals, rather 
than method-specific reference ranges, ii) application of consistent clinical decision limits for 
medical care and best practice guidelines, iii) pooling and comparison of data from various 
studies to facilitate progress in clinical research.
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Based on this study, in the years to come we advise the "hepcidin community" to further 
work on the development of commutable calibrators and reference methods. Meanwhile, 
we intend to regularly update the algorithms by the organization of a bi-annual round robins 
on a fee for participation basis.
The development and validation of hepcidin methods described in Chapter 2 paved the way 
for studies in physiological and pathophysiological and to assess potential applications of 
hepcidin in diagnostic medicine states. Chapter 6 describes studies in a heterogeneous group 
of patients with sickle cell disease and illustrates that the knowledge gained by in vitro and 
mice studies of hepcidin-25 suppression by increased erythropoietic activity, 
counterbalanced by iron stores and (low grade) inflammation, is also valid in man. From this 
study we furthermore conclude that hepcidin could be clinically beneficial in the 
identification and treatment of patients most at risk of iron mediated tissue damage.
In chapter 7 we expand the knowledge on the regulation of hepcidin in man, by following 
hepcidin levels in time in a C282Y homozygous patient with Schnitzler's syndrome (a chronic 
inflammatory auto-immune disease). Until now, it was unclear if the increase of the hepatic 
iron regulatory hormone hepcidin during inflammation in man depends on an intact HFE- 
protein. This in vivo human model, i) supports the importance of an HFE-independent IL-6- 
hepcidin axis in the development of hypoferremia and anemia of inflammation; and ii) 
suggests that chronic inflammation protects patients with HFE-related hereditary 
hemochromatosis from iron accumulation. These results indicate that hepcidin could be a 
useful biomarker in the prediction of iron accumulation in hemochromatosis patients.
Chapter 8 explores hepcidin as a predictive marker of anemia after sepsis in a group of 
patients that presented with sepsis at the emergency ward. We found that hepcidin levels 
were increased at admission and for most patients reduced to normal within 3 days. High 
hepcidin levels were a predictor of the need for transfusions, indicating that hepcidin-25 
may be an important modulator of anemia in septic patients with systemic inflammation.
Chapter 9 presents elevated hepcidin concentrations in patients with the metabolic 
syndrome (MetS). These results in combination with the relation of increased hepcidin levels 
with atherosclerosis previously reported by others suggest serum hepcidin as a determinant 
for the increased prevalence of atherosclerosis in patients with MetS.
Since the discovery of hepcidin 10 years ago, multiple studies have contributed insights into 
the regulation of hepcidin and its functional properties. The first reliable methods to 
quantify hepcidin in human body fluids have recently been developed. Some of these 
methods are able to distinguish between hepcidin isoforms, whereas others are not. Yet, it is 
still unknown whether hepcidin isoforms are of interest in diagnostic medicine. It should 
therefore be realized that the accumulation of hepcidin-22 and -20 isoforms could interfere 
with the interpretation that the measured levels relate to bioactive hepcidin-25 when 
certain immunoassays are used.
Furthermore, proof-of-principle studies in human iron disorders highlight hepcidin as a 
promising novel tool in diagnostic medicine. Large and well-designed studies are required to 
more firmly establish the position of hepcidin in diagnostic medicine. To make these large 
studies comparable and to allow the definition of universal reference values and decision
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limits, worldwide harmonization of methods is eagerly awaited. In this thesis we describe 
the first attempts towards such a harmonization, by making available algorithms which 
enable the various laboratories to report original hepcidin results in international hepcidin 
consensus values, However, meanwhile reference methods and a synthetic commutable 
calibrator should be developed.
Additionally, as the field is moving towards the use of hepcidin-related therapies, it should 
be realized that the outcome of methods that are used to monitor the fate of hepcidin 
during anti-hepcidin therapy, may very well be affected by the hepcidin-interfering 
compounds. In these cases, methods need to be re-validated for this specific application 
before definite conclusions on the efficacy of the therapy can be drawn. In conclusion, 
hepcidin is a promising diagnostic tool but efforts need to be undertaken to assess the 
relevance of specifically measuring hepcidin-25, to harmonize method outcomes throughout 
the world, to define clinical decision limits, and to make methods available to the clinical 
laboratories before hepcidin methods can be fully included in clinical practice.
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Samenvatting, Algemene discussie & toekomstperspectieven
IJzer is belangrijk voor de functie van zuurstof bindende moleculen, vooral voor 
hemoglobine en myoglobine, maar ook voor ijzer-houdende enzymen zoals het cytochroom 
systeem in mitochondriën. Zonder ijzer zijn cellen in het lichaam niet in staat te zorgen voor 
elektronen transport en de energie stofwisseling. Echter, teveel ijzer kan ook lijden tot 
schade. Om het ijzer in het lichaam in balans te houden, is het belangrijk dat er een goede 
communicatie is tussen cellen die ijzer absorberen uit het voedsel (duodenale enterocyten), 
ijzer opnemen (hoofdzakelijk erythroide voorloper cellen) en ijzer opslaan (hepatocyten en 
weefsel macrofagen).
Pas is ontdekt dat het ijzer regulerende eiwit hormoon hepcidine een centrale rol speelt in 
de regulatie van ijzer opname uit het voedsel en de ijzerverdeling in het lichaam door de 
interactie met het cellulaire ijzer-exporterende eiwit ferroportine, wat voorkomt op de 
dunne darmcellen, levercellen en macrofagen. Deze interactie veroorzaakt de afbraak van 
ferroportine en voorkomt zo dat ijzer vrijkomt in de bloedbaan.
Het eiwit hepcidine komt voor in verschillende isovormen. Naast de vorm die 25 aminozuren 
groot is, worden door amino-terminale processen ook de twee kleinere isovormen van 22 en 
20 aminozuren gevormd. Tot op heden is het niet bekend of deze twee kleinere vormen 
worden gevormd via een specifiek of a-specifiek afbraakproces van hepcidin-25. Een andere 
mogelijkheid is dat de hepcidin-22 en -20 isovormen direct gegenereerd worden uit het 
(pre-)pro-hormoon. Interessant is dat de twee kleinere isovormen alleen voorkomen in het 
serum van patiënten met aandoeningen waarbij hepcidin-25 verhoogd is en/of langer in de 
bloedbaan circuleert.
Tot op heden zijn er verschillende methodes ontwikkeld om hepcidin te meten in serum en 
urine van mensen. Deze methodes zijn gebaseerd op massa-spectrometrische en 
immunochemische technieken. Met deze nieuwe methodieken is gevonden dat serum 
hepcidine concentraties verhoogd zijn bij infecties, ontstekingsziekten (kanker, chronische 
nierziekten), en verlaagd bij erfelijke ijzerstapelingsziekten (hemochromatose) en 
ijzerstapelende anemieën, zoals thalassemie.
Tevens, wordt anti-hepcidine nu onderzocht als therapeutisch product voor 
ontstekingsziekten en hepcidine-analogen als vervangingstherapie in ijzerstapelingsziekten. 
Het hoofddoel van dit proefschrift is om verschillende hepcidine methodes te ontwikkelen 
en te vergelijken op hun analytische prestaties, te standaardiseren en de klinische 
toepasbaarheid van hepcidine te onderzoeken.
Hoofdstuk 2 beschrijft de ontwikkeling van een competitieve enzym gelinkte immuno­
sorbent assay (cELISA) toepassing voor hepcidinde kwantificering in serum en de vergelijking 
van deze nieuw ontwikkelde methode, waarbij we serum verrijken voor hepcidine met 
zwakker cationen beads en daarna time-of-flight massa-spectrometrie uitvoeren, met onze 
(WCX)-TOF-MS benadering. Met deze studie hebben we meer inzicht verkregen in de 
analytische sterke punten en de klinische bruikbaarheid van hepcidine. We hebben 
gevonden dat (a) de relatieve verschillen in hepcidine-concentraties in verschillende 
ziektebeelden hetzelfde zijn voor de twee methodes, ook al waren er wel verschillen in de 
absolute concentraties; (b) hepcidine isovormen in aandoeningen zoals chronische 
nierziekten, bijdragen aan de verschillen in hepcidine concentraties tussen de verschillende 
methodes, omdat ELISA alleen alle hepcidine isovormen samen kan meten en geen 
onderscheid kan maken; en (c) hepcidine concentraties gemeten met ELISA gecorreleerd zijn 
met serum ferritine-concentraties < 60 ng/L, en dat deze methode geschikt is om 
onderscheid te maken tussen bloedarmoete door ijzergebrek (ijzergebreksanemie = IDA) en
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het gecombineerde ziektebeeld van IDA en bloedarmoede door een chronische ziekte. 
Hieruit hebben we geconcludeerd dat ELISA de eerste keus methode is voor grote studies 
om serum hepcidine-concentraties te bepalen, omdat deze methode een lage detectiegrens, 
lage gebruikerskosten en een hoge verwerkingssnelheid heeft. Echter, vanwege de 
specificiteit voor hepcidine-25 is de WCX-TOF-MS meer geschikt voor aandoeningen met 
variabele concentraties van de hepcidine isovormen, zoals bij chronische nierziekten.
De bruikbaarheid van hepcidine meetmethodes in de kliniek hangt af van de 
reproduceerbaarheid van een meting. Deze wordt bepaald door de variatie in hepcidine 
tussen metingen aan hetzelfde monster en variatie van hepcidine tussen de monsters 
afgenomen op verschillende tijdstippen op een dag. In hoofdstuk 3 hebben we ons werk 
uitgebreid naar de variatie binnen één persoon en de variatie tussen personen van hepcidine 
met TOF-MS in gezonde controles op 4 tijdspunten gedurende de dag. Op deze dag vonden 
we dat urine hepcidine concentraties gelijk bleven gedurende de ochtend en in de middag 
significant toenamen. Serum hepcidine concetraties, echter, stijgen significant gedurende de 
hele dag. Verder vonden we dat in serum de (pre)analytische variatie kleiner was dan de 
tussen-persoons en de binnen-dag/binnen-persoons variatie vergeleken met de variaties in 
urine. Gebaseerd op deze resultaten, adviseren wij om de bloedafname te standaardiseren 
voor afnametijd en in de toekomstige studies hepcidine in serum te meten om de variatie te 
minimaliseren.
Verschillen tussen de analytische prestaties beletten een goede vergelijking van 
gegenereerde data. In een eerste stap naar de harmonisatie van methodes, hebben we 8 
verschillende hepcidin methodes vergeleken in een rondzending van monsters (Round 
Robin) welke is beschreven in hoofdstuk 4. Eerst hebben we de absolute hepcidin 
concentraties in serum en urine bepaald en gevonden dat deze zeer verschillend waren voor 
de verschillende methodes. Verder vonden we dat de analytische karakteristieken en 
reproduceerbaarheid van de methodes niet ver uit elkaar lagen. Een andere observatie in 
deze studie was dat de analytische variatie als percentage van de totale variatie in hepcidine 
concentraties laag was voor alle methodes. Aldus, alle methodes zijn dus geschikt bevonden 
om monsters op basis van de hepcidine concentraties te onderscheiden.
Om verdere harmonisatie te verkrijgen, raden we vervolgens aan om (i) een interne 
standaard te introduceren voor alle methoden die in klinische studies worden gebruikt, (ii) 
overeenstemming te bereiken voor het bepalen van de hepcidine niveaus en aanpassingen 
die gedaan moeten worden voor de hepcidin niveaus voor de kalibratoren die gebruikt 
worden in elke procedure, (iii) een kalibrator te produceren die patiënten sera nabootst, en 
(iv) regelmatig monsters en / of kalibrators (monsters die in hun analytisch gedrag lijken op 
natuurlijke monsters) uit te wisselen waar een waarde aan is toegekend voor 
kwaliteitscontrole.
Het bereiken van deze eerste stappen naar harmonisatie is zolas hierboven vermeldt 
beschreven in hoofdstuk 4, en het opzetten van een tweede Round Robin voor hepcidine 
methodes, wordt beschreven in hoofdstuk 5. In deze vervolgstudie onderzochten we de 
analytische kracht en reproduceerbaarheid van de methoden, het gedrag van synthetische 
hepcidine in verschillende methodes en test specifieke regressielijnen ten opzichte van een 
consensus om harmonisatie te bereiken. Op basis van de binnen-monster variatie en 
correlatie met andere methoden, hebben we gekozen voor die testen die kunnen worden
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gebruikt voor het bepalen van een consensus waarde voor harmonisatie. Verder hebben we 
bepaald of het synthetische hepcidine monster patiënten serum nabootst en we deze 
daarom kunnen gebruiken voor harmonisatie. Na deze stappen, met behulp van de test 
specifieke regressielijnen t.o.v. de consensus waarden, vonden we een gereduceerde 
variatie van de gerapporteerde hepcidine resultaten. Dus, om de vergelijkbaarheid van de 
verschillende studies te verbeteren, raden we aan deze test specifieke regressielijnen te 
gebruiken. Deze regressielijnen dragen bij aan de eerste stappen op weg naar harmonisatie 
van serum hepcidine methodes, en zal bijdragen tot verdere vooruitgang in het veld en het 
vergemakkelijken van het gebruik van de serum hepcidine test in de medische diagnostiek.
Nu er betrouwbare hepcidine testen beschikbaar zijn, moet de klinische bruikbaarheid 
worden bewezen in menselijke studies. Hoofdstuk 6 beschrijft dat de kennis die is opgedaan 
in vitro en muizen studies over de hepcidin-25 suppressie door verhoogde verhoogde 
activiteit van de aanmaak van rode bloedcellen, gecompenseerd door ijzer voorraad en (licht 
verhoogde) ontstekingsparameters, ook geldt voor de mens. Uit de hepcidine cocnentraties 
in een heterogene groep van patiënten met sikkelcelziekte, kunnen we concluderen dat 
hepcidine klinisch van belang kan zijn bij de identificatie en behandeling van patiënten met 
een groter risico op weefselschade veroorzaakt door verhoogde ijzerconcentraties.
In hoofdstuk 7 hebben we onze kennis uitgebreid over de regulatie van hepcidine in de 
mens. Dit hebben we gedaan door de hepcidine niveaus te volgen in de tijd in een C282Y 
homozygote patiënt met het syndroom van Schnitzler. Tot nu toe was het niet duidelijk of 
de toename van hepcidine bij een ontsteking afhankelijk is van een intact HFE-eiwit. Dit 
model van de mens, i) ondersteunt het belang van een HFE-onafhankelijke IL-6-hepcidine 
reactie bij de ontwikkeling van bloedarmoede en bloedarmoede door onsteking, en ii) doet 
vermoeden dat een chronische ontsteking patiënten met een HFE-gerelateerde erfelijke 
hemochromatose beschermt tegen ijzerstapeling. Uit deze studie kunnen we daarom 
concluderen dat hepcidine een nuttige biomarker kan zijn in de voorspelling van 
ijzerstapeling bij hemochromatose patiënten.
Hoofdstuk 8 beschrijft de potentie van hepcidine als voorspellende biomarker van 
bloedarmoede na bloedvergifitiging. Bloedvergifitiging is vaak gecompliceerd door de 
ontwikkeling van bloedarmoede, en het kan van groot belang zijn voor de patient wanneer je 
zou kunnen vooruitlopen op de ontwikkeling van bloedarmoede bij deze patiënten en 
daarop hun behandeling aan te passen. Daarom hebben we de associatie onderzocht tussen 
hepcidine en bloedvergiftiging-geassocieerde bloedarmoede bij een groep patiënten op de 
eerste hulp afdeling met bloedvergiftiging. We vonden dat hepcidine niveaus hoger werden 
bij opname en binnen 3 dagen weer tot een normaal niveau gezakt waren bij de meeste 
patiënten. Hoge hepcidine niveaus waren een voorspeller van de behoefte aan transfusies, 
hetgeen aangeeft dat hepcidine-25 een belangrijke modulator is van bloedarmoede is bij 
patiënten met bloedvergiftiging en een systemische ontsteking.
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Hoofdstuk 9 beschrijft de hepcidine analyse in patiënten met het metabool syndroom 
(MetS). In deze patiëntengroep, die een hoger risico op hart-en vaatziekten hebben, vonden 
we verhoogde hepcidine concentraties in het serum. In antwoord op een eerder 
gepubliceerd artikel, in samenwerking met ons laboratorium, stellen we dat verhoogde 
hepcidine concentraties wijzen op de aanwezigheid van een mechanisme waarmee deze 
verhoogde concentraties het risico op hart-en vaatziekten vergroten in deze groep patiënten 
met MetS.
Kortom, sinds de ontdekking van hepcidine 10 jaar geleden hebben meerdere onderzoeken 
bijgedragen tot beter inzicht in de regulatie en de functionele eigenschappen van hepcidine. 
De eerste betrouwbare testen om hepcidine in lichaamsvloeistoffen te kwantificeren zijn pas 
recent ontwikkeld. Sommige van deze testen kunnen onderscheid maken tussen de 
verschillende hepcidine isovormen. Tot nu toe is het onbekend of hepcidine isovormen 
belangrijk zijn in de diagnostiek. Bij de interpretatie van de resultaten moet men dus 
rekening houden met de som van hepcidine-22 en -20 isovormen wanneer bepaalde 
immunologische assays worden gebruikt.
Verder laten de eerste proof-of-principle studies zien dat hepcidine een veelbelovend nieuw 
hulpmiddel in de diagnostiek is bij patiënten met stoornissen in het ijzermetabolisme 
stoornissen. Echter, er zijn meer grote goed opgezette studies nodig om beter vast te stellen 
wat de postitie van hepcidine in de diagnostiek is. Om de hepcidine resultaten van deze 
grote internationale studies te kunnen vergelijken, is het essentieel om geharmoniseerde 
methodes te gebruiken. De eerste poging om internationale studies vergelijkbaar te maken 
voor hepcidine niveaus, is de opzet van de round Robin studies beschreven in dit 
proefschrift. Er zijn echter meer harmonisatie stappen nodig voor de verschillende testen, 
zoals de ontwikkeling van een referentiemethode en vervolgens de introductie van een 
synthetische kalibrator, om wereldwijde referentiewaarden en klinische beslisnormen te 
bepalen.
Bovendien, omdat het veld streeft naar het gebruik van hepcidine-gerelateerde therapieën, 
dient men zich te realiseren dat de uitkomst van de testen die worden gebruikt om het 
effect van de hepcidine tijdens anti-hepcidine behandeling te controleren, beïnvloed kan 
worden door hepcidine-storende verbindingen. In deze gevallen moeten testen opnieuw 
worden gevalideerd voor deze specifieke toepassing voordat er definitieve uitspraken 
kunnen worden gedaan over de werkzaamheid van de therapie.
Tot slot, hepcidine is een veelbelovend diagnostisch hulpmiddel maar er moeten nog veel 
stappen worden gezet om de relevantie van het specifiek meten van hepcidine-25 te 
beoordelen, om de internationale resultaten van de verschillende testen te harmoniseren, 
om klinische beslisnormen te definiëren, en om de testen in de klinische laboratoria 
beschikbaar te maken zodat ze gebruikt kunnen worden in de kliniek.
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Aandoeningen (LGEM)) van het UMC St Radboud. Jouw enthousiaste begeleiding heeft me 
gebracht waar ik nu sta, bedankt daarvoor. Ook wil ik je bedanken dat je me steeds weer 
hebt gemotiveerd om door te zetten om de theorie onder de knie te krijgen en natuurlijk 
ook voor je luisterend oor wanneer nodig.
Ook Harold, mijn co-promotor wil ik heel erg bedanken voor je begeleiding tijdens de OIO- 
overleggen, voor je discussies, ideeën en je correcties van mijn artikelen, waardoor ze 
uiteindelijk een stuk beter werden.
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Allereerst Coby, heel erg bedankt voor de introductie in de SELDI-TOF MS wereld, de 
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studies. Het was voor mij daarom ook meteen duidelijk dat je mijn paranimf moest worden 
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Erwin, jou wil ik natuurlijk bedanken voor het meten van een aantal van mijn studies. Zonder 
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dat je dat wilde doen, dank je wel.
Siem, bedankt voor het verzenden van de vele monsters voor de Round Robin over de hele 
wereld en met de monsters uit jouw  Biobank hebben we maar mooi een artikel in Clinical 
Chemistry gekregen.
Rian, jij bedankt voor de gezelligheid op het lab, tijdens de pauzes en een luisterend oor 
wanneer ik dat nodig had.
Anneke en Nicolaï van de Afdeling Chemische Endocrinologie (ACE) (later LGEM) wil ik 
natuurlijk heel graag bedanken voor het opzetten van de hepcidin ELISA. Zonder jullie inzet 
was deze methode er nooit gekomen. Dank hiervoor.
Ook de stagiaires die mee hebben gewerkt aan dit proefschrift wil ik bedanken voor hun 
bijdrage. Succes in jullie verdere carrière.
Teun, jou wil ik bedanken voor de fijne samenwerking tijdens de Round Robin 2. Door jouw 
inzicht, discussies en tips is het een mooi artikel geworden. Hopelijk wordt het snel 
gepubliceerd.
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Dr. Jan Hendriks, u wil ik bedanken voor de vele statistische berekeningen die u voor mijn 
projecten heeft uitgevoerd. Wij snapten heel vaak niet wat u precies met al die modellen 
berekende, maar door uw uitleg is het allemaal duidelijk geworden. Door uw geduld heb ik 
veel geleerd over statistiek. Dank hiervoor.
Ook wil ik heel graag Erwin Kemna, mijn voorganger in het hepcidine onderzoek, bedanken. 
Voor mij was het heel erg fijn dat je na je promotie nog in de buurt was als Klinisch Chemicus 
in opleiding op het AKC. Je hebt me heel erg op weg geholpen in mijn promotie, met je 
goede adviezen en de discussies over de verschillende projecten. Ook wil ik je bedanken 
voor de gezellige babbels over de vakantiefoto's en je luisterende oor voor de 
beslommeringen in het promotieonderzoek. Veel succes met je baan als Klinisch Chemicus in 
Winterswijk.
Annemarie, jij was al een aantal maanden bezig toen ik begon met mijn promotie. In het 
begin trokken we nog niet veel met elkaar op. Het was fijn om in de laatste fase van het 
promotietraject een "soulmate" te hebben om stoom bij af te blazen. Heel veel succes bij je 
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Verder wil ik alle collega's van het AKC bedanken die betrokken zijn geweest bij een of meer 
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Papa, mama en Linda, heel erg bedankt voor jullie steun tijdens mijn promotie. Zonder jullie 
was ik nooit zover gekomen. Ik vind het fijn om zo'n gezellig en warm thuis te hebben, waar 
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gesteund hebben de afgelopen jaren. Dit boekje is dan ook voor jullie.
Tony, nu kunnen we aan de toekomst gaan bouwen, in ons nieuwe huis, met een nieuwe 
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Addendum 1
Sample selection, characteristics and hepcidin concentrations 
Sample selection
The samples included in this study are from:
i) healthy controls after overnight fasting (8.30 am) (n=23),1 ii) patients with iron deficiency 
anemia (IDA) (n=10), defined as microcytic anemia (mean corpuscular volume (MCV) <80 fl, 
hemoglobin (Hb) <7.4 mmol/L for women and <8.1 mmol/L for men), decreased serum 
ferritin concentrations (<15 ng/L), decreased serum iron concentrations (<10 |amol/L), and a 
normal to increased total iron binding capacity (TIBC) (>60 |amol/L), and a decreased 
transferrin saturation (TS) (<20%),2-6 iii) patients with anemia of chronic disease (ACD) 
(n=10), defined as normocytic to microcytic anemia (MCV <100 fl, Hb <7.4 mmol/L for 
women and <8.1 mmol/L for men), normal or increased serum ferritin concentrations (>100 
ferritin ng/L), decreased serum iron concentrations (< 10 |amol/L), a decreased TIBC (< 60 
|amol/L), and a decreased TS (< 20%), and an increased C-reactive protein (CRP) (>20 mg/L),2- 
6 iv) patients with multiple myeloma (MM) (n=6), of which 3 patients were suffering from 
active disease and 2 patients from progressive disease, all in different stages of treatment, v) 
hereditary hemochromatosis (HH) patients at stage of presentation (n=9), vi) hereditary 
hemochromatosis patients in the maintenance phase (n=8) of their venesection treatment 
(>5 weeks after last treatment),7 vii) C282Y/H63D HFE compound heterozygous HH patients 
at stage of presentation (n=5), viii) hemojuvelin (HJV) mutated HH patients after venesection 
treatment, (n=3) (>5 weeks after last treatment),8 ix) patients with chronic kidney disease 
(CKD) (n=84), GFR 6-93 mL/min/1.73m2,9 x) patients that underwent coronary artery bypass 
graft surgery (CABG) (n=22), samples were collected within 24 hrs from surgery,10 xi) 
patients with septic shock (sepsis) (n=19), samples were collected within 24 hrs from 
noradrenalin treatment, patients were diagnosed by the presence of > 2 diagnostic criteria 
for systemic inflammation11 and a suspected source of infection, xii) healthy volunteers that 
were injected with lipopolysaccharide (LPS) (n=5),12 and xiii) patients with metabolic 
syndrome (MetS) (n=5).
To evaluate clinical utility of the three hepcidin assays, we selected samples from 27 anemic 
patients diagnosed with rheumatoid arthritis (RA) and samples from 19 patients with ferritin 
concentrations <60 ng/L. To this end, we selected 27 RA patients with a hemoglobin 
concentration < 8.1 mmol/L for men and < 7.4 mmol/L for women from 106 patients with 
RA who visited the outpatient clinic of the Radboud University Nijmegen Medical Centre for 
a routine check-up. These rheumatic patients with anemia were subsequently categorized in 
3 groups, IDA (n=8) , IDA and ACD (n=8) and ACD (n=11). Patients were considered to have
1) IDA, when they had a CRP < 10 mg/L, TS < 16 %, ferritin < 30 ^g/L, 2) ACD, when they had 
CRP > 10 mg/L, TS< 30%, ferritin > 30 |ag/L and soluble transferrin receptor (sTfR)/log ferritin 
< 1 and 3) ACD with true iron deficiency when they had CRP> 10 mg/L, TS < 30%, ferritin > 30 
|ag/L and sTfR/log ferritin > 1. The 19 "< 60 |ag/L ferritin" patients comprise all the 10 
patients with IDA from the total group of 209 patients described above, and 9 additional 
patients. These 19 samples were all derived from patients that had laboratory results that 
excluded the presence of inflammation, HH or matriptase-2 defects.2
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Sample characteristics
The characteristics, (hemoglobin (Hb), mean corpuscular volume (MCV), transferrin
saturation (TS), ferritin, Alanine-aminotransferase (ALAT), CRP and serum creatinine), of the
patients (n=186) and healthy controls (n=23) are shown in Table 1.
Hepcidin concentrations
Hepcidin medians and ranges for the various diseases obtained by the various methods are
shown in Table 2.
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Table 1. Population characteristics
Disease
Ref N Gender
(m/f)
Hb
(mmol/L)
MCV
(fi)
Ferritin
(Hg/L)
TS
(%)
CRP
(mg/L)
ALAT
(U/L)
Creatinine
(nmol/L)
Median Range Median Range Median Range Median Range Median Range Median Range Median Range
Healthy controls l 23 (11/12) 8.8 7.9-8.9 87 82-93 103 12-224 32.7 19.0-49.1 <5 <5 23 9-39 75 54-102
IDA 10 (5/5) 6.6 4.1-8.3 76 62-79 6 4-11 5.8 2.5-12.0 <5 <5-33 - - - -
ACD 10 (5/5) 6.2 5.2-7.8 82 73-86 435 110-1094 11.8 4.9-18.8 84 13-157 - - - -
MM 6 (4/2) 7.4 4.0-9.0 - - 402 73-5266 40.0 25.0-69.1 11.5 5-20 - - 5.3 2.4-11.8
HH C282Y pres. 9 (6/3) 8.5 8.2-10.2 92 82-97 417 227-1688 77.5 75.0-92.3 <5 <5 44 16-44 - -
HH C282Y de pi. 7 8 (6/2) 8.4 7.8-10.0 91 74-96 38 11-90 50.0 45.0-68.0 <5 <5 33.5 18-68 - -
HH C282Y/H63D pres. 5 (4/1) 8.5 7.8-9.4 94 88-95 1226 302-2070 34.2 26.3-42.0 26.5 8-45 40.5 36-45 - -
HH HJV depl. 8 3 (3/0) 8.5 8.3-8.7 92 89-94 124 60-187 87.4 78.3-96.4 <5 <5 14 13-15 63 56-70
CKD 9 84 (60/24) - - - - 111 10-610 24.4 9.1-59.6 <5 <5-75 - - 151 62-842
CABG 10 22 (17/3) 6.6 5.2-8.1 - - 137 42-417 9.0 3.1-36.4 25 11-122 22 14-50 85 41-131
Sepsis 19 (14/5) 5.8 4.7-7.3 - - 759 135-15000 12.3 3.6-96.8 183 18-363 40.5 15-407 171 30-540
LPS 12 5 (4/1) - - - - 196 130-233 31.2 16.7-52.4 <5 <5-11 - - - -
MetS 5 (4/1) 8.6 7.5-10.0 - - 448 116-892 28.3 19.4-60.4 <5 <5-14 62 27-148 - -
Population comprises 209 samples from patients with various iron disorders. IDA, iron deficiency anemia; ACD, anemia of chronic disease; MM, multiple myeloma; HH, 
HFE-hereditary hemochromatosis; HH HJV, HH due to mutation in HJV gene; CKD, chronic kidney disease; CABG, coronary artery bypass surgery; LPS, volunteers injected 
with lipopolysaccharide; MetS, metabolic syndrome; n, number of samples; Hb, hemoglobin; MCV, mean corpuscular volume; ferritin; TS, transferrin saturation; CRP, C- 
reactive protein; ALAT, alanine aminotransferase; parameters not measured.
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Table 2. Hepcidin concentrations measured by 3 different hepcidin methods in various disorders of iron metabolism
Disease N WCX-TOF MS c-ELISA IC-TOF MS
He pc-20 Hepc-22 Hepc-25 Total Hepcidin Total Hepcidin He pci din-25
Median Range Median Range Median Range Median Range Median Range Median Range
Healthy controls 23 <0.5 n.a. <0.5 n.a. 2.9 (<0.5-8.2) 2.9 (<0.5-8.2) 3.9 (0.1-18.8) 0.1 (<0.1-0.14)n=2
IDA 10 <0.5 n.a. <0.5 n.a. <0.5 n.a. <0.5 n.a. 0.3 (0.1-1.8) <0.1 (<0.1-0.3)
ACD 10 3.5 (<0.5-8.0) <0.5 (<0.5-2.4) 14.8 (7.8-23.0) 17.7 (10.9-23.1) 20.3 (9.8-42.7) - -
MM 6 <0.5 n.a. <0.5 n.a. 11.3 (<0.5-26.9) 11.3 (<0.5-26.9) 18.7 (6.3-40.3) 1.4 l
HH C282Y pres. 9 <0.5 n.a. <0.5 n.a. 4.7 (3.8-15.8) 4.7 (3.8-15.8) 8.8 (1.3-20.0) - -
HH C282Y depl. 8 <0.5 n.a. <0.5 n.a. <0.5 n.a. <0.5 n.a. 0.5 (0.15-2.4) <0.1 (<0.1-1.3)
HH C282Y/H63D pres. 5 <0.5 n.a. <0.5 n.a. 3.6 (<0.5-12.0) 3.6 (<0.5-12.0) 3.6 (1.9-19.8) 0.4 l
HH HJV depl. 3 <0.5 n.a. <0.5 n.a. <0.5 n.a. <0.5 n.a. 0.2 (0.16-0.28) <0.1 l
CKD 84 1.6 (<0.5-6.4) <0.5 (<0.5-2.2) 4.6 (<0.5-29.5) 6.2 (<0.5-34.9) 7.1 (0.5^4.0) - -
CABG 22 0.5 (<0.5-2.0) <0.5 n.a. 5.0 (0.7-11.0) 5.0 (0.7-11.1) 6.6 (1.1-16.4) - -
Sepsis 19 3.1 (<0.5-5.4) 2.4 (<0.5-6.3) 26.3 (6.0-82.5) 27.9 (6.0-82.5) 34.6 (7.7-77.5) - -
LPS 5 <0.5 n.a. <0.5 n.a. 24.1 (21.0-25.2) 24.1 (21.0-25.2) 24.1 (33.0-60.0) - -
MetS 5 0.5 (<0.5-4.0) <0.5 n.a. 4.9 (<0.5-17.5) 4.9 (<0.5-17.5) 15.6 (3.6-24.8) - -
Total 209 <0.5 (<0.5-8.0) <0.5 (<0.5-6.3) 4.6 (<0.5-17.5) 5.2 (<0.5-82.5) 6.6 (0.14-77.5) 0.11 (<0.1-1.4)25
Concentrations are expressed in nM. N, number of samples measured, unless otherwise indicated in superscript, samples used for measurement with IC- 
TOF MS were selected from the total of 209 samples, i.e. n=25 with hepcidin <0.5 nM; n.a., not applicable, since all samples were measured below the 
detection limit; -, no samples measured for this disease by the method.
IDA, iron deficiency anemia; ACD, anemia of chronic disease; MM, multiple myeloma; HH, HFE-hereditary hemochromatosis; HH HJV, HH due to mutation 
in HJV gene; CKD, chronic kidney disease; CABG, coronary artery bypass surgery; LPS, volunteers injected with lipopolysaccharide; MetS, metabolic 
syndrome; WCX, weak cation exchange beads. When samples were below the detection limit, this was indicated as <0.5 nM (WCX-TOF MS) or <0.1 nM 
(IC-TOF MSI
Addenda
Addendum 2
Weak Cation Exchange - time of flight mass spectrometry (WCX-TOF MS) 
Detailed description of the methodology '
WCX-TOF MS was performed as described previously by a combination of WCX bead-based 
hepcidin enrichment followed by TOF MS. To a volume of 50 uL 25% (v/v) WCX beads, we 
added 50 |aL serum together with 5 |aL of 0.1 |aM synthetic hepcidin-24 (Peptide Institute, 
Osaka, Japan) as an internal standard (final concentration of 10 nM). After incubation and 
washing with 25 mM NH4-Ac (pH 7.5) and 25 mM NH4-Ac 2% HAc, the sample was eluted 
from the beads with 25 |aL 50 % acetonitrile (ACN) + 2% trifluoroacetic acid (TFA). A volume 
of 1.5 |aL of the sample and 1.5 |aL of a-Cyano-4-hydroxycinnamic acid (CHCA) matrix was 
spotted on the MALDI-TOF MSP 96 steel plate (Microflex LT, Bruker Daltonics GmbH, 
Bremen, Germany). Mass-to-charge (m/z) spectra were generated using MALDI-TOF-MS 
(Microflex LT, Bruker Daltonics GmbH, Bremen, Germany) in positive, linear ion mode and 
500 laser shots. Initial laser power 60%, offset 25% and range 20%. Pulsed ion extraction was 
set to 150 ns. The mass resolution was determined as a peak resolution > 100, a signal noise 
> 2 and a peak width of 10 m/z. The mass accuracy (peak assignment tolerance) was "user 
determined" at 500 ppm. The mass range during acquisition was set on 2,000-10,000 m/z 
with the peak selection from 2,000-3,000 m/z. Calibration was performed i) when the m/z 
ratio of the hepcidin-24 standard deviated from 2,436.06 and ii) after source cleaning. 
Spectra were analyzed using Bruker Daltonics FlexAnalysis software. The internal standard 
was used for quantification.1,2 Total hepcidin was defined as the sum of hepcidin 25, -22 and 
-20 concentrations.
The LLOD of this method for serum was 0.5 nM. The lower limit of detection (LLOD) of this 
method for serum was 0.5nM with an intra-run coefficient of variation (CV) of 3.7% at 
7.9nM, 2.3% at 13.4nM and 2.2% at 3.1nM. The inter-run CV is 9.1% at 7.8nM and 3.9% at 
12.9nM. The median reference level of serum hepcidin-25 is 4.2nM, with a range of 0.5-13.9
nM.2
Results
Accuracy of assigned concentration of isoforms
We tested the binding efficiency to WCX-beads and ionization efficiency by spiking known 
concentrations of hepcidin-20 -22, -24 and -25 to deionized H2O. We measured the 
concentrations in the sample by applying the spiked sample i) directly to the MALDI-TOF 
plate and ii) to the MALDI-TOF plate after WCX enrichment. We calculated the 
concentrations of the hepcidin isoforms from the intensities of both MS spectra (using 
hepcidin-24 as the internal standard) and for both protocols found that the calculated 
concentrations did not differ from those of the spiked peptides. This indicates that both the 
binding efficiency to the WCX-beads and ionization efficiency of these isoforms are similar.
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Addendum 3
Competitive enzyme-linked immunosorbent assay (c-ELISA)
Method description
Hepcidin was biotinylated by incubating 11.5 |ag hepcidin-25 (Peptide International, 
Louisville, KY, USA) with 8.17 |ag No-WeighTM Sulfo-NHS-Biotin (20-fold molar excess) 
(Pierce, Rockford, IL, USA) during 30 minutes at ambient temperature. The excess of non­
reacted biotin reagent was removed by loading the reaction mixture onto a pre-equilibrated 
Octadecyl (C18) SPE column (Mallinckrodt Baker, Deventer, the Netherlands). The column 
was washed three times with 0.5 mL of an aqueous solution of 20% Methanol and 0.1% 
trifluoroacetic acid (TFA). Biotin-labeled hepcidin-25 was eluted from the SPE column by 0.5 
mL 80% Methanol and 0.1% TFA. After evaporation of the methanol, 200 |al PBS containing 
10 g/L BSA, 1 mL/L Tween-20 and 200 |aL glycerol was added to the biotin-labeled hepcidin 
and subsequently stored at -20°C.
The procedure started with coating of the microtiter plate (96-well Nunc Maxisorb™ flat 
bottomed) with 100 ^L/well of goat-anti-rabbit IgG (Fc) antibody (Pierce, Rockford, IL, USA) 
(4 mg/L in 50 mM NaHCO3/Na2CO3, pH 9.6) overnight at 4°C. The plate was then washed 
four times with 300 ^L/well of washing buffer (1 mL/L Tween-20 in PBS) by use of a 96PW 
plate washer (Tecan, Männedorf, Switzerland). The plates were blocked with 10 g/L BSA 
(Sigma Aldrich, St. Louis, MO, USA) in PBS (300 ^L/well) for 2h at ambient temperature and 
washed four times with washing buffer. The next step was the incubation with rabbit-anti- 
human hepcidin polyclonal antibody1 [100 ^L/well; 0.3 mg/L in dilution buffer (10 g/L BSA in 
washing buffer)] for 2h at ambient temperature. After four washings, the calibrator 
(hepcidin-25), the unknown samples (20-fold diluted in dilution buffer), and the reference 
sample (75 ^L/well in dilution buffer) were added to the wells, where after 75 ^L/well 
biotinylated hepcidin (dilution 10,000x) in dilution buffer was added and the plates were 
incubated overnight at 4°C. The plates were washed four times with 300 |al washing buffer 
and subsequently plates were incubated with 100 ^L/well Streptavidin-POD conjugate 
(Roche Diagnostics GmbH, Penzberg, Germany) (dilution 50,000x) during 1h at ambient 
temperature. Plates were washed 5 times with 300 |al washing buffer and incubation with 
substrate solution (4 mg OPD in borate/citrate buffer) was performed in darkness for 15 
minutes. The color reaction was stopped by addition of 100 |al 0.5 nM H2SO4 per well and 
optical density was measured using an automated c-ELISA reader (Lab Systems, Oy, Helsinki, 
Finland) at 492 nm.
Results
Detection limit, precision and specificity
Hepcidin-25 was used as a calibrator to generate the dose-response curve of the 
competitive ELISA (Figure 1A). The analytical sensitivity, defined as the minimum hepcidin 
concentration evoking a response significantly different from that of the zero calibrator, was 
20.8 pM. The functional sensitivity was calculated from the precision profile (at 20%) 
constructed from the CVs of duplicate measurements of 953 routine samples and was 26.5 
pM (precision profile, Figure 1B).
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Figure 1. Hepcidin competitive ELISA characteristics.
(A) Dose-response (calibration curve (•)) and sensitivity of the hepcidin competitive ELISA. The 
imprecision (o) was obtained on the basis of 23 plates assayed on 9 days. (B) Precision profile (solid 
line) constructed from 953 individual duplicate CVs.
The mean hepcidin concentration of the reference preparation sample (denoted 140799) 
was 6.7 nM, while the intra-run coefficient of variation (CV) and the inter-run CV were 4.8% 
(n=12) and 11.2% (n=40), respectively.
The competitive ELISA detected hepcidin-25 as well as hepcidin-20 and hepcidin-22 (Figure
2). On a molecular basis (at 50% displacement of the tracer) the competitive ELISA cross 
reacts for 47% and 68% with hepcidin-22 and hepcidin-20, respectively.
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Figure 2. Dose-response curves for hepcidin isoforms.
Specific responses evoked by different dilutions in dilution buffer of three hepcidin preparations: 
hepcidin-25, -22 and -20.
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Linearity and recovery
Linearity was tested by measuring hepcidin concentrations at different dilutions of eight 
serum samples. The hepcidin concentrations obtained in the undiluted samples ranged from 
2.5-177.1 nM. For each sample, the dilution curve was close to linear, confirming parallelism 
between the calibrator and the serum samples (Figure 3). To eight serum samples 
(endogenous hepcidin concentrations of 1.8-15.1 nM) we added the calibrator at 0.09, 0.5, 
and 1.6 nM. The recoveries ranged in the serum samples from 86% to 114% with a mean 
recovery of 98%.
Figure 3. Linearity of dilution curves for serum samples.
Data presented are the results of serial dilutions with dilution buffer of eight samples containing 2.5 
()), 8.6 (3), 14.7 (+), 15.4 (,) , 31.9 (%), 45.9 (&), 113.3 (i), 177.1 (#) nM hepcidin, respectively.
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Addendum 4
Immunocapture time of flight mass spectrometry (IC-TOF-MS)
Method description
Protein A sepharose beads were washed 4 times with phosphate buffered saline (PBS) -  0.1 
% Triton X-100 (PBS-Tx). 3 |aL of rabbit-anti-human hepcidin polyclonal antibody (0.15 
mg/mL)1 was added to 100 |aL 25% (v/v) beads, incubated for 1 hour at room temperature 
(RT) and gently mixed. The beads were washed 3 times with 250 |aL PBS-Tx. 200 |aL serum 
together with 2 |aL of 50 nM synthetic human hepcidin-24 (Peptide Institute, Osaka, Japan)2 
as an internal standard of -  final concentration 0.5 nM -  was added to 30 |aL beads in 300 |aL 
PBS-Tx and incubated for 1 hour at RT and gently mixed. The beads were washed 3 times 
with PBS-Tx and 3 times with distilled water, DNase/RNase Free, GIBCO®. Hepcidin was 
eluted with 15 |aL 50% acetonitrile (ACN) and 0.5 % trifluoroacetic acid (TFA) after which a 1 
|aL sample with eluted peptides and a-Cyano-4-hydroxycinnamic acid (CHCA) matrix was 
applied to a MSP 96 polished steel plate (Microflex LT, Bruker Daltonics GmbH, Bremen, 
Germany). Mass-to-charge (m/z) spectra were generated using MALDI-TOF-MS (Microflex LT, 
Bruker Daltonics GmbH, Bremen, Germany) in positive, linear ion mode and 500 laser 
shots.Initial laser power 60%, offset 25% and range 20%. Pulsed ion extraction was set to 
150 ns.2,3 The mass resolution was determined as a peak resolution > 100, a signal noise > 2 
and a peak width of 10 m/z. The mass accuracy (peak assignment tolerance) was "user 
determined" at 500 ppm. The mass range during acquisition was set on 2000-10000 with the 
peak selection from 2000-3000 m/z. Calibration was performed i) when the m/z ratio of the 
hepcidin-24 standard deviated from 2436.06 and ii) after source cleaning. Spectra were 
analyzed using Bruker Daltonics FlexAnalysis software.
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Figure 1. Increased sensitivity of IC-TOF MS.
Upper panel shows the mass/charge (m/z) spectrum of a serum sample with a hepcidin 
concentration below the detection level of 0.5 nM of WCX-TOF MS; 5 nM internal standard (IS) 
hepcidin-24 was added to the sample prior to the procedure. The lower panel shows the same 
sample measured by IC-TOF MS, based on the known concentration of IS (1 nM), the hepcidin 
concentration in this case was calculated as 0.24 nM.
Results
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Detection limit, precision and specificity
The intra-assay CV was 11.0 % at 0.1 nM (n=8), 13.1 % at 0.2 nM (n=8) and 3.9 % at 1.3 nM 
(n=8). The functional sensitivity, defined as a hepcidin peak > 3 signal/noise in a TOF-MS 
spectrum was 0.1 nM.
The increased sensitivity of IC-TOF MS in comparison to weak cation exchange (WCX)-TOF- 
MS (hepcidin enrichment by WCX chromatography prior to TOF-MS analysis) is shown by the 
mass spectra of Figure 1.
The hepcidin antibody cross reacts for 100% with the internal standard hepcidin-24. Because 
the immunocapture is followed by TOF-MS, the combined procedure of immunocapture 
with MS, is 100% specific for hepcidin-25.
Linearity and recovery
Linearity was tested by a series of 9 dilutions of a serum sample (7 nM) in "blank" serum. 
For the sample, the dilution curve was tested to be close to linear (y = 6.91x + 0.15, R=0.999) 
by linear regression analysis (Figure 2).
The mean recovery of the IC-TOF-MS method was 95% (range 95-105%, n=4).
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Figure 2: Linearity of dilution curve for one serum sample (7nM).
Spearman's R and the linear regression formula is shown.
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